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Abstract 
Despite a rise in breast cancer incidence, mortality rates have fallen. This 
improvement in mortality is due to the success of anti-cancer treatments such as 
chemotherapy and radiotherapy. Such treatments, however, are known to be 
associated with a range of symptoms. A number of studies exploring patients’ 
chemotherapy-related symptom experiences have shown that patients consistently 
rate nausea and fatigue highly, not only in relation to severity, but also in relation to 
the associated distress they experience.  
The subjective and non-observable nature of both nausea and fatigue complicates 
their assessment. While a range of assessment tools exists to evaluate patients’ 
experiences of these two symptoms, there is currently no gold standard assessment 
tool for assessing either symptom. Moreover, while a range of pharmacological and 
non-pharmacological interventions have been developed for both symptoms, further 
evaluation is often needed to provide the level of evidence required to recommend 
their implementation in real life clinical environments.  
The SNA↔P (structured nursing assessment into practice) study arose in response 
to this clinical situation. The SNA↔P study was a longitudinal study that evaluated 
the impact of a complex evidence-based intervention, incorporating structured 
multidimensional symptom assessment and multiple symptom management 
techniques, on patients’ experiences of nausea and fatigue during a course of 
chemotherapy for breast cancer. Using complementary quantitative and qualitative 
research methods not only allowed in-depth understanding of patients’ experiences 
and patterns of nausea and fatigue during a course of chemotherapy, but also 
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facilitated a rounded evaluation of the intervention, incorporating both statistical 
elements and those of personal significance. The use of these methods showed that 
the implementation of the SNA↔P intervention in routine clinical practice has 
significant potential for improving patients’ symptom experiences during a course 
of chemotherapy. In so doing, it also highlighted a number of areas in which clinical 
practice can be influenced, and research conducted, to further improve patients’ 
symptom experiences. 
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Preface – The development of the SNA↔P study 
This PhD study arose from my involvement in a European cancer nursing study 
called WISECARE+ (2001-2003). The WISECARE+ study aimed to evaluate the 
impact of structured symptom management on patients’ chemotherapy-related 
symptoms. WISECARE+ was pan-European, involving five clinical sites in 
Denmark, England, Ireland and Scotland, and was funded by the Royal Marsden 
NHS Foundation Trust. 
To ensure clarity about the relationship between WISECARE+ and my PhD, in this 
preface I will outline: 
• The aims and design of WISECARE+ 
• The roles of those involved in WISECARE+  
• The inter-relationship between WISECARE+ and this thesis 
The aims and design of WISECARE+ 
The aim of WISECARE+ was to evaluate the impact of structured symptom 
assessment and management, facilitated by the WISETool, on patients’ 
chemotherapy-related symptoms. The study focused on four physical 
chemotherapy-related symptoms identified by nurses involved in the study as 
problematic in their daily clinical practice: nausea, vomiting, fatigue and oral 
problems. These have also been consistently identified in the literature as prevalent 
and troublesome symptoms experienced by those receiving chemotherapy (Coates 
et al. 1983; Love et al. 1989; Griffin et al. 1996; Tierney et al. 1991; Cooper and 
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Georgiou 1992; Sitzia et al. 1995; Foltz et al. 1996; de Boer-Dennert et al. 1997; 
Lindley et al. 1999; Carelle et al. 2002).  
WISECARE+ followed a before and after design with data collection taking place 
over two distinct time periods (times 1 and 2). The intervention took place between 
these two time periods (see Figure 1).  
Figure 1: WISECARE+ Design 
 
A convenience sample of patients was recruited from all five clinical sites and the 
samples from times 1 and 2 were not matched. The inclusion/exclusion criteria for 
the sample are presented in Table 1 below. 
Table 1: WISECARE+ patient inclusion and exclusion criteria 
Inclusion Exclusion 
• Aged 18 years or over 
• Aware of their cancer diagnosis 
• Able to give informed consent 
• Able to read/write English 
• Scheduled to receive chemotherapy 
for breast, lung, ovarian or colorectal 
cancer, osteosarcoma, leukaemia or 
lymphoma 
• Patients deemed by any member of 
the clinical team as being physically 
or psychologically unfit to 
participate in the study 
• Patients who had previously received 
a course of chemotherapy 
Time 1 Intervention
Structured nursing 
assessment & 
practice
Symptom 
data 
collection
Mar 2002 Dec 2002 Jan 2003 Feb 2003
Time 2
Symptom 
data 
collection
Mar 2003 Mar 2004
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Ethical approval was granted in each clinical site and all patients gave written 
informed consent prior to their recruitment to, and participation in, WISECARE+. 
Patients completed a daily structured symptom questionnaire for 14 days following 
each cycle of chemotherapy. The questionnaire asked patients about the incidence, 
severity and distress of any nausea, vomiting, fatigue or oral problems that they 
experienced that day. A total sample of 249 patients was recruited from the 5 
clinical sites. These patients (127 participating during period 1 and 122 during 
period 2) completed a total of 12,227 symptom questionnaires. All participating 
patients completed at least 1 cycle of chemotherapy, and so, were included in the 
analysis. The impact of the intervention was evaluated by comparing symptom 
outcomes between times 1 and 2, and found statistically significant improvements in 
nausea, vomiting and oral problems, but not fatigue. 
Those involved in the WISECARE+ study 
WISECARE+ was managed by a Steering Group (see Appendix A) who met on a 
four-six monthly basis to plan and oversee the study. The Steering Group was 
comprised of myself (Research Fellow, MM), Professor Nora Kearney (Principle 
Investigator), Professor Walter Sermeus (statistical and IT advisor), Derek Hoy 
(software design and support), Dickon Weir-Hughes and Sara Lister (representing 
the funding body and advising on general study conduct), and Dr Faith Gibson 
(paediatric advisor, as it was envisaged that future development of WISECARE+ 
would involve a paediatric aspect, and advisor on all study aspects). Professor Nora 
Kearney is also one of my PhD supervisors. In addition to the Steering Group there 
was also a group of nurses from each of the clinical sites involved in the 
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WISECARE+ study. While these nurses met face-to-face only at the start and end of 
the study, they frequently communicated by e-mail, discussing their involvement in 
the study and providing each other with peer support. 
My role in the research ideas for the WISECARE+ study started before funding had 
been received. I was responsible for developing the research proposal and working 
with clinical sites to secure their involvement in WISECARE+. Thus, I had 
considerable influence over the research design and choice of research methods. I 
was solely responsible for the development and introduction of the intervention for 
the WISECARE+ study in all 5 clinical sites. During the planning of the 
WISECARE+ study and throughout its duration, I also had a close working 
relationship with Derek Hoy, who was responsible for the development and 
maintenance of the WISETool. The WISETool was the electronic patient record, 
designed specifically for WISECARE+, into which patient data was entered. The 
WISETool had an integral role in the study’s intervention, as it provided nursing 
staff with feedback of patients’ symptom outcomes, as well as prompts for 
appropriate nursing interventions. Liasing between Derek and nursing staff involved 
in the study, it was my responsibility to ensure that the WISETool was user-friendly 
and provided the nursing staff with relevant patient and symptom information. It 
was also my role to ensure that the nursing staff were competent in their use of the 
WISETool, so using it to its full potential. During the implementation of the 
WISECARE+ study, I was responsible for working with the nursing staff in each 
clinical site to ensure adherence to the data collection process. Working with the 
nurses involved visits to each clinical site and, at least, weekly e-mail contact. The 
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number of visits varied between each clinical site, depending on the nurses’ 
previous research experience, and geographical location of the clinical sites. 1 
The inter-relationship between the WISECARE+ study and my PhD 
As this thesis arose from my involvement in the WISECARE+ study, it inevitably 
draws on the design of WISECARE+ and the WISECARE+ intervention (structured 
nursing assessment and practice) which I developed and implemented across the 5 
clinical sites involved in the WISECARE+ study. However, this thesis describes the 
SNA↔P study (Structured Nursing Assessment into Practice study). Figure 2 
demonstrates the inter-relationship between the WISECARE+ study and the 
SNA↔P study. 
 
                                                 
1 As Principal Investigator for the study I can confirm that although the idea for the 
study was not generated by Morven she had significant input to the subsequent 
development and execution of the study and as a consequence was involved in 
refining the methods for the study. She had responsibility for the development of the 
intervention, development of links and ongoing collaboration with the clinical sites 
throughout the study, development and integration of the literature reviews and 
symptom management information into the WISETool.  In addition she led the 
clinical team in ensuring feasibility and acceptability of the WISETool across the 
clinical sites.  Professor Nora Kearney February 2008 
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Figure 2: Inter-relationship between WISECARE+ and SNA↔P studies 
 Time 1 Time 2Intervention
Site 1
Site 2
Site 3
Site 4
Site 5
Structured nursing 
assessment & 
practice
Site 1
Site 2
Site 3
Site 4
Site 5
Control 
site Standard practice
Symptom 
data 
collection
Symptom 
data 
collection
Symptom 
data 
collection
Control 
site
Symptom 
data 
collection 
& 
interviews
WISECARE+ 
Study
SNA↔P 
Study
 
Figure 2 shows that the SNA↔P study involved one site from the WISECARE+ 
study. The intervention from the WISECARE+ study, developed and implemented 
by me, was also utilised in the SNA↔P study. However, the SNA↔P study differs 
significantly from the WISECARE+ study in 3 ways: 
1. It focuses only on women receiving chemotherapy for breast cancer 
WISECARE+ involved a heterogeneous sample of patients receiving 
chemotherapy. While this sample reflected the patient populations of the clinical 
sites involved in the WISECARE+ study, I felt it was important to explore the 
impact of the intervention in a more homogenous population. I chose women 
with breast cancer for a number of reasons. Firstly, I had developed a particular 
interest in this patient population through my clinical experience. Secondly, they 
represented the largest patient population in the clinical sites that I had identified 
for my study, so giving me access to the greatest number of patients during the 
data collection period, and so increasing the power of the study.  
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2. It includes a control group 
Before and after designs are made stronger with the addition of a control group 
that receives the same measurement but not the intervention (Burns and Grove 
2005). This design increases the strength of the confidence that any 
improvement observed in symptoms during time 2 was due to the intervention 
rather than other variables, such as a change in policy for example, between the 
two timepoints. 
3. It incorporates simultaneous quantitative and qualitative exploration of symptom 
experiences  
Through my involvement in the WISECARE+ study I grew to appreciate that, 
although measuring symptoms in a structured fashion was helpful in evaluating 
the impact of an intervention, it did not describe how symptoms are experienced, 
or their impact on the lives of those experiencing them. Thus, in the design of 
the SNA↔P study, I included structured interviews with a sub-sample of 
patients to explore the relationship between the quantitative measurement of 
symptoms and the personal significance and meaning of symptoms to 
individuals. This novel method of exploring symptoms, that is, using 
quantitative data to facilitate the qualitative exploration of the meaning of 
specific symptom scores for individual patients, produced illuminating results. 
As the SNA↔P study arose from my involvement in the WISECARE+ study, it is 
constrained to some extent by the methods utilised in the WISECARE+ study. I 
have, (in the relevant methods and discussion chapter), highlighted these methods. 
The remainder of this thesis will focus on my study: the SNA↔P study. 
8 
1 CHAPTER 1 – INTRODUCTION 
Cancer remains one of the most feared of illness, and receiving a diagnosis has been 
shown to be a dramatic and life-changing experience (Saegrov and Halding 2004). 
Breast cancer is the most common malignancy among women, with an average 
lifetime risk of approximately 10% (Benson 2007). Worldwide, more than a million 
women are diagnosed with breast cancer every year, accounting for a tenth of all 
new cancers and 23% of all female cancer cases (Ferlay et al. 2004). Breast cancer 
incidence rates vary considerably, with the highest rates in the developed world and 
the lowest rates in Africa and Asia (Ferlay et al. 2004). In Scotland, during 2002 
(where and when the SNA↔P study was performed), 3,691 women were diagnosed 
with breast cancer and 1,105 women died of the disease (Information and Statistics 
Division 2007a; Information and Statistics Division 2007b). However, despite the 
continued rise in incidence of the disease, with almost half a million deaths annually 
worldwide, mortality rates have fallen over the last two decades (Benson 2007). The 
most recent estimate suggests around 172,000 women are alive in the UK having 
had a diagnosis of breast cancer (Micheli et al. 2002), and in Scotland, at the end of 
2003, there were 32,821 women living with breast cancer, which equates to 1.249% 
of the female population ( Information and Statistics Division 2007c). The 
improvements in survival are due to the success of a range of strategies, including 
screening, and cancer therapies such as chemotherapy and radiotherapy.  
However, anti-cancer therapies are associated with a range of symptoms that have 
been shown to have a negative effect on quality of life (Dikken and Sitzia 1998; 
Department of Health 2000; National Institute for Clinical Excellence 2004). This 
finding, in tandem with the shift in the administration of chemotherapy from in-
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patient to out-patient services, means that the majority of patients receiving 
chemotherapy cope with chemotherapy-related symptoms while they are at home 
without the direct support of trained oncology health professionals (McCaughan and 
Thompson 2000). It is such chemotherapy-related symptoms, specifically nausea 
and fatigue, that are the focus of this thesis. 
1.1 Plan of Thesis 
In the following chapter of this thesis, the evidence concerning chemotherapy-
related symptoms will be reviewed. A considerable body of research utilising a 
variety of research methods has generated evidence that shows chemotherapy is 
associated with a plethora of physical and psychosocial symptoms. However, 
despite the range of research methods and methodological limitations, 
chemotherapy-related nausea and fatigue have been consistently identified by 
patients as high ranking symptoms of concern. As both these symptoms are non-
observable they present a considerable challenge to health professionals in their 
assessment and management.  
Chapters 3 and 4 explore the current evidence concerning chemotherapy-related 
nausea and fatigue, respectively. The causes of nausea and fatigue will be 
considered in these chapters, before critical analysis of the available assessment and 
management techniques demonstrate that, not only is there a variety of effective 
ways of assessing nausea and fatigue, there is also growing evidence of effective 
interventions. However, despite advances in assessment and management, 
exploration of the symptom experience for both nausea and fatigue continues to 
show the overriding negative impact these symptoms have on the lives of those 
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experiencing them. Explanations for the minimal impact of interventions on 
experiences will be offered and the potential role for nursing staff in these 
interventions will be explored. Chapter 5 provides a brief summary of this literature 
review and presents a rationale for the development of the SNA↔P study. 
Chapter 6 describes the design and methods used in the SNA↔P study, a study 
undertaken to evaluate the impact of a nurse-led intervention incorporating 
structured assessment and practice on chemotherapy-related nausea and fatigue. 
Details of the pilot study will be given before the methods used in the main study, 
both quantitative and qualitative, are detailed. The intervention itself is described in 
detail in chapter 7. The results of the SNA↔P study are presented in chapter 8. 
Finally, the overall conclusions from the SNA↔P study are discussed in chapter 9. 
Key aspects of the study and its implications for practice in relation to symptom 
assessment and management are presented. Areas for future research are also 
identified. 
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2 CHAPTER 2 – EXPERIENCES OF CHEMOTHERAPY - 
RELATED SYMPTOMS 
2.1 Introduction 
Chemotherapy is one of the most common and successful anti-cancer treatments, 
however it is associated with a range of related symptoms. This chapter will, firstly, 
consider ‘symptoms’ and the ‘symptom experience’ in general, before moving on to 
review the body of research, developed over the last 3 decades, that specifically 
explores patients’ experiences of chemotherapy-related symptoms. 
2.2 Symptoms and the symptom experience 
Multiple definitions of ‘symptom’ have been developed, but they all agree that 
symptoms can be defined as a subjective experience reflecting changes in the 
biopsychosocial functioning, sensations or cognition of an individual (Giardino and 
Wolf 1993; Hegyvary 1993; McDaniel and Rhodes 1995; Larson et al. 1999; Dodd 
et al. 2001a; Fu et al. 2004; Larson et al. 1994). Lexical information and the 
literature support the assumption that a symptom is an experience that is perceived 
and verified only by the individual experiencing the phenomenon (Fu et al. 2004), 
making a symptom subjective and experiential.  
Symptoms motivate people to seek care, they cause distress and they disrupt quality 
of life (Caldwell and Miaskowski 2000). There is a growing body of evidence that 
supports the concept of symptom clusters, which can be defined as: three or more 
concurrent symptoms that are related to each other (Dodd et al. 2001b). This 
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concept of symptom clusters will be returned to in the discussion chapter of this 
thesis. Because symptoms, either alone or arising in combination, can interfere with 
every element of a person’s life (Teel et al. 1997; Hyden and Sachs 1998; Dodd et 
al. 2001b), the term ‘symptom experience’ broadens the definition of symptom to 
include altered social interactions, diminished functional status and/or decreased 
economic capabilities. Indeed, in an analysis of multidisciplinary knowledge 
relating to chronic illness, the centrality of the symptom experience to the patient 
was highlighted (Dluhy 1995), a position supported by numerous authors (Bury 
1991; McWilliam et al. 1996; Liaschenko 1997). Moreover, the significance 
attached to a symptom by the patient strengthens the need for those caring for them 
to value, as well as relieve or control, the symptom (Baumann et al. 1989; Vessey 
and Richardson 1993; Peay and Peay 1998; Russell et al. 1998). Thus, symptoms 
are more than ‘simply the windows into a disease process… and demand more than 
control or elimination’ (Haworth and Dluhy 2001, p303). Instead, managing 
symptoms from a nursing perspective requires understanding the person’s 
experience and the meanings they associate with each symptom. This concept of 
understanding and appreciation of the symptom experience is reflected in the 
symptom experience component of the Symptom Management Model (Larson et al. 
1994). 
2.3 The Symptom Management Model 
The Symptom Management Model (SMM), first published in 1994 by Larson and 
her colleagues and later revised by Dodd and her colleagues in 2001, provides a 
holistic perspective of symptoms. It has been developed and tested using a wide 
range of symptoms, including cancer and cancer-treatment related symptoms (Wells 
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et al. 2007; Im 2006), and is practical and straightforward, so useful for clinical 
practice, both of which make the model appropriate for consideration within this 
thesis. It provides a generic conceptual framework based on the premise that 
effective management of any given symptom requires that symptom experience, 
symptom management strategies and symptom outcomes are considered. The model 
presents a comprehensive organising structure that includes a broad array of 
variables well suited to understanding and characterising symptoms. The symptom 
experience component is comprised of the perception, evaluation and response to a 
symptom; the symptom management component investigates interventions used to 
manage the symptom experience; while the resulting outcomes component 
evaluates symptom status, including quality of life, mortality and morbidity.  
2.3.1 Component parts of the symptom experience 
Understanding the symptom experience includes developing an appreciation of the 
inter-relationship between an individual’s perception of a symptom, evaluation of 
the meaning of the symptom, and response to a symptom (see Figure 3). Based on 
work undertaken following the initial development of the model by Larson et al 
(1994), Dodd et al (2001) described the perception and evaluation of and response 
to symptoms. 
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Figure 3: The symptom experience component of the SSM 
 
Perception of symptoms refers to whether an individual notices a difference from 
the way they usually feel or behave. For a valid self-report of symptoms, the person 
reporting must be responding to their perception of the symptom (Dodd et al. 
2001a). Indeed, differences in symptom perceptions have been consistently shown 
between patients, family and professional carers (Vogelzang et al. 1997; Stone et al. 
2003; Eisenberg et al. 2003; Grunberg et al. 2004; Fromme et al. 2004; Liau et al. 
2005). Additionally, factors such as culture and developmental stage also have a 
bearing on perceptions of symptoms (Dodd et al. 2001a).  
Evaluation of symptoms is undertaken by making judgements about the severity, 
cause, treatability and the effect of symptoms on an individual’s life and involves a 
complex set of factors that characterise the symptom experience, including 
Symptom 
experience
Perception 
of 
symptoms
Evaluation 
of 
symptoms
Response 
to 
symptoms
(Dodd et al 2001)
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intensity, location, temporal nature, frequency, and affective impact (Dodd et al. 
2001a).  
Finally, response to symptoms can be physiological, psychological, sociocultural or 
behavioural. Indeed, one or more of these responses can be seen with a single 
symptom (Dodd et al. 2001a).  
However, it is important to note that the most intense or frequent symptom 
experiences are not consistently the most distressing for patients (Rhodes et al. 
1984), a concept that could be lost within the SMM. The reason for differences 
between intensity, frequency and distress may be because symptom distress relates 
to meanings that the symptom or illness itself holds for individuals as well as the 
fact that the meanings ascribed to symptoms are relative to one’s personal life 
situation (McClement et al. 1997), that is, the individual human response to 
symptom occurrence. Thus, the extent of physical or mental anguish related to a 
symptom is dependent upon the individual’s subjective perceptions. Consequently, 
the symptom experience is subjective, and so, understanding patients’ experiences 
of chemotherapy-related symptoms, a key component of this thesis, relies on reports 
from patients themselves. The SMM was used to guide the choice of the symptom 
questionnaire and development of the interview schedule used within the SNA↔P 
study (details of which are presented in chapter 6) to ensure that the essential 
variables were included in order to understand and characterise patients’ symptom 
experiences. A growing body of evidence has been built concerning patients’ 
experiences of chemotherapy-related symptoms and is presented in the following 
section.  
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2.4 Patients’ experiences of chemotherapy-related symptoms 
Health professionals need to understand patients’ experiences of symptoms to allow 
them to meet their symptom management needs. During the previous 3 decades, 
efforts have been made to better understand which chemotherapy-related symptoms 
patients perceive as being the most important or troubling. Ranking techniques, that 
is, asking patients to rank symptoms in order of importance, have been used in a 
number of studies (Coates et al. 1983; Griffin et al. 1996; de Boer-Dennert et al. 
1997; Carelle et al. 2002), while other techniques including interviews, symptom 
diaries and questionnaires have also been implemented (Love et al. 1989; Tierney et 
al. 1991; Cooper and Georgiou 1992; Sitzia et al. 1995; Foltz et al. 1996; Lindley et 
al. 1999; Tierney et al. 1992). The results of these studies are presented below 
according to the techniques they adopted. 
2.4.1 Studies using ranking techniques 
Four groups of medical researchers have explored patients’ experiences of 
chemotherapy-related symptoms using a near-identical survey and ranking 
technique (Coates et al. 1983; Griffin et al. 1996; de Boer-Dennert et al. 1997; 
Carelle et al. 2002). This technique involved using 2 groups of cards (Group A: 45 
cards listing physical chemotherapy-related symptoms, and Group B: 28 cards 
listing non-physical chemotherapy-related symptoms), and asking patients to select 
any card that they attributed to their current chemotherapy. Patients were asked to 
rank the cards they had selected from each group, and the top 5 cards from each 
group were combined. Patients were then asked to identify the 5 most severe 
symptoms regardless of group, putting them in order from most to least severe. In 
an effort to obtain a ranking of the relative severity of symptoms, a scale was 
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defined by which 5 points were allocated to the symptom ranked as most severe, 
decreasing to one point for that symptom ranked as 5th. The points allocated to each 
symptom were then added and expressed as a percentage of the number of patients 
in the group to give an overall score. The results of these studies are presented in 
Table 2.  
Table 2: Comparison of symptom ranking studies 
 Coates et al 
(1983) 
Griffin et al 
(1996) 
de Boer-
Dennert et al 
(1997) 
Carelle et al 
(2002) 
1 Being sick 
(vomiting) 
Feeling sick 
(nausea) 
Feeling sick 
(nausea) 
Affects my 
family or partner 
2 Feeling sick 
(nausea) 
Constantly tired Loss of hair Loss of hair 
3 Loss of hair Affects my 
family or partner 
Being sick 
(vomiting) 
Constantly tired 
4 Thought of 
coming for 
treatment 
Not reported Constantly tired Affects my 
work, home 
duties 
5 Length of time 
treatment takes 
at clinic 
Being sick 
(vomiting) 
Having to have 
an injection 
Affects my 
social activities 
6 Having to have 
an injection 
Not reported Constipation Loss of sexual 
feelings 
7 Shortness of 
breath 
Not reported Thought of 
coming for 
treatment 
Giddiness on 
standing up 
8 Constantly tired Not reported Affects family or 
partner 
Diarrhoea 
9 Difficulty 
sleeping 
Not reported Feeling low, 
miserable 
(depression) 
Weight gain 
10 Affects my 
family or partner 
Not reported Feeling anxious 
or tense  
Shortness of 
breath 
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Table 2 demonstrates the plethora of symptoms that patients identify when asked to 
rank the symptoms they experience during chemotherapy treatment. However, it 
should be recognised that the pool of symptoms from which patients were invited to 
choose was developed by Coates et al (1983), and, although designed to be 
comprehensive, they were, necessarily, limited. Moreover, they were developed by 
the researchers themselves without patient involvement and so, were inherently 
open to personal and professional biases. That said, patients did not add to this list 
of symptoms when asked to do so following their involvement in the study. 
Comparison of the studies is complicated by differences in the study populations 
that differ with respect to diagnosis, chemotherapy treatment, number of 
chemotherapy treatments received, age, and gender. The original work by Coates 
and colleagues included only patients with advanced cancer which, although 
appropriate at the time when most chemotherapy was given with palliative rather 
than curative intent, does not apply to today’s climate of treatment intent. Indeed, it 
is important to consider whether symptom experiences are likely to differ according 
to the aim of treatment, be it curative or palliative. This question could have been 
addressed by Griffin et al (1996), who included both patients receiving curative and 
palliative chemotherapy, however, as they aimed to compare their results with 
Coates’ earlier work, they failed to report the results of those patients receiving 
curative treatment. While this was a sensible decision from a methodological 
perspective, it failed to address a clinically interesting and important question. 
Neither de Boer-Dennert (1997) nor Carelle (2002) described their population in 
relation to treatment intent. However, all 4 studies did involve a range of cancer 
diagnoses and, although heterogeneity within a sample is not always problematic, in 
such studies where the cancer diagnosis and chemotherapy regime is likely to have a 
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bearing on patients’ symptoms experiences, it may reduce the power of the analyses 
and the conclusions which can be drawn from them.  
Inconsistent use of terminology also complicates the comparison of these ranking 
studies. During the initial ranking process, patients were asked to rank their 
symptoms according to ‘severity’ (Coates et al. 1983; Carelle et al. 2002), 
‘troublesomeness’ (Griffin et al. 1996), or ‘distress’ (de Boer-Dennert et al. 1997), 
while the second ranking was, in the main, based on ‘severity’ of the symptoms 
(Coates et al. 1983; Griffin et al. 1996; Carelle et al. 2002). However, ranking 
according to distress continued to be used by de Boer-Dennert and his colleagues 
(1997). Indeed, while de Boer-Dennert and his colleagues sought to validate their 
results by comparing them with those of Coates (1983) and Griffin (1996), one can 
question whether this comparison is feasible, given the differences in terminology 
(severe, troublesome and distressing) used in the three studies.  
It is also important to note that all these studies, apart from that by Coates et al in 
1983, were conducted following the introduction of 5HT3 receptor antagonists 
during the early 1990s, heralded as significant progress in the management of 
chemotherapy-related nausea and vomiting, and expected to significantly improve 
patients’ experiences of these two symptoms (Kaiser et al. 1994; Campora et al. 
1994; Franchi and Zamnaboni 1995; Morrow et al. 1995). While Chapter 3 explores 
the actual impact of 5-HT3 receptor antagonists on nausea, the general picture 
presented from these ranking studies suggests that although patients’ experiences of 
vomiting improved, nausea remained a symptom of significant concern. 
Furthermore, one can question whether ‘symptoms’ such as ‘the thought of coming 
for treatment’, ‘length of time treatment takes at clinic’ and ‘having to have an 
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injection’ are actual symptoms of chemotherapy or whether they are consequences 
of service delivery. Certainly, within the summary definition of symptoms used in 
this thesis (see page 11) that identifies a symptom as a subjective experience 
reflecting changes in the biopsychosocial functioning, sensations or cognition of an 
individual, such physical processes involved with chemotherapy administration 
would not be considered symptoms at all. Such ‘symptoms’ were not included in the 
second group of studies that used a range of techniques to explore patients’ 
symptom experiences during chemotherapy.  
2.4.2 Studies using miscellaneous techniques 
Perhaps in recognition of the limitations of the ranking technique described above, a 
number of studies adopted alternative methods to explore patients’ perceptions of 
chemotherapy-related symptoms. These studies vary widely in their choice of 
methods, and a combination of structured and unstructured approaches to explore 
symptoms was frequently used (see Table 3). In all studies, the questionnaires and 
interview schedules were developed specifically for the study, and in all but one 
(Sitzia et al. 1995), little detail was provided of the process of development and 
testing of the tool.  
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Table 3: Miscellaneous methods of exploring symptom experiences 
Authors Methods used 
Love et al (1989) Longitudinal semi-structured interviews, daily diary containing 
13 symptoms to be rated 0-11 for severity 
Tierney et al 
(1991, 1992) 
Interviews and single questionnaire at end of treatment 
Cooper & 
Georgiou (1992) 
Symptom and quality of life questionnaires (no further detail 
provided) 
Sitzia et al 
(1995) 
Longitudinal ranking of physical symptoms over at least 3 
cycles of chemotherapy 
Foltz et al (1996) Self-care diary 
Lindley et al 
(1999) 
5 point likert scale for 41 chemotherapy-related symptoms, 
serial ranking questionnaire adapted from Coates et al 1983 
The results of these studies, as well as the component of the symptom experience 
that each study sought to explore (symptom distress, severity or frequency), can be 
seen in Table 4. As with the ranking studies described in Table 2, Table 4 shows the 
plethora of physical symptoms that patients experience as a consequence of their 
chemotherapy.   
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Table 4: Results of symptom experience studies 
Love et al 
(1989) 
Tierney et al 
(1991) 
Cooper & Georgiou 
(1992) 
Sitzia et al 
(1995) 
Foltz et al 
(1996) 
Most 
distressing 
symptoms 
Most 
frequent 
symptoms 
Most 
frequent 
symptoms
Most 
distressing 
symptom 
Most 
troublesome 
symptoms 
Most severe 
symptoms 
Tiredness Alopecia Tiredness Tiredness Alopecia 
Nausea Tiredness Alopecia Hair loss Fatigue 
Loss of 
appetite 
Lack of 
energy 
Nausea Nausea Nausea 
Mouth sores Decreased 
sexual 
interest 
 Night sweat Taste change 
Pain   Difficulty 
sleeping 
Appetite loss 
sickness   Feeling 
generally 
unwell 
Sleep 
problems 
Sore eyes   Difficulty 
concentrating 
Constipation 
   Dry mouth Headache 
   Weight up Sore mouth 
Nausea, 
alopecia & 
tiredness 
experienced 
by >80% of 
patients. 
   Physical 
weakness 
Pain 
There are a number of positive aspects of these studies that should be highlighted. 
The first of these is the longitudinal evaluation of symptom experiences (Love et al. 
1989; Sitzia et al. 1995) that takes into consideration the potential for changes in 
symptoms over time. Through such longitudinal evaluation, Love and colleagues 
(1989) demonstrated that patients perceive an increase in the ‘difficulty’ of 
chemotherapy over time due to their symptom experiences, with the number of 
different symptoms acting as the best predictor of the level of ‘difficulty’. It was 
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also positive that Tierney and her colleagues (1991, 1992) sought to explore 
symptom experiences within a homogenous population of women with breast 
cancer. However, this sample was compromised somewhat, as it included women 
receiving both curative and palliative chemotherapy. Finally, Cooper and Georgiou 
(1992) attempted to capture a multidimensional picture of symptom experiences 
through exploring both the frequency and associated distress of patients’ 
chemotherapy-related symptoms.  
Nevertheless despite these shortcomings, these studies do replicate many of the 
limitations of the previous symptom ranking research. There was continued 
arbitrary selection of symptoms for inclusion within questionnaires and interviews 
(Love et al. 1989; Tierney et al. 1991; Tierney et al. 1992; Cooper and Georgiou 
1992; Foltz et al. 1996) with Sitzia and his colleagues (1995) being the only 
researchers to involve patients in the identification of symptoms to be evaluated. 
Also, there was variation in the terminology used with regards to which component 
of the symptom experience was being evaluated (see Table 4). Furthermore, the 
heterogeneous populations involved in each study with respect, not only to 
diagnosis, but also chemotherapy treatment, treatment intent, in-/out-patient 
treatment, gender and age, complicates drawing comparisons between each of the 
studies.  
2.4.3 Comparing and contrasting results from ranking studies and 
those employing miscellaneous approaches 
Despite the limitations of both the ranking replication studies and those that 
employed a range of approaches, or perhaps because of them, it is clear that, 
regardless of diagnosis, chemotherapy treatment, treatment intent, age, gender and 
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the component of the symptom being explored, patients experience a wide range of 
symptoms as a consequence of their chemotherapy. The results of both the ranking 
studies and those that adopted multiple methods to explore symptom experiences 
have been combined and are presented in Table 5. This table shows that patients 
identified 32 physical and psychological symptoms, social consequences, or 
physical processes involved with chemotherapy administration. Physical symptoms 
were, by far, the most commonly identified, perhaps as they were the focus of the 
studies that employed miscellaneous approaches to explore symptom experiences. 
Indeed, as the researchers were predominantly responsible for determining the 
symptoms for ranking or discussion within each of the studies, it is likely that the 
focus on physical symptoms is due to the preferences, conscious or otherwise, of the 
researchers themselves, rather than those of the patients. 
Combining the results of these 10 studies (as seen in Table 5) provides illuminating 
results. Three symptoms stand out from the others with regards to the frequency of 
their reports: tiredness, nausea and alopecia being identified 10, 9 and 8 times 
respectively out of a possible 10. However, not only are they the most frequently 
identified symptoms, tables 2 (page 17) and 4 (page 22), in which symptoms were 
ranked in order of importance to the patient, demonstrate that in 8 out of the 10 
studies, fatigue, alopecia and nausea were consistently ranked by patients within 
their top 4 symptoms of concern. Although these are three completely different 
symptoms, nausea and fatigue are similar in the fact that they are non-observable 
and, as such, present a considerable challenge to oncology health professionals in 
relation to their assessment and subsequent management. These symptoms were 
consequently chosen as the symptoms of focus within this thesis.  
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Table 5: Combined results of ranking and miscellaneous studies exploring chemotherapy-
related symptoms 
 Ranking 
technique: 
times 
symptom 
identified 
(out of a 
possible 4) 
Miscellaneous 
techniques: 
times symptom 
identified (out 
of a possible 6) 
Total times 
symptom 
identified 
(out of a 
possible10) 
Physical symptoms 
Symptom class Descriptor  
Constantly tired 4 -- 4 
Tired -- 6 6 
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Lack of energy -- 1 1 
Difficulty sleeping 1 2 3 
 
 
Tiredness 
Physical weakness -- 1 1 
Alopecia 3 5 8 Appearance 
Weight gain 1 1 2 
Nausea 3 6 9 
Vomiting 3 1 4 
Mouth sores -- 2 2 
Appetite loss -- 2 2 
Dry mouth -- 1 1 
 
 
Upper 
gastrointestinal 
Taste change -- 1 1 
Constipation -- 1 1 Lower 
gastrointestinal Diarrhoea 1 -- 1 
Pain -- 2 2 Pain 
Headache -- 1 1 
Respiratory Shortness of breath 2 -- 2 
Giddiness on 
standing up 
1 -- 1 
Night sweat -- 1 1 
Sore eyes -- 1 1 
 
Other 
Generally unwell -- 1 1 
Psychological symptoms 
Depression 1 -- 1 
Anxiety 1 -- 1 
Difficulty concentrating -- 1 1 
Social consequences 
Affects family/partner 4 -- 4 
Affects work/home duties 1 -- 1 
Affects social activities 1 -- 1 
Loss of sexual feelings 1 1 2 
Physical process involved with chemotherapy administration 
Thought of coming for treatment 2 -- 2 
Length of time treatment takes at clinic 1 -- 1 
Having to have an injection 2 -- 2 
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2.5 Conclusion 
This chapter firstly presented a summary definition of symptoms in general as well 
as highlighting and describing the component parts that should be considered when 
exploring patients’ symptom experiences. Thereafter, it demonstrated the plethora 
of symptoms that patients experience as a consequence of chemotherapy through a 
number of studies that employed a range of research techniques. Comparing and 
contrasting this body of research evidence, despite its methodological flaws, has 
shown that chemotherapy-related nausea and fatigue were not only the most 
frequently identified symptoms but were also consistently highly ranked symptoms.  
Ranking and ordering of symptoms are helpful in understanding the variety of 
symptoms that patients experience, as are their perceptions regarding which 
symptoms are most severe or distressing. However, this approach does not provide 
insight into why patients have ranked specific symptoms and how it feels to 
experience them. It also raises questions with regards to currently available 
intervention strategies for managing or alleviating these symptoms and so 
improving patients’ symptom experiences. Such issues are especially important for 
chemotherapy-related nausea and fatigue, as they are non-observable symptoms, a 
fact which challenges their assessment and complicates their management. The 
following two chapters will provide further detail on chemotherapy-related nausea 
and fatigue respectively, with regards to current assessment and interventions, and 
will seek to understand patients’ experiences of these symptoms.  
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3 CHAPTER 3 – CHEMOTHERAPY-RELATED NAUSEA 
3.1 Introduction 
This chapter will consider chemotherapy-related nausea. Chapter 2 demonstrated 
that chemotherapy-related nausea is not only one of the most frequently reported 
symptoms by patients, but is also highly ranked. However, such a ranking process 
does not explain why patients have identified the symptom, how it feels to 
experience that symptom, nor the available interventions or techniques that have the 
potential to improve this symptom experience. 
This chapter will briefly detail definitions of chemotherapy-related nausea, vomiting 
and retching as well as the various forms that chemotherapy-related nausea can take. 
It will then consider the current assessment tools and management interventions for 
chemotherapy-related nausea, demonstrating the various methods available to 
improve patients’ experiences. Thereafter, the literature detailing patients’ 
experiences of chemotherapy-related nausea and its impact on quality of life will be 
reviewed. Finally, possible reasons for patients’ continued negative experiences of 
chemotherapy-related nausea, despite currently available assessment and 
interventions, will be explored. 
3.2 Defining chemotherapy-related nausea 
The term ‘emesis’ has been used to collectively describe vomiting and retching 
(Hesketh et al. 1998) as well as nausea, vomiting and retching (Multinational 
Association of Supportive Care in Cancer 1998). However, nausea, vomiting and 
retching are 3 distinct symptoms that should be clearly defined and understood to 
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ensure accurate assessment and subsequent management. Thus, to ensure clarity 
throughout the remainder of this thesis, the following definitions will be used for 
each.  
Nausea has been defined as a subjective and unobservable phenomenon of an 
unpleasant sensation often associated with a feeling that vomiting is imminent 
(Andrews 1996). This definition is appropriate for this thesis as it highlights the 
subjective and non-observable nature of nausea while recognising that it is an 
unpleasant sensation. It is also in keeping with the summarised definition of a 
symptom given in chapter 2, as it refers to subjective experiences and a change in 
sensation. However, it is important to note that chemotherapy-related nausea does 
not always culminate in vomiting. Moreover, while essentially non-observable, 
nausea can be accompanied by objectively observable activity of the autonomic 
nervous system causing pupil dilation, cutaneous vasoconstriction, sweating, 
salivation, tachycardia, and gastric relaxation (Morrow et al. 2002). Vomiting is the 
forceful expulsion of the contents of the stomach through the oral or nasal cavity 
(Rhodes and McDaniel 2001), while retching is the attempt to vomit, and has been 
described by patients as ‘dry heaves’ and ‘gagging’ (Rhodes and McDaniel 2001).  
Chemotherapy-related nausea has been classified into 5 distinct categories:  
• Acute - occurring within the first 24 hours following chemotherapy 
administration (Jordan et al. 2005); 
• Delayed - beginning the day following chemotherapy administration and 
may last 6-7 days (Kris et al. 1994; National Comprehensive Cancer 
Network 2007b); 
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• Anticipatory – learned from previous experiences or associations and 
experienced at any time prior to the administration of chemotherapy or when 
the patient thinks of aspects relating to chemotherapy (Morrow et al. 1998); 
• Breakthrough – nausea that occurs despite optimal preventative therapy in 
the acute or delayed phase and that requires additional therapy (Aapro 
2002); 
• Refractory – failure to respond to prevention and/or intervention during the 
previous cycle of chemotherapy (Aapro 2002). 
This thesis focuses on an intervention to improve patients’ experiences of 
chemotherapy-related nausea following chemotherapy administration and, as such, 
the remainder of this chapter will not include literature that addresses anticipatory 
nausea. Much of the literature addressing nausea also includes vomiting, however, 
where possible, only the evidence concerning nausea will be presented. 
3.3 Assessing chemotherapy-related nausea 
Assessment and documentation of nausea, as well as an evaluation of the 
effectiveness of any treatment, are essential components of optimal symptom 
control (Rhodes 1997) and, as such, are important tasks for nurses caring for people 
with chemotherapy-induced nausea. This assessment is necessarily an ongoing 
process, beginning with the patient’s initial consultation and continuing throughout 
their entire treatment journey, and involves skilful observation and effective, 
efficient methods of information collection. During chemotherapy treatment the 
ideal assessment tool would be quick to complete and review while simultaneously 
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capturing the symptom experience. However, three factors complicate the 
assessment of chemotherapy-related nausea.  
3.3.1 Factors complicating the assessment of nausea   
The first factor complicating the assessment of chemotherapy-related nausea is its 
close association with vomiting. Despite the fact that nausea and vomiting are 
distinct entities with their own physiology, the terms used to describe them are used 
interchangeably (Hesketh et al. 1998; Multinational Association of Supportive Care 
in Cancer 1998), leading to confusion both in practice and research. Large 
randomised trials often fail to distinguish between the two symptoms, assessing and, 
subsequently, presenting data for these symptoms simultaneously (Hesketh 2000; 
Gralla et al. 2003). This perpetuates the belief that these symptoms do not occur 
independently and prevents a full understanding of each symptom in relation to its 
appropriate assessment and interventions.  
Secondly, despite physiological changes such as pupil dilation, sweating, salivation 
and tachycardia, chemotherapy-related nausea is difficult to observe. Both 
physicians and nurses have been shown to consistently and substantially 
underestimate the incidence of both acute and delayed nausea (Eisenberg et al. 
2003; Grunberg et al. 2004), especially in relation to moderately emetogenic 
chemotherapy (Liau et al. 2005). Such a discrepancy between those experiencing 
nausea and those caring for them is cause for concern and may compromise optimal 
assessment and management. As such, chemotherapy-related nausea is best 
measured subjectively by the person experiencing it (Jenns 1994).  
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Most patients receive chemotherapy as an out-patient, leaving the hospital shortly 
after chemotherapy administration is complete. However, the practice of symptom 
assessment is characteristically performed when patients return to the clinical 
setting for further treatment or review (Brown et al. 2001). This complicates the 
assessment of nausea, as many patients experience it while at home, away from the 
presence, support and assessment of oncology health professionals. One could argue 
that by the time patients return for their subsequent cycle of chemotherapy, usually 
three-to-four weeks later, their recollction of nausea experiences and its impact on 
their quality of life will be diminished. Moreover, as health professionals do not 
witness first hand the severity and distress that can accompany chemotherapy-
related nausea, one could argue that they may not fully appreciate the severity or 
distress associated with the symptom. 
Thus, the assessment of nausea is challenging, not only because of its frequent 
association with vomiting, but also because it is non-observable. Furthermore, 
patients’ experiences of nausea are seldom witnessed first hand by health 
professionals. However, there are a number of factors that can be assessed to 
promote the effective management of nausea. The first involves the assessment of 
specific risk factors associated with higher levels of nausea and the second involves 
the assessment of actual nausea experiences, so allowing health professionals to 
initiate appropriate interventions or evaluate the effectiveness of specific 
management techniques.  
32 
3.3.2 Assessment of risk factors associated with chemotherapy-
related nausea 
One could argue that assessing for personal factors associated with increased 
susceptibility to chemotherapy-induced nausea would allow nursing staff to ensure 
that patients with an increased risk are treated with more aggressive interventions. 
There are a range of individual characteristics, both physiological and 
psychological, that predispose individuals to experience chemotherapy-induced 
nausea.  
Patients’ expectations of developing nausea have been consistently shown to be 
associated with post-treatment nausea in a number of studies (Rhodes et al. 1988; 
Haut et al. 1991; Rhodes et al. 1995; Roscoe et al. 2000; Molassiotis et al. 2002a), 
although earlier studies that refute such an association do exist (Cassileth et al. 
1985; Andrykowski and Gregg 1992). A number of other factors have been 
identified as potentially or partly associated with the development of chemotherapy-
induced nausea. These include:  
• Age – a younger age (<50 years old or <40 years in some studies) has been 
shown to be associated with greater nausea (Morrow et al. 1991; Molassiotis 
et al. 2002a) 
• Gender – females are more likely to experience nausea than males (du Bois 
et al. 1992; Osoba et al. 1997a) 
• Susceptibility to nausea when eating certain foods (Jacobsen et al. 1988) 
• The taste of drugs during the infusion (Nerenz et al. 1986) 
• Low alcohol use (Osoba et al. 1997a) 
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• Psychological status and stress (Tsavaris et al. 1991; Dibble et al. 2003; 
Higgins et al. 2007) 
• Previous history of labyrinthitis or vestibular dysfunction (Molassiotis et al. 
2002a) 
• Susceptibility to motion sickness (Morrow 1985; Leventhal et al. 1988; 
Morrow et al. 1991) 
• Experience of acute nausea is predictive of delayed nausea (Molassiotis et 
al. 2002a) 
There is also a growing and frequently updated knowledge base that classifies 
chemotherapy agents and regimes according to their emetogenic potential (Laszalo 
1982; Strum et al. 1984; Craig and Powell 1987; Lindley et al. 1989; Aapro 1993; 
Hesketh et al. 1997; Grunberg et al. 2004). Indeed, this classification is used to 
guide clinicians as to the most appropriate pharmacological antiemetic therapies for 
prescription (National Comprehensive Cancer Network 2007a). However, this 
classification is calculated solely on the risk of vomiting. While the basis for this 
classification limits its relevance to this thesis, it provides an example of how 
experiences of nausea are often overlooked in favour of vomiting.  
3.3.3 Assessment of experiences of chemotherapy-related nausea 
There are a range of methods available for assessing chemotherapy-related nausea. 
It is important that an assessment tool clearly distinguishes between the phenomena 
of nausea, vomiting and retching, using patient-friendly descriptors to dispel the 
confusion between these three symptoms (Kaye 1991). Indeed, a rounded 
assessment that describes the patient’s symptom experience in terms of frequency, 
severity and distress will provide the most accurate and complete picture of the 
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symptom and so facilitate implementation of the most appropriate interventions 
(Rhodes and McDaniel 1999). The range of tools available to assess chemotherapy-
related nausea, with details of their development and usability, can be found in 
Table 6.
 Table 6: Nausea assessment tools 
Unidimensional tools 
Instrument/author Consists of Clinical utility 
CTCAE 
National Cancer Institute 
(1999), Trotti et al (2003) 
Range of treatment-related 
symptoms to be graded from 
0-4 by a health professional 
Quick to complete. Physician-led, relates nausea to patients’ 
functional ability to eat, does not consider frequency, severity or 
distress, no data to substantiate validity 
VAS (Visual Analogue 
Scale) 
 
 
A 10cm horizontal line and 
verbal ‘anchors’ such as ‘no 
nausea’ and ‘worst possible 
nausea’ and patients are 
asked to rate their subjective 
experience 
Simple and quick way of assessing symptoms from the patients’ 
perspective, avoids language descriptors to signify graduations of a 
subjective phenomena, sensitive, reliable and valid tools when used 
properly. Verbal anchors should be tested for understanding by and 
meaningfulness to patients, respondents find the instructions on their 
use confusing, patients need thorough instruction from trained 
personnel to ensure reliable answers which has the potential to 
introduce investigator-related bias, as designed to be used with 
seated subjects there has been questions raised as to their reliability 
with supine patients 
Ordinal Scales 
 
Grades of nausea such as ‘no 
nausea’, ‘mild’, ‘moderate’ or 
‘severe’ and patients are 
asked to indicate which most 
describes their nausea 
Easier than VAS for clinicians and researchers to interpret, requires 
less patient instruction than VAS. May become less sensitive over 
time than VAS in detecting change due to their limited responses 
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 Multidimensional tools 
Instrument/author Domains of 
factors 
No. of items 
& scaling 
Reliability & Validity Clinical utility 
Index of Nausea Vomiting 
and Retching 
(INVR) 
Rhodes and Watson 
(1984), Rhodes and 
McDaniel (1999) 
Nausea. Vomiting 
and retching and 
the components 
(frequency/ 
amount, duration, 
severity, distress) 
of each symptom 
8 total, 5 
occurrence,
3 distress 
5 point 
Likert scale 
Reliability: 
Spearman correlation total: 
0.87 individual items: 0.71-
0.95 
Equivalency: 79%-98% 
(p=0.05) 
Validity: 
Spearman’s correlation, 
r=0.87 
Ease of use. Provides 
information about nausea, 
vomiting and retching total 
experience, occurrence, distress 
and individual symptoms. 12 
hour time frame. Used with 
varied populations. No 
indication of time taken to 
complete 
Morrow Assessment of 
Nausea and Emesis 
(MANE) 
Morrow (1992) 
Anticipatory and 
post-treatment 
nausea and 
vomiting, 
frequency during 
and after 
treatment, 
duration, severity, 
time when worse 
16 
Severity – 6 
point scale 
Occurrence 
– yes/no 
Duration – 
number of 
Reliability: 
Test-retest reliability: 0.72-
0.96  
Validity: 
Convergent validity 0.26-
0.33 
Primarily used with antiemetic 
studies. Long time frame (24 
hours). 
Does not include the concept of 
symptom distress, 
No indication of time taken to 
complete 
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 hours 
Divergent validity 0.04-0.08 
Functional Living Index – 
Emesis  
(FLIE) 
Lindley et al (1992) 
Effect of nausea 
and vomiting on 
physical activity, 
social and 
emotional 
function and 
eating 
18 
9 nausea 
9 vomiting 
1-7, 7 point 
scale 
Reliability: 
Cronbach’s alpha 0.9 
Pearson item-scale 
correlations 0.40-0.82 pre-
treatment and 0.81-0.96 post-
treatment 
Validity: 
Factor analysis not reported 
Pearson correlation with 
nausea and vomiting 0.65 
and 0.68 
Correlation with Function 
Living Index – Cancer 
nausea factor – 0.83 
Ease of use. Provides 
information about the effect of 
nausea and vomiting on 
functional status. Correlates with 
quality of life measures.  
Patients were not involved in 
deciding the concepts addressed 
within the tool, 
No information available on time 
taken to complete the tool. 
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Table 6 demonstrates the variety of assessment tools. The choice of instrument 
should be guided by the purpose of the assessment. One could argue that some of 
the multidimensional specific tools such as the Index of Nausea and Vomiting 
(INVR) (Rhodes and McDaniel 1999) and the Morrow Assessment of Nausea and 
Emesis (MANE) (Morrow 1992) are too extensive, limiting their usefulness and 
appropriateness for daily clinical practice, as they demand both significant patient 
energy to complete and clinician time to evaluate. Visual analogue scales or ordinal 
scales may be preferred as an alternative for use in clinical practice, as they are 
quick and simple for patients to complete and for clinicians to interpret (Molassiotis 
and Borjeson 2006). A study that compared concordance between VAS and a 4-
point ordinal scale for assessing the intensity of nausea demonstrated good 
similarities between these two methods, making them both appropriate for use in 
clinical practice (Borjeson et al. 1997), however, no data was provided as to the 
relative reliability and validity of each method. A more in-depth evaluation of 
nausea, such as that obtained through multidimensional instruments such as INVR 
(Rhodes and McDaniel 1999), MANE (Morrow 1992) or Functional Living Index – 
Emesis (FLIE) (Lindley et al. 1992), while more time consuming to complete, may 
provide a more thorough and in-depth understanding, and so be wholly appropriate 
for use within a research setting. It is unfortunate that all the multidimensional 
assessment tools address nausea and vomiting and, as such, afford clinicians the 
opportunity to report vomiting data only in their evaluation of antiemetic therapies.  
The choice of tool should be based on the needs of the particular situation and 
should take into consideration patient individuality, that is, which tools are 
appropriate for which patients and at what specific times (Kaye 1991). Thus, 
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choosing the most appropriate tool provides clinicians and researchers with 
information about individuals’ experience of chemotherapy-related nausea. The next 
step is using this information to implement the most appropriate interventions for 
managing and alleviating chemotherapy-related nausea.  
3.4 Current management techniques for chemotherapy-related 
nausea 
The array of assessment tools for chemotherapy-related nausea is matched by a 
variety of management techniques. Within intervention studies, nausea and 
vomiting continue to be inextricably linked, with almost all studies exploring the 
impact of a particular intervention on both symptoms simultaneously (Morrow et al. 
1995; Roscoe et al. 2000; The Italian Group for Antiemetic Research 2000; Hesketh 
et al. 2003; Poli-Bigelli et al. 2003; Olver 2004; DeWalt and Haines 1969; Warr et 
al. 2005; de Wit et al. 2004). This association between nausea and vomiting makes 
it difficult to establish the most appropriate interventions for nausea alone. The 
following sections evaluate the current pharmacological and non-pharmacological 
interventions for chemotherapy-related nausea, alone when possible, or in tandem 
with vomiting. 
3.4.1 Pharmacological management of chemotherapy-related nausea 
Chemotherapy-related nausea is most commonly managed with antiemetic drugs. 
However, if nausea is experienced despite prophylactic treatment, changes in the 
drugs used can result in an improvement for patients (Koeller et al. 2002; Grunberg 
et al. 2005). Indeed, a combination of antiemetic drugs with different modes of 
actions, is often necessary to provide optimal symptom control (Jordan et al. 2005). 
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Table 7 provides a summary of the main classes of antiemetic drugs, their actions, 
uses, and clinical considerations. 
 
 
 Table 7: Main classes of pharmacological antiemetic therapies 
Class of drug Mode of action Clinical uses Potential side-effects Clinical considerations 
5-HT3 receptor 
antagonists  
e.g. Dolasetron 
Granisetron 
Ondansetron 
Tropisetron 
Inhibits selective 5-
HT3 receptor sites both 
centrally and in the GI 
tract 
Moderate to highly 
emetogenic 
chemotherapy 
Constipation, headache, 
transient light-headedness 
may occur during infusion 
Ideal for use in elderly patients 
Use with stool softener, increased fluids 
and bran to prevent constipation 
Efficacy increased when used on 
conjunction with corticosteroids 
NK1 receptor 
antagonist 
e.g. Aprepitant 
 
Acts centrally Highly and moderately 
emetogenic 
chemotherapy 
Weakness, excessive 
fatigue, dizziness, 
diarrhoea, constipation, 
stomach pain or upset, 
hiccups, loss of appetite.  
Impact on chemotherapy-induced acute 
and delayed nausea remains under 
question 
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 Class of drug Mode of action Clinical uses Potential side-effects Clinical considerations 
Benzamides 
e.g. 
Metoclopramide 
 
Dopamine receptor and 
5-HT3 receptor (low 
affinity) inhibition, 
increase in gastric 
emptying 
Beneficial in managing 
the effects of low to 
moderately emetogenic 
chemotherapy regimes 
Associated with extreme 
extrapyramidal side effects, 
especially in those aged 
under 30 years of age 
The risk of agitation and dystonic 
reactions can be minimised by infusing 
the drug over 30 minutes in conjunction 
with Diphenhydramine. 
Enhances gastric emptying so combating 
the sense of fullness caused by gastric 
stasis, heartburn caused by 
chemotherapy and the slowed colonic 
transit time caused by 5HT3 receptor 
antagonists 
Corticosteroids 
e.g. 
Dexamethasone 
Betamethasone 
 
Uncertain Used for both acute and 
delayed emesis 
May cause psychotic 
reactions and affect 
glucose metabolism as well 
as agitation, insomnia, 
increased appetite and 
euphoria 
Perirectal burning, commonly felt when 
Dexamethasone is administered 
intravenously, can be avoided by 
increasing the length of infusion time to 
10 minutes 
Benzodiazepines 
e.g. Lorazepam 
Diazepam  
Anxiolytic, sedative Most effective in 
alleviating anticipatory 
nausea and vomiting 
and in reducing anxiety 
Causes all levels of CNS 
depression 
Should be used with caution in older 
patients and those with compromised 
respiratory status as well as patients with 
compromised hepatic or renal function 
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 Class of drug Mode of action Clinical uses Potential side-effects Clinical considerations 
Phenothiazines 
e.g. 
Prochlorperazine 
Dixyrazine 
Mainly dopamine 
receptor blockade 
Mild emetogenic 
chemotherapy 
Can be used in 
combination with 
5HT3 receptor 
antagonists 
Sustained release form 
may prevent delayed 
nausea and vomiting 
induced by 
chemotherapy 
Extrapyramidal reactions 
(especially if aged 30 years 
or younger) 
Prophylactic Diphenhydramine or 
Benztropine may be given to prevent 
extrapyramidal reactions 
Older patients may experience excessive 
sedation, fatigue and an unsteady gait 
requiring dose adjustment 
Butyrophenones 
e.g. Haloperidol 
Droperidol 
Mainly dopamine 
receptor blockade 
Most useful when 
anxiety and 
anticipatory symptoms 
aggravate the degree 
and intensity of the 
nausea and vomiting 
experienced by patients 
Akathisia, dystonic 
reactions and severe 
extrapyramidal effects 
When these drugs are used in 
combination with other central nervous 
system depressants, their effects can be 
additive 
Cannabinoids 
e.g. Nabilone 
Dronabilone 
Cannabinoid receptor 
blockade 
May be useful in 
patients who have a 
low tolerance or 
minimal response to 
other antiemetics 
Short-term use of 
marijuana has been shown 
to lead to sedation, a high 
and smoking intolerance in 
some patients. 
Poorly tolerated by older people. Should 
be used with caution in patients 
suffering from hypertension or heart 
disease as well as those patients already 
receiving sympathomimetic drugs 
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Despite advances in the anti-emetic therapies detailed in Table 7, nausea remains a 
significant problem for patients receiving chemotherapy (Morrow et al. 1995; 
Roscoe et al. 2000; The Italian Group for Antiemetic Research 2000). Two large 
evaluation studies have demonstrated that while the introduction of 5-HT3 receptor 
antagonists were effective in mitigating against vomiting, they were less successful 
in controlling nausea (Morrow et al. 1995; Roscoe et al. 2000). The evaluation by 
Morrow et al (1995) highlighted that for all 5HT3 receptor antagonists except 
granisetron, a complete response is defined as someone who experienced no 
vomiting throughout the 24 hours following chemotherapy administration. 
Consequently, the use of the endpoint ‘complete control’ is potentially misleading 
as a patient could feel very nauseated yet be judged as a ‘complete responder’. 
Moreover, in the studies in which nausea was evaluated, its control remained 
incomplete for approximately half the patients who received a 5HT3 receptor 
antagonist (Morrow et al. 1995). This finding was supported by a later study of 
1,413 patients’ experiences of nausea (and vomiting) following the introduction of 
5HT3 receptor antagonists. This study showed that although patients’ frequency of 
vomiting episodes was improved, the frequency of post-chemotherapy nausea did 
not (Roscoe et al. 2000).  Moreover there was an average increase in the duration of 
nausea following chemotherapy administration (Roscoe et al. 2000). Further large 
scale research by The Italian Group for Antiemetic Research (2000) involving 705 
patients receiving moderately emetogenic chemotherapy showed that despite 
optimal antiemetic therapy of 5HT3 receptor antagonists and steroids, 57.1% of 
patients experienced delayed nausea. Thus, the development of 5HT3 receptor 
antagonists did not have the positive impact on patients’ experiences of nausea that 
was initially anticipated. 
45 
More recent pharmacological advances have been seen with the development of 
aprepitant, a new neurokinin antagonist, with studies commending its 20% 
improvement in the control of ‘emesis’ (Olver 2004; Jordan et al. 2005). However, 
as with the 5HT3 receptor antagonist research above, a complete response has often 
been defined as ‘no emesis or rescue therapy’ with no reference to experiences of 
nausea (Hesketh et al. 2003; Poli-Bigelli et al. 2003). While a large study involving 
1,099 patients receiving highly emetogenic chemotherapy has shown that the 
addition of aprepitant to the best available antiemetic therapy (a 5HT3 receptor 
antagonist and dexamethasone) results in consistently better antiemetic protection 
using the endpoint of ‘no vomiting and no significant nausea’, that is, nausea that 
interferes with normal activities (de Wit et al. 2004), 36.3% of patients receiving 
aprepitant in tandem with best available antiemetic therapy continued to experience 
nausea and/or vomiting. Indeed, further clarification of its effects on nausea and 
vomiting independently are required as a more recent phase II study exploring the 
effectiveness of aprepitant on the nausea and vomiting experienced by 1,043 
patients following moderately emetogenic chemotherapy demonstrated that 40% of 
patients continued to experience significant nausea as measured by the FLIE, a 
multidimensional, valid and reliable assessment tool (Warr et al. 2005).  
Given the volume of research surrounding the pharmacological management of 
chemotherapy-induced nausea (and vomiting), one can appreciate the problems 
clinicians experience in trying to stay informed of the most up-to-date treatments for 
their patients. A range of antiemetic guidelines have been developed by groups or 
societies in an effort to facilitate the management of these complex problems in 
clinical practice ( Multinational Association of Supportive Care in Cancer 1998; 
Gralla et al. 1999; American Society of Health-Systems Pharmacists 1999; ESMO 
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Guidelines Task Force 2001; National Comprehensive Cancer Network 2007a). 
Such guideline development involves synthesising an extensive amount of research 
evidence to provide clinicians with comprehensive, technical documents that detail 
the most effective pharmacological interventions across a wide range of clinical 
circumstances. However, these documents are often unwieldy and difficult to use in 
clinical practice. As an alternative, consensus meetings have been held in which 
experts from a range of disciplines seek to produce condensed summaries of such 
guidelines in a succinct and usable format (Koeller et al. 2002; Borjeson 2002). As 
these summaries are more user-friendly, one could argue that their 
recommendations are more likely to be implemented in clinical practice. Recent 
consensus statements based on high quality evidence advocate for the combination 
of antiemetics to achieve maximum effect (Koeller et al. 2002; Borjeson 2002). 
However, as even the current best available antiemetic therapy continues to leave a 
significant percentage of patients experiencing nausea (de Wit et al. 2004; Warr et 
al. 2005) with vomiting, rather than nausea, as the focus of research, the 
management of chemotherapy-related nausea remains a significant clinical 
challenge. Given that many patients’ nausea is refractory to available antiemetic 
therapies, there is a need to seriously consider non-pharmacological interventions 
that enhance current pharmacological therapies. 
3.4.2 Non-pharmacological interventions for chemotherapy-induced 
nausea 
There is a large and mainly convincing body of evidence that explores the 
effectiveness of non-pharmacological interventions in alleviating or preventing 
patients’ experiences of chemotherapy-related nausea and vomiting. These 
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interventions involve behavioural and psychoeducational techniques, such as 
progressive muscle relaxation training, guided imagery and psychoeducational 
support and information. 
3.4.2.1 Progressive muscle relaxation training 
Progressive muscle relaxation training (PMRT) involves focusing on and isolating 
various muscle groups while moving progressively up and down the body to 
establish a state of deep relaxation. Focused breathing is often used along with 
PMRT. A meta-analysis of 10 published, randomised, intervention-controlled 
studies involving 399 patients from the United States, Sweden and the United 
Kingdom, demonstrated significant beneficial effects of relaxation to decrease 
nausea (Leubert et al. 2001). A number of studies have explored the impact of 
PMRT on not only nausea, but also vomiting and anxiety (Arakawa 1995; Arakawa 
1997; Molassiotis 2000; Molassiotis et al. 2002b; Yoo et al. 2005; de Carvalho et al. 
2007). While these studies employed various methods of delivering PMRT and 
assessed nausea, vomiting and anxiety using a multitude of assessment tools overall, 
the results demonstrate that PMRT, in tandem with pharmacological therapy, is 
effective in reducing the nausea (and vomiting and anxiety) associated with 
chemotherapy, see Table 8.  
 Table 8: Summary of studies evaluating progressive muscle relaxation training 
Author Aim Design Sample Procedure & Instrument Findings Limitations 
Arakawa 
(1995) 
To explore the 
effects of 
PMRT on 
nausea, 
vomiting and 
anxiety 
Pilot RCT 8 Japanese 
women 
receiving 
chemotherapy 
for a range of 
cancer 
diagnoses 
The experimental group received 
training in relaxation techniques 
and performed these twice a day 
either before meals or two hours 
after meals. Assessments were 
made using MANE and 
Spielberger State-Trait Anxiety 
Inventory 
Both groups showed 
a reduction in nausea 
and vomiting. 
Average decrease in 
state anxiety in the 
experimental group.  
Snapshot view of a 
single cycle of 
chemotherapy. 
Small sample size. 
Heterogeneity in 
relation to cancer 
diagnosis, treatment 
and antiemetics 
received. Reliability 
of MANE not tested 
in Japanese 
population. 
Arakawa 
(1997) 
To explore the 
effects of 
PMRT on 
nausea, 
vomiting and 
anxiety 
RCT 60 Japanese 
patients 
receiving 
chemotherapy 
for a range of 
cancer 
diagnoses 
The experimental group received 
training in relaxation techniques 
and performed these twice a day 
either before meals or two hours 
after meals. Assessments were 
made using MANE and 
Spielberger State-Trait Anxiety 
Inventory 
The experimental 
group showed a 
decrease in nausea 
and vomiting. 
Snapshot view of a 
single cycle of 
chemotherapy. 
Heterogeneity in 
relation to cancer 
diagnosis, treatment 
and antiemetics 
received. Reliability 
of MANE not tested 
in Japanese 
population. 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Molassiotis 
(2000) 
To assess 
effectiveness 
of PMRT in 
management 
of 
chemotherapy-
induced 
nausea and 
vomiting 
Pilot RCT 8 Chinese 
women with 
breast cancer 
scheduled to 
receive 
moderately 
emetogenic 
chemotherapy 
Control group received standard 
anti-emetics and were asked to 
complete the Morrow Nausea 
and Vomiting Scale daily for 6 
days. The Experimental group 
received PMRT with a trained 
research nurse 1 hour before 
chemotherapy as well as 
standard anti-emetics. The nurse 
visited patients at home for the 
next 5 days giving them a 
session of PMRT. They also 
completed the questionnaire for 
6 days 
Duration and 
intensity of nausea 
were lower in the 
experimental group, 
although the former 
was at a borderline 
level of significance. 
Duration and 
intensity of vomiting 
were lower in the 
experimental group 
Not conclusive 
results for nausea. 
Small sample. No 
exploration of 
extraneous 
variables that could 
have influenced the 
results. 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Molassiotis 
et al  
(2002) 
To assess 
effectiveness 
of PMRT in 
management 
of 
chemotherapy-
induced 
nausea and 
vomiting 
RCT 71 Chinese 
women with 
breast cancer 
scheduled to 
receive 
moderately 
emetogenic 
chemotherapy 
Control group received standard 
anti-emetics. The Experimental 
group received standard 
antiemetics as well as PMRT one 
hour before chemotherapy 
administration and thereafter for 
5 consecutive days. Each session 
lasted 25 minutes and was 
followed by 5 minutes of 
imagery techniques 
All patients completed the 
Morrow Nausea and Vomiting 
Scale daily for 7 days, the 
Chinese version of the Profile of 
Mood States and State-Trait 
Anxiety Inventory before 
chemotherapy and at days 7 and 
14 after chemo. 
No difference 
between the 
experimental and 
control groups in 
relation to intensity 
of nausea and 
vomiting. However, 
there was a 
significant reduction 
in the duration and 
frequency of nausea 
and vomiting. These 
differences were 
noted most during 
days 1-4 of the cycle 
of chemotherapy. 
Intervention was 
conducted only on 
the first cycle of 
chemotherapy. 
Patients received 
antiemetic therapy 
that was not in 
keeping with 
current guidelines at 
that time. 
Consequently, the 
results may only be 
applicable to 
patients with a poor 
control of nausea 
and vomiting. 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Yoo et al 
(2005) 
To evaluate 
the efficacy of 
PMRT and 
guided 
imagery on 
experiences of 
anticipatory 
and post-
chemotherapy 
nausea and 
vomiting 
RCT 30 patients 
with breast 
cancer 
randomised to 
either control 
or 
experimental 
group 
Patients in the experimental 
group received a PMRT and 
guided imagery session for one 
hour immediately before each 
cycle of chemotherapy as well as 
a tape recording of their first 
session for home use. Patients 
completed Multiple Affect 
Adjectives Checklist, 
anticipatory nausea and vomiting 
and post-chemotherapy nausea 
and vomiting were recorded 
using a 7 point Likert scale. 
Patients also rated their nausea 
and vomiting  for 3 days 
following each cycle of 
chemotherapy and completed the 
Functional Assessment of 
Cancer Therapy – Breast at 
baseline and after 3 and 6 
months 
The experimental 
group experienced 
significantly less 
nausea and vomiting 
before and after 
chemotherapy. 6 
months following 
treatment, the quality 
of life of those in the 
experimental group 
was higher than that 
of the control group. 
Small sample size 
and a short-term 
follow up. Cost of 
the intervention not 
considered.  
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
de 
Carvalho et 
al 2007 
To evaluate 
the effects of 
PMRT on the 
nausea and 
vomiting 
Descriptive 
study 
30 patients 
with a range 
of cancer 
diagnoses 
who were 
receiving 
chemotherapy 
Pre-relaxation data (demographic 
data, vital signs, salivation, 
perspiration, pupil dilation, skin 
colour, muscle reaction and 
patients’ spontaneous comments) 
were collected. Patients also 
completed a 10cm visual 
analogue scale for nausea and 
then for vomiting. Following the 
PMRT these physiological 
measures of nausea and vomiting 
were collected again as well as 
the patient’s self-assessed nausea 
and vomiting levels using the 
visual analogue scale. 
Statistically 
significant 
differences were seen 
in physiological and 
muscular measures, 
except for skin colour 
following PMRT. 
Statistically 
significant reductions 
in self-report of 
nausea and vomiting 
using the visual 
analogue scales were 
seen following 
PMRT. 
No control group 
and a heterogeneous 
population with 
respect to 
chemotherapy and 
antiemetic therapy 
received. It is 
unclear as to during 
which cycle of 
chemotherapy 
patients 
participated. 
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Only Yoo and colleagues (2005) recognised the need for longitudinal evaluation of 
PMRT and conducted a study that included 6 months post-chemotherapy follow-up. 
The remaining studies focused on a single cycle of chemotherapy and so provided a 
limited view of the potential of PMRT. Future research involving longitudinal 
follow up would allow conclusions to be drawn concerning the benefits of long term 
use of PMRT. Self report was the most common method of exploring patients’ 
experiences of nausea using a variety of assessment tools such as MANE (Arakawa 
1995; Arakawa 1997; Molassiotis 2000; Molassiotis et al. 2002b), Likert scales 
(Yoo et al. 2005), the Spielberger State-Trait Anxiety Inventory (Arakawa 1995; 
Arakawa 1997; Molassiotis et al. 2002b), the Profile of Mood States (Molassiotis et 
al. 2002b), and the Functional Assessment of Cancer Therapy – Breast (Yoo et al. 
2005), with just one study choosing to add objective measures of patients’ vital 
signs, salivation, perspiration, pupil dilation, skin colour and muscle reactions to 
evaluate the impact of PMRT on nausea (de Carvalho et al. 2007). While in research 
terms this inconsistent use of assessment tools can be criticised, it demonstrates that, 
no matter how experiences of nausea are assessed, PMRT positively influences 
patients’ experiences of this symptom. 
However, the practicalities of implementing PMRT outwith a research setting are 
not considered in these studies, for example, the availability of trained staff, the 
time required to provide the service, or the availability of a quiet space in which to 
deliver PMRT. Neither are the cost implications of providing a PMRT service 
addressed in any research reports. Thus, although effective, the issues associated 
with the delivery of such a service in the real clinical setting are not addressed by 
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those exploring the intervention. Future studies that seek to implement and evaluate 
PMRT in real clinical settings are urgently required.  
3.4.2.2 Psychoeducational support and information 
A meta-analysis of 116 intervention studies indicated that psychoeducational and 
psychosocial care have beneficial effects for nausea and vomiting associated with 
cancer (Devine and Westlake 1995). More recent supportive evidence for the use of 
psychoeducational interventions in the reduction of chemotherapy-related nausea is 
presented in Table 9.  
 Table 9: Summary of studies evaluating psychoeducational support and information 
Author Aim Design Sample Procedure & Instrument Findings Limitations 
Gaston-
Johansson 
et al 2000 
To determine 
whether a 
comprehensive 
coping 
strategy 
programme 
was effective 
in reducing 
pain, fatigue, 
psychological 
distress and 
nausea  
RCT 110 patients 
with breast 
cancer 
undergoing 
autologous 
bone marrow 
transplant 
Patients in the experimental 
group were taught a coping 
strategy programme at least 2 
weeks before admission to 
hospital for treatment. This 
included relaxation training and 
guided imagery which was also 
given as an audiotape to patients. 
Patients were instructed to use 
the tape at least once a day. 
Evaluation tools used were: the 
Gaston-Johnasson Painometre; a 
100mm VAS for nausea severity 
and fatigue; the State-Trait 
Anxiety Inventory; and the Beck 
Depression Inventory 
Nausea was significantly 
lower in patients who 
participated in the coping 
strategy programme 
compared with those 
receiving standard care, 
even after controlling for 
relevant variables 
The sample 
population is a 
very specific 
group, making it 
difficult to 
generalise the 
results. No 
consideration 
given to the 
practicalities or 
cost of the 
intervention 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Williams 
and 
Schreier  
2004 
To evaluate 
the 
effectiveness 
of 
informational 
audiotapes on 
patients’ self-
care 
behaviours, 
anxiety and 
the occurrence 
and intensity 
of common 
symptoms 
associated 
with 
chemotherapy 
RCT Women with 
breast cancer 
(n=70) about 
to start a 
course of 
chemotherapy 
Patients in the experimental 
group (n=38) received standard 
education and they were mailed 
two 20-minute audiotapes about 
the nutritional management of 
symptoms and exercise and 
relaxation techniques to manage 
fatigue, anxiety and difficulty 
sleeping. They were instructed to 
listen to the tapes 12-24 hours 
before each cycle of 
chemotherapy and as often as 
they wanted during their entire 
course of treatment. Patients 
were interviewed using the 
State-Trait Anxiety Instrument 
and the modified Nail Self-Care 
Diary 3 times by phone by the 
same interviewer: before the 
start of their treatment; at one 
month following the start of 
treatment; and two months 
thereafter 
In the experimental group, 
the number of women 
reporting nausea and 
vomiting almost halved 
between the second and 
third interviews. However, 
more nausea and vomiting 
was reported in the 
experimental group than 
the control group at the 
second interview and only 
marginally less nausea and 
vomiting was reported by 
the experimental group 
during the third interview. 
While this study supports 
the use of audiotapes as 
teaching tools, it does not 
provide conclusive proof 
of the benefits for 
managing nausea and 
vomiting 
Nausea and 
vomiting were 
addressed as a 
single symptom. 
While data 
collection was 
longitudinal it did 
not span the whole 
duration of 
chemotherapy. 
Assessment relied 
on patient recall 
over a long period 
of time 56 
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These studies were longitudinal, although did not always span the entire duration of 
patients’ chemotherapy treatment (Gaston-Johansson et al. 2000; Williams and 
Schreier 2004). Furthermore, they did not consider the practicalities of 
implementing these interventions in the real clinical setting or conduct a cost/benefit 
analysis of sustaining such services. They did, however, demonstrate innovative 
methods of presenting educational material, for example, via audiotape (Gaston-
Johansson et al. 2000; Williams and Schreier 2004), which is especially relevant, 
given that the majority of patients receive chemotherapy as an out-patient, and so 
spend the majority of their time at home, a factor that limits the time available for 
patient education by health professionals.  
3.4.2.3 Acupuncture and Acupressure 
Acupuncture and acupressure have been shown to have a positive effect on nausea 
and vomiting (Vickers 1996; Dibble et al. 2000; Roscoe et al. 2003; Ezzo et al. 
2005; Molassiotis et al. 2007). They are based on traditional Chinese medical 
concepts of meridians which carry energy throughout the body and involve 
stimulation of a specific point by fine needles or pressure (Vickers 1996; Klein and 
Griffiths 2004; Ezzo et al. 2005). Two reviews have been conducted that summarise 
the efficacy of acupuncture for the management of chemotherapy-related nausea 
(Vickers 1996; Ezzo et al. 2005). Taking a general approach to nausea, Vickers 
describes 12 high quality randomised controlled trials that explored the antiemetic 
benefits of acupuncture for nausea associated with surgery, chemotherapy or 
pregnancy. In 11 of these 12 studies, involving nearly 2,000 patients, acupuncture 
had a positive effect on nausea. More recently Ezzo, and her colleagues (2005) 
focused on chemotherapy-induced nausea and in a review of 11 trials of 
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acupuncture and acupressure involving 1,247 patients, they concluded that 
acupuncture has a demonstrable benefit for acute chemotherapy-related nausea, 
however, studies that evaluate the impact of acupuncture in tandem with current 
best antiemetic therapies, as well as studies exploring the impact of acupuncture on 
delayed nausea, are required to establish the usefulness of this intervention in 
clinical practice. 
Acupressure was explored in a mini systematic review reporting on 2 randomised 
controlled trials involving 482 patients receiving chemotherapy, which concluded 
that acupressure may decrease chemotherapy-related nausea (Klein and Griffiths 
2004). Details of a more recent study evaluating the impact of acupressure 
wristbands are found in Table 10. 
 Table 10: Summary of studies evaluating acupressure 
Author Aim Design Sample Procedure & Instrument Findings Limitations 
Molassiotis 
et al 2007 
To evaluate 
the impact of 
acupressure 
wristbands 
RCT 36 patients 
with breast 
cancer having 
chemotherapy 
Patients in the intervention 
group wore wrist bands for 
5 days following 
chemotherapy 
administration. The revised 
Rhodes Index of Nausea, 
Vomiting and Retching 
(INVR) was used to 
measure patients’ 
experiences and was 
completed every evening 
for 5 days following 
chemotherapy 
administration 
Nausea was experienced 
significantly less often in the 
experimental group. Only at day 
3 following treatment did both 
groups have the same level of 
nausea. Nausea also occurred 
significantly less frequently in 
the experimental group across 
the 5 assessment days (day 3 had 
similar levels of nausea between 
the 2 groups). The experimental 
group reported significantly less 
distress associated with their 
experience of nausea than did the 
control group 
Small sample size. 
Non-standardised 
antiemetics days 2-
5. No rationale 
given for attrition 
rate of 34%. Only 
explored during 
first cycle of 
chemotherapy 
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Such results demonstrate the positive impact that acupressure can have on the 
various dimensions of the experience of chemotherapy-related nausea, although it is 
unfortunate that there was no longitudinal follow up to explore whether its positive 
effects can be maintained across chemotherapy cycles. The multidimensional 
evaluation of nausea by Molassiotis and his colleagues (Molassiotis et al. 2007) 
clearly demonstrated the positive impact of acupressure on all dimensions of the 
symptom experience. However, the lack of cost/benefit analysis and small sample 
size (Molassiotis et al. 2007) compromise these studies, and future research that 
addresses these methodological flaws is necessary.  
Nevertheless, despite the problems associated with small sample sizes and the 
variety of assessment tools used, the results from acupuncture and acupressure 
studies show positive outcomes, indicating that they offer a viable adjunct to 
optimal antiemetic therapy. 
3.4.2.4 Other non-pharmacological interventions 
There are a range of other non-pharmacological interventions that have been 
evaluated for their efficacy for chemotherapy-induced nausea, including guided 
imagery (Troesch et al. 1993), music therapy (Standley 1992; Ezzone et al. 1998; 
Sahler et al. 2003), and massage (Billhult et al. 2007) - see Table 11.
 Table 11: Summary of studies evaluating other non-pharmacological interventions 
Author Aim Design Sample Procedure & Instrument Findings Limitations 
Troesch et 
al 1993 
To explore 
whether the 
addition of 
guided 
imagery to a 
standard 
antiemetic 
regime 
decreased the 
occurrence of 
nausea, 
vomiting or 
retching and 
distress 
Pilot RCT Convenience 
sample of 28 
patients 
receiving 
Cisplatin-
based 
chemotherapy 
Both groups received the 
standard antiemetic therapy 
while the experimental group 
participated in guided imagery. 
This consisted of listening to a 
20 minute audiotape 60 minutes 
before treatment, the following 
morning before breakfast and the 
following evening. Patients were 
asked to complete 5  INV-2 for 
each cycle of chemotherapy. 
Patients also completed the 
Chemotherapy Experience 
Survey (developed for the study) 
to evaluate overall perceptions of 
the chemotherapy experience. 
Descriptive statistics of both 
groups were compared and 
differences explored 
Statistical 
significance was not 
demonstrated with 
respect to symptom 
occurrence and 
distress with the 
addition of guided 
imagery. Patients in 
the guided imagery 
group described their 
overall chemotherapy 
experience more 
positively than those 
subjects who did not 
receive the guided 
imagery 
Involving only 
patients receiving 
cisplatinum based 
chemotherapy as 
well as the small 
sample size limits 
generalisability of 
results. Researchers 
were unable to 
control hospital 
activities that may 
have influenced or 
disrupted the patient 
when listening to 
the guided imagery 
tape 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Standley et 
al 1992 
To explore the 
effects of 
music on the 
frequency and 
degree of 
anticipatory 
nausea and 
vomiting and 
nausea and 
vomiting 
during and 
after 
chemotherapy 
Descriptive 
study 
15 subjects 
who received 
4 or more 
chemotherapy 
sessions 
Participants were randomly 
assigned to one of 4 groups: 
listening to music during 
chemotherapy cycles 1-4; 
listening to music chemotherapy 
cycles 2-5; did not listen to 
music cycle 1 & 2; did not listen 
to music cycle 2 – 5. Data were 
collected at 4 time points: 
entering the treatment room; 
immediately prior to infusion of 
chemotherapy; 15 minutes after 
start of chemotherapy; at the end 
of treatment. Data were also 
collected by telephone interview 
48 hours after chemotherapy 
Both music groups 
reported less nausea 
than the 2 no music 
groups. The length of 
time before nausea 
began was longer for 
the music groups 
compared to the no 
music groups 
All the patients 
volunteered for the 
study so this may 
have biased the 
results 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Ezzone et 
al 1998 
To explore the 
effects of 
music on 
patients 
undergoing 
bone marrow 
transplant 
RCT 33 patients 
undergoing 
bone marrow 
transplant 
Patients were assigned to either 
the control group (n=17) who 
received antiemetics according 
to the standard antiemetic 
protocol or the experimental 
group (n=16) who received 
standard antiemetics plus music 
intervention during the 48 hours 
of high-dose cyclophosphamide 
administered as part of the 
preparatory chemotherapy 
regime. Incidence of nausea was 
measured on a visual analogue 
scale 
The experimental 
group experienced 
less nausea. 
Results are limited 
to this particular 
population and a 
short period of time 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Sahler et al 
2003 
To explore the 
impact of 
music therapy 
and relaxation 
imagery on the 
nausea 
experienced 
by patients 
Case control 
study 
Patients 
(n=23) 
undergoing 
bone marrow 
transplant 
The intervention incorporated a 
45 minute session of integrated 
music therapy and relaxation 
imagery provided twice weekly 
from enrolment in the study to 
day of discharge from the bone 
marrow transplant unit. Sessions 
were designed to be a non-
disruptive as possible and were 
scheduled around patients’ 
treatment needs. Antiemetics 
were given to all patients as per 
routine protocol. The music was 
the patient’s choice. Nausea was 
assessed at the beginning and 
end of each session using a 10cm 
visual analogue scale with the 
anchors ‘worst nausea’ and ‘least 
nausea’ 
Patients’ self-reports 
of nausea 
significantly 
decreased following 
music therapy 
The sample was not 
randomised and the 
frequency of the 
intervention was 
lower than planned 
due to a 
misconception 
among staff that 
some patients were 
‘too sick’ to 
participate. The 
study included both 
paediatric and adult 
patients, age range 
5-65 years (mean 
47.5) with no detail 
was given as to the 
breakdown of these 
ages. One can 
question whether 
the visual analogue 
scale would be an 
appropriate scale 
for both adults and 
children 
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 Author Aim Design Sample Procedure & Instrument Findings Limitations 
Billhult et 
al 2007 
To evaluate 
the effects of 
massage on 
nausea, 
anxiety and 
depression 
RCT Patients with 
breast cancer 
receiving 
chemotherapy 
(n=39) 
Patients were randomly assigned 
to a massage group (20 minutes 
of massage on 5 occasions) or a 
control group (five 20 minute 
visits). Nausea and anxiety were 
assessed using a visual analogue 
scale before and after each 
intervention with the verbal 
anchors ‘no nausea’ and ‘worst 
nausea’. Patients also completed 
the Hospital Anxiety and 
Depression Scale 
A significant 
reduction in nausea 
between the 
intervention and 
control groups when 
improvement was 
measured as a 
percentage of all 5 
treatments. It is not 
clear whether there 
was an improvement 
following each of the 
5 treatments alone. 
There was no 
difference between 
groups in relation to 
anxiety or depression.
Small sample. 
Unidimensional 
measurement of 
nausea does not 
fully capture the 
experience of 
nausea. Cost or 
practicalities not 
considered 
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While guided imagery does appear to have benefits concerning overall experiences 
of chemotherapy, used in isolation it does not appear to impact directly on 
experiences of nausea (Troesch et al. 1993). While there is a growing evidence base 
for the use of music therapy as demonstrated within Table 11, future research will 
be required to overcome the methodological flaws of existing studies, such as small 
sample sizes and patient self-selection, to increase confidence in the results. Finally, 
although initial results demonstrated a positive impact of massage on 
chemotherapy-related nausea (Billhult et al. 2007), this is based on a single study 
and continued research is required before definite conclusions can be drawn as to its 
efficacy. 
It is clear then, that non-pharmacological interventions have a valuable role in the 
management of chemotherapy-related nausea. However, despite the positive impact 
on chemotherapy-related nausea that these interventions have almost consistently 
demonstrated, they are not often integrated into the care of patients receiving 
chemotherapy (Molassiotis et al. 2002b). A variety of reasons have been given for 
lack of integration in practice including: health professionals’ unfamiliarity with the 
techniques; the time required to administer the interventions; lack of education in 
the necessary techniques; and the associated costs of delivering them (Molassiotis et 
al. 2002b). However, given the positive impact that such interventions have on 
patients’ experiences, innovative methods are necessary to overcome the 
practicalities of providing these non-pharmacological interventions. For example, 
the use of tape recordings for the delivery of PMRT may be helpful in overcoming 
staff shortages and the time taken to deliver the intervention (Gaston-Johansson et 
al. 2000; Cheung et al. 2003; Williams and Schreier 2004).  
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3.4.3 Summary of current management techniques for chemotherapy-
related nausea 
New developments in the pharmacological management of nausea and vomiting 
have had limited impact on patients’ experiences of nausea with significant 
percentages of patients receiving chemotherapy continuing to experience nausea 
during their treatment (Morrow et al. 1995; Roscoe et al. 2000; The Italian Group 
for Antiemetic Research 2000; de Wit et al. 2004; Warr et al. 2005). However, a 
wide range of non-pharmacological interventions have been successfully evaluated 
as an adjunct to standard anti-emetic therapies, resulting in improved experiences of 
chemotherapy-related nausea. Unfortunately, these non-pharmacological therapies 
are rarely implemented in routine clinical practice. Indeed, the research that 
explores the efficacy of these interventions consistently fails to address the 
practicalities of introducing and maintaining these services in day-to-day clinical 
practice. Given these facts, it is important to consider patients’ actual experiences of 
chemotherapy-related nausea.  
3.5 Patients’ experiences of chemotherapy-related nausea 
Chemotherapy-related nausea not only aggravates patients’ general health and 
cancer-related symptoms such as cachexia, lethargy and weakness (Griffin et al. 
1996; American Society of Clinical Oncology 1996; Roscoe et al. 2000), but has 
also been shown to impair quality of life and cause emotional distress (Grunberg et 
al. 1996; Osoba et al. 1997a; Rusthoven et al. 1998; Dibble et al. 2003; Glaus et al. 
2004; Bergkvist and Wengstrom 2006; Ballatori et al. 2007). This section will 
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explore the research to date that explores patients’ experiences of nausea during 
chemotherapy.  
Little research explores in depth the ways in which nausea is experienced and its 
impact on the quality of patients’ daily lives. No rationale for this is evident within 
the literature, however, it may be the result of a number of factors. Firstly, as 
already highlighted, nausea is inextricably linked with vomiting. Chemotherapy-
related vomiting is simpler to quantify and describe than nausea and studies that set 
out to explore both nausea and vomiting often focus on vomiting as it is easier than 
nausea to evaluate and report (Hesketh et al. 2003; Poli-Bigelli et al. 2003). 
Secondly, clinicians and researchers may believe that the significant developments 
in antiemetic therapies have alleviated patients’ nausea. However, such perceptions 
are erroneous. As already shown, while chemotherapy-related vomiting has been 
improved, nausea remains a significant symptom for patients (Morrow et al. 1995; 
Roscoe et al. 2000; The Italian Group for Antiemetic Research 2000; Hesketh et al. 
2003; Poli-Bigelli et al. 2003). Finally, the majority of current research concerning 
chemotherapy-related nausea focuses on evaluating or comparing therapies and 
interventions rather than describing patients’ experiences. These three factors 
together may explain the relative lack of research that explores the lived experience 
of chemotherapy-related nausea. However, there is some evidence that can be drawn 
together to gain an understanding of patients’ experiences of chemotherapy-related 
nausea. While a minority of this literature focuses solely on nausea (Dibble et al. 
2003), the majority explores both nausea and vomiting (Grunberg et al. 1996; Farley 
et al. 1997; Osoba et al. 1997a; Rusthoven et al. 1998; Glaus et al. 2004; Bergkvist 
and Wengstrom 2006; Ballatori et al. 2007), however, where possible, only the 
evidence relating to nausea will be considered.  
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There is a consistent body of evidence that supports the negative effects of nausea 
on patients’ quality of life (Grunberg et al. 1996; Osoba et al. 1997a; Farley et al. 
1997; Rusthoven et al. 1998; Dibble et al. 2003; Glaus et al. 2004; Lee et al. 2005; 
Bergkvist and Wengstrom 2006; Ballatori et al. 2007). A large study involving 832 
patients receiving chemotherapy demonstrated the deleterious effects of nausea on 
cognitive and social functioning and global quality of life, as well as fatigue, 
anorexia and insomnia, as measured using the European Organisation for Research 
and Cancer (EORTC) core quality of life questionnaire (QLQ-C30) (Osoba et al. 
1997a). Indeed, patients with nausea scores equal to or greater than the median did 
not show greater deterioration in quality of life scores than did those with nausea 
scores below the median, suggesting that even a relatively low amount of nausea 
has a negative effect on quality of life (Osoba et al. 1997a). Similarly, using the 
EORTC QLQ-C30, Rusthoven and his colleagues demonstrated a decline in 
physical, social and role functioning as well as global quality of life in tandem with 
declines in symptom scores for fatigue, anorexia and insomnia in patients reporting 
nausea 2 days following chemotherapy (Rusthoven et al. 1998). These declines in 
functioning continued to be reported 6 days following chemotherapy with 
constipation and dyspnoea also reporting declining symptom scores (Rusthoven et 
al. 1998).  
Other methods of evaluating the impact of nausea on quality of life support the 
results from the QLQ-C30. Asking patients receiving chemotherapy (n=30) to rate 
their quality of life in the hypothetical presence and absence of nausea, highlighted 
the impact of nausea on quality of life with a mean quality of life score of 79/100 in 
the absence of nausea, and just 27/100 in its presence (Grunberg et al. 1996). Using 
the Functional Living Index for Emesis (FLIE), patients (n=115) reported their 
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experiences of nausea (and vomiting) 72 hours following the administration of 
highly or moderately emetogenic chemotherapy, describing their inability to 
complete usual household tasks (Farley et al 1997). Again using the FLIE, patients 
(n=248) receiving moderately and highly emetogenic chemotherapy described their 
nausea as too severe to allow normal daily functioning on a physical, psychological 
and social level (Glaus et al. 2004). Significant decreases in patients’ functional 
status (physical functioning, role limitations, general health, vitality and social 
functioning), as measured by the Medical Outcomes Study Short Form (SF-36), 
were shown to be associated with the experience of delayed nausea in a longitudinal 
(2 cycles of chemotherapy) study involving 303 women receiving chemotherapy for 
breast cancer (Lee et al. 2005).  Qualitative data of indepth interviews with patients 
(n=9) receiving chemotherapy support the impact of nausea on quality of life, 
demonstrating the negative impact of chemotherapy-related nausea on eating, 
weight loss, reduced social interaction, anxiety, sleep patterns and exhaustion 
(Bergkvist and Wengstrom 2006). Using both the FLIE and a daily diary, 33% of 
patients with acute nausea, 61% of patients with delayed nausea and 92% of patients 
with both acute and delayed nausea reported an impact on their daily lives (Ballatori 
et al. 2007). These results suggests that delayed nausea has a greater impact than 
acute nausea, and may mean that the duration of nausea plays a significant role in its 
impact on patients’ lives. 
Just 3 studies have explored patterns of nausea experiences in relation to quality of 
life, and nausea on the third day following chemotherapy has been identified by 
patients as the worst (Dibble et al. 2003; Glaus et al. 2004; Lee et al. 2005). 
However, while an increase in nausea over successive cycles of chemotherapy has 
been demonstrated (Rhodes et al. 1987), there has been no attempt to correlate this 
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with a longitudinal evaluation of quality of life. As patients commonly receive 
between 6-8 cycles of chemotherapy over 6-8 months, such a limited perspective, 
such as that gleaned from 2 cycles of chemotherapy (Dibble et al. 2003; Lee et al. 
2005), or snap-shots from various cycles of chemotherapy (Farley et al. 1997; 
Bergkvist and Wengstrom 2006; Ballatori et al. 2007), cannot wholly reflect 
patients’ actual experiences. Longitudinal evaluation could identify how changes in 
nausea impact on patients’ quality of life over time. 
It is also noteworthy that the majority of these studies have a predominantly female 
population: 66% in Osoba et al; 73% in Grunberg et al; 76% in Rusthoven et al; 
77.5% in Glaus et al; 100% in Dibble et al and Bergkvist and Wengstrom.  As 
highlighted earlier in this chapter, women are more susceptible to developing 
chemotherapy-related nausea. Thus, caution should be taken before applying the 
results of these studies unconditionally to men receiving chemotherapy.  
The antiemetics received by patients during these studies should also be considered. 
For example, 21% of patients did not receive prophylactic antiemetics for delayed 
nausea in the study by Osoba and his colleagues, no details were given of the 
antiemetics received by patients in Rusthoven’s study, and less than half of the 
patients participating in Ballatori’s study received appropriate prophylaxis for 
delayed nausea and vomiting. One can question the effects that such under-
treatment has on experiences of nausea and the subsequent impact on patients’ 
quality of life. 
Finally, a concept that has not been addressed within this evidence-base that may 
affect patients’ perceptions of nausea and its impact on their quality of life is that of 
treatment intent. Treatment intent has been shown to have an impact on patients’ 
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satisfaction with care during chemotherapy (Holtedahl et al. 2005). Thus, whether a 
patient is receiving chemotherapy with curative or palliative intent may impact on 
how they perceive chemotherapy-related nausea. Further research that explores this 
concept is much needed.  
However, despite these methodological flaws, there is evidence to suggest that 
chemotherapy-related nausea is an unpleasant symptom for patients and is 
associated with reduced quality of life and distress (Grunberg et al. 1996; Osoba et 
al. 1997a; Rusthoven et al. 1998; Dibble et al. 2003; Glaus et al. 2004; Lee et al. 
2005; Bergkvist and Wengstrom 2006; Ballatori et al. 2007). The following section 
will consider potential explanations for why nausea persists despite the available 
range of therapies and interventions and why it is one of the most frequently 
reported and highly ranked symptoms associated with chemotherapy (as shown in 
chapter 2). 
3.5.1 Potential explanations for continued negative experiences of 
nausea 
Regardless of the extensive research over the last 3 decades exploring 
chemotherapy-related nausea, it remains a major problem for patients. Reasons for 
this lack of improvement have not been addressed per se in the literature, however, 
there are a number of explanations that either alone or together have the potential to 
inhibit optimal patient outcomes. 
The first of these is poor assessment of nausea in the clinical setting: both in relation 
to evaluating the likelihood of patients’ developing nausea and measuring their 
actual experiences. While there are established classifications of chemotherapy 
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emetogenicity, these are based on the likelihood of vomiting so fail to acknowledge 
nausea (Hesketh et al. 1997; Hesketh 1999; Grunberg et al. 2005), and there are no 
established assessment tools for personal factors that increase an individual’s 
susceptibility for chemotherapy-related nausea. As such, structured and consistent 
assessment of personal factors that contribute to experiences of nausea in clinical 
practice is at best sporadic, meaning that patients at increased risk of nausea may or 
may not be identified for greater attention and interventions. Assessing actual 
experiences of chemotherapy is also problematic: the range of available assessment 
tools give little indication as to the clinical situations for which they are most 
appropriate; how and when to administer them; and what to do with the results 
(Rhodes and McDaniel 1999; Morrow 1992; Lindley et al. 1992; National Cancer 
Institute 1999; Trotti et al. 2003). 
Secondly, the array of available antiemetic drug therapies may cause confusion for 
health professionals. Antiemetic guidelines that condense and consolidate the vast 
amounts of research that compares and contrasts antiemetic therapies are often 
unwieldy and difficult to use in day-to-day practice (Aapro 2002). While consensus 
statements simplify this process (Koeller et al. 2002; Borjeson 2002), there is no 
doubt that patients continue to receive inappropriate antiemetic therapy. For 
example, even within studies whose primary focus was nausea and vomiting, 
patients have been shown to receive inappropriate antiemetic therapy (Osoba et al. 
1997b; Molassiotis et al. 2002a; Ballatori et al. 2007). 
Thirdly, while currently available anti-emetic therapies have positively impacted on 
patients’ experiences of vomiting, the same is not true of nausea (Morrow et al. 
1995; Roscoe et al. 2000; The Italian Group for Antiemetic Research 2000; de Wit 
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et al. 2004; Warr et al. 2005). Acknowledging that nausea and vomiting are two 
distinct symptoms that can be addressed and researched independently may 
encourage studies that explore interventions solely to improve experiences of 
nausea.  
The final potential explanation for continued negative experiences of nausea may be 
that the non-pharmacological interventions that have proven successful in the 
research setting are difficult to translate into day-to-day clinical reality as they 
involve unfamiliar techniques for many health professionals with the required 
training being costly in terms of staffing, time and money (Molassiotis et al. 2002b). 
Moreover, it could be argued that some of the interventions are simply not practical 
for the real world of clinical practice, for example one hour of PMRT for 5 days 
following chemotherapy with a trained therapist (Molassiotis 2000).  
3.6 Conclusion 
This chapter has provided definitions of chemotherapy-related nausea, vomiting and 
retching and briefly described the various forms that chemotherapy-related nausea 
can take. It has shown the range of available assessments for chemotherapy-related 
nausea, both before and during chemotherapy, highlighting their appropriateness to 
clinical or research environments, while demonstrating that nausea is seldom 
assessed in isolation as all the currently available multidimensional assessment tools 
assess nausea and vomiting. Pharmacological developments in the management of 
chemotherapy-related nausea have been shown to have limited impact on patients’ 
experiences of nausea with a significant percentage of patients continuing to 
experience nausea following chemotherapy administration. Optimistically, non-
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pharmacological techniques have been shown to enhance experiences of nausea, 
however, it is disappointing that these remain rooted in research with little 
translation into day-to-day clinical practice. Therefore, it is not surprising that 
chemotherapy-related nausea continues to be experienced by a significant 
proportion of patients and that it has a deleterious effect on their quality of life. 
Potential explanations for this continued negative effect have been offered.  
Chemotherapy-related nausea and fatigue are the two most frequently identified 
symptoms by patients receiving chemotherapy and are consistently highly ranked. 
They are both non-observable and subjective. Thus one can question whether the 
picture for fatigue reflects that of nausea or whether there are fresh challenges for 
health professionals in its assessment and management. Chapter 4 will consider 
chemotherapy-related fatigue, its assessment and management, as well as patient 
experience of fatigue. 
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4 CHAPTER 4 – FATIGUE 
4.1 Introduction 
This chapter will consider chemotherapy-related fatigue. Chapter 2 showed that 
fatigue is not only the most frequently identified symptom by patients receiving 
chemotherapy, but it is also consistently highly ranked as a symptom of concern to 
them. The emergence of fatigue as the most common unrelieved symptom 
associated with cancer is likely due to advances in cancer symptom management, 
such as improved pain management (Smets et al. 1993; Dean and Stahl 2002; Ryan 
et al. 2007), longer cancer survival (de Jong et al. 2002), as well as increased 
attention to quality of life (Iop et al. 2004). However, acknowledging fatigue as a 
highly ranked symptom does not provide insight into why patients began to identify 
fatigue as a symptom of concern or what fatigue means to patients in their daily 
lives.  
This chapter will firstly consider the terminology surrounding cancer-related 
fatigue, briefly describe the main theoretical concepts for fatigue, and reflect on 
potential aetiologies. As with nausea in chapter 3, the current assessment techniques 
for fatigue will be considered before available therapeutic interventions are 
evaluated. Finally, patients’ experiences of chemotherapy-related fatigue will be 
explored in light of existing interventions.   
4.2 Defining fatigue 
‘Fatigue’ is defined as extreme tiredness or weariness resulting from physical or 
mental activity or illness (Concise Oxford English Dictionary 2006). In a healthy 
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person fatigue occurs as an indispensable sensation that prompts the desire to rest to 
protect against overexertion or promote healing. However, as the focus of this 
chapter is cancer- and, more specifically, chemotherapy-related fatigue, it is 
important to consider specific definitions of these.  
In contrast to ‘normal’ fatigue, cancer-related fatigue is perceived as being of 
greater magnitude, disproportionate to activity or exertion, and not completely 
relieved by rest (Irvine et al. 1994; Glaus et al. 1996; Morrow et al. 2005; Johnston 
and Coward 2001; Holley 2000a). Defining cancer- and chemotherapy-related 
fatigue is complicated, as it is non-observable and subjectively experienced, as well 
as multidimensional and multifactorial (Ryan et al. 2007). There is also a linguistic 
problem in some European countries, as the term ‘fatigue’ does not exist in German, 
Italian or Swedish, meaning there is no universal word that can be shared by the 
scientific community. However, various definitions of cancer-related fatigue pepper 
the literature - indeed, it is cancer-related rather than cancer treatment-related 
fatigue that is defined throughout.  
In response to myriad definitions, a concept analysis was conducted in 1996 which 
concluded that cancer-related fatigue was ‘a subjective, unpleasant symptom which 
incorporates total body feelings ranging from tiredness to exhaustion creating an 
unrelenting overall condition which interferes with individuals’ ability to function to 
their normal capacity’ (Ream and Richardson 1996 p527). More recently, the 
National Comprehensive Cancer Network defined cancer-related fatigue as ‘a 
persistent, subjective sense of tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and interferes with usual 
functioning’ (National Comprehensive Cancer Network 2007b, pFT-1). Both these 
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definitions are suitable for use within this thesis, as they highlight the persistence 
and subjectiveness of fatigue and demonstrate its detrimental impact on patients’ 
normal or usual lives. They also concur with the description of symptoms proposed 
in chapter 2, as it stresses the subjectivity of symptoms as well as their impact on 
functioning. However, as this thesis addresses fatigue associated with 
chemotherapy, the latter definition from the NCCN will be used because it identifies 
the role of cancer treatment in causing fatigue.  
4.3 Theoretical models of, and potential aetiologies of, 
chemotherapy-related fatigue 
4.3.1 Theoretical models 
There are a few theoretical models of fatigue, but despite studies exploring the 
causes of fatigue, no clear support for any of the major hypotheses have emerged 
(Nail 1997). The accumulation hypothesis proposes that fatigue is due to a build up 
of waste products within the body (Simonson 1971); the depletion hypothesis is 
based on the supposition that muscular activity is impaired when certain substances 
such as carbohydrates, fats, proteins, adenosine triphosphate and adrenal hormones 
are not readily available (Simonson 1971); the biochemical and physiochemical 
hypotheses suggest changes in the production, distribution, use, balance and 
movement of substances such as muscle proteins, glucose, electrolytes and 
hormones are important factors that influence the experience of fatigue (Taylor and 
Rachman 1988); the hypothesis of adaptation and energy reserves proposes that 
every individual has a certain amount of energy available for adaptation to fatigue 
and, that when that energy supply is depleted, resting for a time allows energy to be 
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replenished so that adaptation can continue (Nail et al. 1991), and; the 
psychobiologic-entropy hypothesis defines fatigue in relation to energy and function 
and seeks to associate activity, fatigue, symptoms and functional status 
(Winningham 1992; Lucia et al. 2003). 
However, the most established and commonly cited model for cancer-related fatigue 
is the Integrated Fatigue Model (IFM) (Piper et al. 1987), which provides a 
comprehensive framework for explaining fatigue associated with cancer. A 
deductive approach was used to develop the model blending the knowledge from 
the 5 primary areas of fatigue research: psychology, ergonomics, physiology, 
medicine and care. The IFM, a synthesis of much of the available data on cancer-
related fatigue (Berger and Walker 2001), encompasses 6 manifestations or 
dimensions of subjective fatigue: temporal, sensory, cognitive or mental, affective 
or emotional, behavioural or severity, and physiologic (Piper et al. 1987). The IFM 
delineates the multiple inter-related factors that lead to fatigue in patients with 
cancer, such as life event patterns, social patterns, environmental patterns, 
regulation or transmissions factors, psychological patterns, symptom patterns, 
oxygenation patterns, innate host factors, accumulation of metabolites, energy or 
energy substrate patterns, activity and rest patterns, sleep and wake patterns, and 
disease and treatment patterns (Piper et al. 1987; Berger et al. 2003). The significant 
outcome of Piper’s model is the Revised Piper Fatigue Scale (Piper et al. 1998) – an 
assessment instrument which is reviewed in the assessment section of this chapter 
(page 86). Psychometric evaluation of this tool involving 715 survivors of breast 
cancer confirmed 4 key subscales for the model associated with cancer-related 
fatigue: behavioural/severity, affective meaning, sensory and cognitive mood (Piper 
et al. 1998). 
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Thus, while there is a range of hypotheses that are all potentially relevant in the 
explanation of cancer-related fatigue, with the exception of Piper’s Integrated 
Fatigue Model, they have not been fully evaluated in patients with cancer. 
Consequently, they present no more than conjecture of possible theories of cancer-
related fatigue. There is, however, a developing body of knowledge surrounding 
specific causes of fatigue.  
4.3.2 Potential aetiologies of fatigue 
Specific mechanisms for the development of fatigue are not completely known or 
understood. Indeed, it is likely that there are a number of factors that contribute to 
the fatigue experienced by each individual. A growing number of potential causes 
are being explored. These can be categorised as physiological and biochemical, 
psychosocial, or demographic factors.  
4.3.2.1 Physiological and biochemical factors 
Anaemia, a deficiency of red blood cells or haemoglobin which leads to a reduction 
in the oxygen-carrying capacity of the blood, is one of the most studied 
physiological factors contributing to fatigue in patients with cancer. Anaemia in 
cancer can be the result of haemorrhage, haemolysis or nutritional deficiencies, as 
well as the increased production of cytokines which reduce the production of 
erythropoietin and contribute to impaired iron utilisation (Heinz and Fritz 1998). It 
is commonly associated with chemotherapy with over one third of patients 
becoming anaemic after 3 cycles of chemotherapy (Glaspy et al. 2002). 
Haemoglobin concentration has been shown to have an impact on patients’ 
experiences of fatigue. A study of patients with solid or haematological 
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malignancies (n=50) demonstrated that those with haemoglobin levels of <12g/dl 
reported significantly more fatigue, worse physical and functional wellbeing, and 
generally reduced quality of life compared with patients whose haemoglobin levels 
were >12g/dl (Cella 1997). The relationship between haemoglobin levels and 
quality of life were further defined in a retrospective analysis from 2 community 
studies involving 4,382 patients with cancer and anaemia (Crawford et al. 2002). In 
these patients, the maximum quality of life gain was in those whose haemoglobin 
levels were increased to 12g/dl (range 11-13g/dl) (Crawford et al. 2002). However, 
while involving a larger number of patients and so increasing confidence in the 
results, this study measured quality of life using the Linear Analogue Scale 
Assessment and the more detailed Functional Assessment of Cancer Therapy-
Anaemia scale, and did not directly evaluate fatigue (Crawford et al. 2002). A study 
of 444 patients with different cancer diagnoses and stage of disease as well as 
treatment modalities compared levels of anaemia with patient reports of fatigue 
intensity measured using the Fatigue Assessment Qustionnaire (Glaus and Muller 
2000). This large study established that patients with a higher level of fatigue had 
haemoglobin levels of <11g/dl, indicating that fatigue was a function of the grade of 
anaemia. This correlation was most noted in relation to patients’ physical 
functioning.  While there is a growing body of evidence that suggests a link 
between haemoglobin level and fatigue, further large prospective studies are 
required to evaluate whether fatigue and haemoglobin are correlated, or whether a 
number of factors are responsible for influencing fatigue.  
Cancer treatments have also been linked to patients’ fatigue experiences. A 
systematic review of cancer-related fatigue during anticancer therapy identified 40 
studies employing either cross-sectional or longitudinal designs and in a range of 
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patient populations with respect to diagnosis and treatment (Prue et al. 2006). They 
concluded that cancer-related fatigue was evident in patients during treatment and, 
through the use of comparison groups, that patients’ fatigue was more severe than 
‘normal’ fatigue (Prue et al. 2006). In relation to chemotherapy-related fatigue, 
there have been some efforts to establish whether patterns of fatigue can be 
detected. Studies have failed to agree on a single pattern. For example, a sharp rise 
in fatigue immediately following chemotherapy that declined midway through each 
cycle of chemotherapy was experienced by two studies of women (n=72, n=31) 
receiving chemotherapy for breast cancer (Berger 1998; Schwartz 2000), whereas, a 
peak in fatigue was reported just 3 days post-chemotherapy by Chinese patients 
(n=42) receiving chemotherapy (Molassiotis and Chan 2001). A third study differs, 
indicating the constant presence of fatigue for 14 days following chemotherapy 
shown to increase with subsequent cycles detected in a longitudinal exploration of 
chemotherapy-related symptoms in a heterogeneous sample of 249 patients (Miller 
et al. 2007). The variation in patterns between these studies is likely due to small 
samples (apart from Miller’s study), heterogeneity of the samples, differences in 
factors such as chemotherapy treatment and dose, cancer diagnosis, and the tools 
and timing of the fatigue assessment. Thus, while there is substantial evidence to 
support the impact of treatment on fatigue (Prue et al. 2006), there is no consistent 
body of evidence that supports specific patterns of chemotherapy-related fatigue.  
The cancer itself should also be considered as a factor in experience of fatigue. 
Comparing four groups of patients (n=227), differences in the prevalence of severe 
fatigue was clearly demonstrated: 15% in women recently diagnosed with breast 
cancer, 16% in men recently diagnosed with prostate cancer, 50% in those with 
inoperable non small cell lung cancer and 78% in patients receiving specialist 
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inpatient palliative care (Stone et al. 2000a). Moreover, a study of people older than 
65 (n=841), newly diagnosed, with a range of cancer diagnoses, has shown that 
those with late stage disease have greater levels of fatigue (Given et al. 2001). 
While these studies suggest that disease burden has an impact on fatigue 
experiences, these findings have been refuted in studies including patients (n=95) 
with a range of advanced cancer diagnoses, including lung, breast and prostate 
cancer (Stone et al. 1999) and patients with advanced lung cancer (n=157) 
(Okuyama et al. 2001). However these results may be due to the small numbers of 
patients of each type and stage of disease in both these studies. Thus, while there is 
not a consistent body of evidence that supports a link between the cancer and 
fatigue, there is evidence from these studies that is suggestive of some form of 
relationship between the stage of cancer and its impact on the level of fatigue 
experienced by patients.  
Cytokines are the final biochemical factor that potentially contributes to fatigue. 
Pro-inflammatory cytokines are proteins that mediate cell-to-cell communication 
and are released in greater amounts in patients with cancer due to the host response 
to the tumour, in response to tissue damage, or due to the depletion of immune cell 
subsets associated with cancer treatments. Support for the role of cytokines in the 
aetiology of fatigue comes from reports of elevated cytokine levels in patients with 
chronic fatigue syndrome (Ryan et al. 2007), and, although one study has found no 
evidence of correlations between serum cytokine levels in patients with breast 
cancer, this may be due to the fact that measurements of fatigue were made at just 3 
timepoints during one cycle of chemotherapy, rather than throughout the course of 
chemotherapy (Pusztai et al. 2004). Further research is required before definite 
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conclusions can be drawn in relation to the role of cytokines in cancer-related 
fatigue.  
4.3.2.2 Psychosocial factors 
A number of studies have shown fatigue to be associated with psychosocial factors 
of anxiety and/or depression (Hann et al. 1999; Stone et al. 2000a; Stone et al. 
2000b; Roscoe et al. 2002; Haghighat et al. 2003) and sleep problems (Berger and 
Farr 1999; Jacobsen et al. 1999; Berger and Higginbotham 2000). However, while 
these studies utilised multidimensional fatigue measures with established reliability 
and validity, such as the Piper Fatigue Scale (Berger and Farr 1999), the 
Multidimensional Assessment of Fatigue (Roscoe et al. 2002), the Cancer Fatigue 
Scale (Haghighat et al. 2003), FACT-F (Stone et al. 2000b) and the Fatigue 
Symptom Checklist (Roscoe et al. 2002), as well as measures of depression and 
wakefulness/activity, the majority based their conclusions on small samples ranging 
from 14-78 (Berger and Farr 1999; Hann et al. 1999; Jacobsen et al. 1999; Berger 
and Higginbotham 2000; Stone et al. 2000a; Roscoe et al. 2002). Moreover, these 
studies failed to demonstrate whether fatigue results in the development of anxiety 
and/or depression, as well as sleep problems, or whether they contribute to patients’ 
experiences of fatigue. Both options are possible, and further research that fully 
explores their complex relationships is necessary.  
4.3.2.3 Demographic factors 
There is conflicting evidence of a relationship between fatigue and demographic 
factors, such as age and gender. While the majority of studies report no relationship 
between age (Smets et al. 1998; Jacobsen et al. 1999; Stone et al. 2000a; Haghighat 
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et al. 2003; Donovan et al. 2004) and fatigue, one longitudinal study that 
specifically explored mental fatigue in women (n=157) with breast cancer receiving 
adjuvant chemotherapy demonstrated an association between increasing age and 
lower fatigue (de Jong et al. 2005). Thus, further research to specifically explore 
and clarify the relationship between age ranges and each dimension of fatigue is 
necessary.  
While one study failed to establish a link between fatigue and gender (Smets et al. 
1998) this finding has been refuted by other studies. A small study of 20 patients 
undergoing a range of cancer treatments demonstrated that women reported 
significantly higher mean levels of fatigue compared with men (Glaus 1993), while 
a study of 81 patients receiving radiotherapy for a range of cancers showed that 
women experienced more fatigue than men, both at the end of therapy, and 1 and 3 
months following radiotherapy (Furst and Ahsberg 2001). Fatigue disruptiveness, 
measured using the fatigue symptom inventory, has also been shown to be higher in 
women than men in a study of 77 men and women aged 60 and above (Respini et al. 
2003). Extending the age range of those involved and replicating this study would 
clarify whether this is an issue for all ages or just older age groups, and the reasons 
for their fatigue. Thus, the evidence that supports a relationship between gender and 
fatigue is based on small sample sizes, and further work that includes larger samples 
and explores fatigue longitudinally across a range of cancer treatments is necessary 
before firm conclusions can be drawn as to the relationship between fatigue and 
gender. 
Thus, several mechanisms for the development of fatigue have been proposed. 
However, while there is a growing body of evidence of potential aetiologies for 
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fatigue, the necessary quality of evidence that allows firm conclusions to be drawn 
about definite causative factors is not currently available. Indeed, it is likely that the 
aetiology of fatigue is multifactorial, involving a combination of these potential 
mechanisms (Ryan et al. 2007). So, while the identification of these proposed 
mechanisms may be helpful in developing appropriate assessment and therapeutic 
interventions to combat fatigue, further research is necessary to fully understand the 
interrelationships between them and the development of cancer-related fatigue. This 
situation contrasts with other cancer-related symptoms such as pain, for which there 
is clear understanding (Smets et al. 1993; Donnelly et al. 1995; Dean and Stahl 
2002). Despite this lack of understanding, however, there are already a number of 
assessment tools and interventions for fatigue. The assessment of fatigue will be 
addressed in the following section with an evaluation of available interventions 
following. 
4.4 Assessing fatigue 
Decisions about managing fatigue are based on understanding the level of fatigue a 
person experiences and its impact on their life (Nail 2002). Indeed, if interventions 
are to be implemented, there should be measures available to evaluate their effects. 
However, the goals of clinical and research-based assessment of fatigue are 
different. Clinical assessment of fatigue seeks to measure levels of fatigue and its 
distress with minimum effort from patients, who may be already significantly 
fatigued, in order that patients can be educated and/or interventions that will 
improve patients’ fatigue experiences initiated and evaluated. Research-based 
assessment seeks to understand, in-depth, patients’ experiences of fatigue and/or 
evaluate which interventions in what circumstances can alleviate or minimise 
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patients’ fatigue experiences. Although both approaches require assessment 
instruments that are valid and sensitive to change, assessment tools that are 
appropriate for one approach are unlikely to meet the needs of the other. For 
example, while validated multidimensional tools provide an in-depth method of 
assessing fatigue, they are often unwieldy for use in clinical practice, as they not 
only take patients a considerable time to complete, but also require sophisticated 
analysis. Such tools are more practical for use within a research setting. A more 
basic assessment, yet one which incorporates incidence, severity and associated 
distress, has been proposed for use in clinical practice (Portenoy and Itri 1999). 
They suggest the routine clinical use of 3 questions to facilitate both the assessment 
of fatigue and its impact on the individual over time: 
1. Are you experiencing any fatigue? 
2. If so, how severe has it been on average during the past week? 
3. How does the fatigue interfere with your ability to function? 
Asking patients to grade their responses to questions 2 and 3 using a numeric rating 
scale of 0-10 will give the clinician an understanding of the patient’s fatigue 
experiences (Portenoy and Itri 1999). However, information on patterns, 
exacerbating and relieving factors, the impact of fatigue on day-to-day activities, 
and the meaning of the fatigue to the individual, are additional factors that are 
important to fully appreciate experiences of fatigue (Winningham et al. 1994), and 
are not addressed in this short clinical assessment of fatigue.  
The National Comprehensive Cancer Network in the United States have included a 
detailed algorithm for clinical assessment of fatigue within each version of their 
88 
clinical guideline for cancer-related fatigue involving a brief screening instrument 
and including screening, primary evaluation and intervention tailored to active 
treatment, long term follow up, or end of life care (National Comprehensive Cancer 
Network 2007b). However, no outcomes research has been conducted to determine 
the effectiveness of the algorithm in clinical practice. This lack of research is likely 
due to the fact that, while the algorithm is comprehensive and provides an overall 
framework for clinical practice, it is lengthy (currently spanning 5 pages), which 
makes its usefulness for daily clinical practice questionable. 
As fatigue is a subjective phenomena, self-report measures are the most appropriate 
method of assessment, and various instruments have been specifically designed to 
measure cancer-related fatigue. These tools follow one of three formats: 
incorporating fatigue into tools that measure broader concepts, such as the Symptom 
Distress Scale (McCorkle and Young 1978), or quality of life scales such as the 
EORTC QLQ C-30 (Aaronson et al. 1993) and the Rotterdam Symptom Checklist 
(de Haes et al. 1990); unidimensional instruments that measure a single aspect of 
the fatigue experience, such as intensity or distress; or multidimensional instruments 
that capture multiple characteristics and manifestations of fatigue, as well as its 
impact on function. Examples of the range of available fatigue-specific tools can be 
found in Table 12.
 Table 12: Fatigue assessment tools 
Instrument/author Consists of Reliability & Validity Clinical utility 
Rhoten Fatigue 
Scale  
(Rhoten 1982) 
One-item 11 point 
rating scale to assess 
current level of fatigue. 
Reliability has not been assessed.  
Validity: patients’ ratings are correlated 
with investigators’ based on observation 
and interviews. 
Short and simple to complete. 
Developed for post-operative fatigue. 
Cannot be evaluated for many forms 
of statistical reliability. Does not 
describe fatigue experiences 
multidimensionally 
Multidimensional 
fatigue Inventory 
(MFI)  
(Smets et al 1995) 
20 item, 7 point scale. 
Measures: general, 
physical and mental 
fatigue as well as 
reduced motivation and 
activity. 
Reliability: Reasonable to good internal 
consistency (0.65-0.80). 
Construct validity: significant differences 
were found between known groups that 
suggest that these differences were related 
to circumstances or activity levels.   
Convergent validity: significant correlation 
between Visual Analogue Scale - Fatigue 
findings  and MFI in radiotherapy patients 
(0.22<r<0.78). 
Multidimensional measure o fatigue, 
groups with/without cancer compared 
in different circumstances and 
activity levels. No reporting of test-
retest reliability, instrument 
development was based on 
researcher’s perspective. 
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Functional 
Assessment of 
Cancer Therapy-
Fatigue (FACT-F) 
(Yellen et al 1997) 
41 item 5 point Likert 
self-report scale 
ranging from 0-4 
consisting of 28 FACT-
General and 13 item 
fatigue subscales. 
Assesses quality of life 
across the domains of 
physical, social, family, 
emotional and 
functional well being, 
relations with physician 
and fatigue 
Reliability: FACT-F showed good internal 
consistency (alpha 0.95) on initial and retest 
administration; good stability (test-retest 
r=0.87) over a 3-7 day window. Fatigue 
subscales independently showed good 
internal consistency (alpha 0.93-0.95) and 
test-retest reliability (r=0.90). 
Convergent/divergent validity: both the 
FACT-F and fatigue subscales showed a 
significant negative relationship with 
POMS-F and PFS and a positive 
relationship with PIMS-V. Non-significant 
findings were noted with Marlowe-Crowne 
Social Desirability Scale (MC-20). 
Discriminant validity: both the FACT-F and 
fatigue subscale were significantly 
correlated with haemoglobin with greatest 
effect in differentiating the very low 
haemoglobin group from the highest. 
High internal consistency and test-
retest reliability. 
Length of entire questionnaire could 
burden fatigued patients, however 
fatigue subscale is brief and easy to 
use. 
Designed for patients in treatment 
which may be a limitation depending 
on the population under investigation. 
Items generated from patients’ 
perspective. 
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Revised Piper 
Fatigue Scale (Piper 
et al 1998) 
22 item, 0-10 
numerical self-report 
scale and 5 open ended 
questions to measure 4 
dimensions: 
behavioural/severity, 
affective meaning, 
sensory and 
cognitive/mood 
Reliability: internal consistency alphas 
ranged from 0.92-0.96 for 4 sub-scales, 
standardised alpha for entire scale – 0.97 
Construct validity: four factor solutions. 
Shorter and easier than previous Piper 
Fatigue scale, multidimensional 
assessment of fatigue with theoretical 
foundation. Comprehensive tool for 
research purposes but may be 
burdensome for use in clinical 
practice. Complex scaling system.  
Questions apply only to those 
experiencing fatigue so must screen 
for fatigue before using. 
Brief Fatigue 
Inventory (BFI) 
(Mendoza et al 
1999) 
9 item, 0-10 numeric 
rating scale to assess 
severity and impact of 
fatigue. 
Reliability: internal consistency alpha – 
0.96. 
Construct validity: factor loadings 0.81-0.92 
show that a single factor accounted for 75% 
variability. 
Concurrent validity: BFI significantly 
correlated with FACT (r=-0.88) and Profile 
Of Mood States (0.84) fatigue subscales. 
Short and easy to use. Good for 
clinical practice. Single dimension of 
fatigue. Tool was not developed from 
patients’ perspective. 
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Schwartz Cancer 
Fatigue Scale 
(Schwartz 1998) 
28 item, 5 point scale 
from 1 (not at all) to5 
(extremely). Measures 
4 dimensions of 
fatigue: physical, 
emotional, cognitive 
and temporal. 
Reliability: alpha internal consistency 0.96 
for total scale and 0.82-0.93 for subscales. 
Content validity: supported by item 
evaluation by both patients with cancer and 
oncology nurse experts. 
Construct validity: factor analysis resulted 
in 4 factor solution for 70% of variance, 
preliminary construct validity was 
supported by differences in fatigue between 
those receiving treatment and those who had 
completed treatment and by VAS fatigue 
scales. 
Long but simply worded 
multidimensional assessment of 
fatigue. Majority of validation 
population had completed cancer 
treatment so further validation 
required.  
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Revised Schwartz 
Cancer Fatigue Scale 
(Schwartz and Meek 
1999) 
6 item 5 point scale. 
Measures 2 dimensions 
of fatigue: physical and 
perceptual. 
Reliability: Good internal consistency of 
alpha – 0.90 for total scale, 0.88 for 
physical subscale, 0.81 for perceptual 
subscale. 
Construct validity: was supported by Lisrel 
Goodness of Fit Index >0.98 and adjusted 
GFI > 0.94. 
Discriminant validity: subjects receiving 
treatment scores significantly higher 
(p<0.001) on all items and both subscales 
and total subscales than those who had 
completed treatment. Significant differences 
were found for each item, subscale, total 
score and time since last treatment 
(p<0.001). 
Brief, simple, tested by advanced 
statistical techniques. Shortest 
multidimensional assessment for 
cancer-related fatigue. First 
instrument to measure perceptual 
aspects of fatigue.  
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Cancer-Related 
Fatigue Distress 
Scale (Holley 2000) 
20 item 0-10 numeric 
rating scale assessing 
fatigue distress in 
relation to physical, 
social, psychological, 
cognitive and spiritual 
components. 
Reliability: Good internal consistency, 
alpha 0.9788 for the total 20 item scale. 
Content validity: content validity indices 
ranged from 0.6-1.0 with a mean of 0.91. 
Construct validity: Factor analysis 
confirmed that all items were loaded on 
only one factors >0.70. 
Short, requires no training and easy to 
read therefore clinically useful. 
Psychometrically sound for 
measurement of distress associated 
with cancer-related fatigue. 
Only captures single dimension of 
fatigue distress rather than whole 
picture of fatigue experiences. 
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 Instrument/author Consists of Reliability & Validity Clinical utility 
Cancer Fatigue Scale 
(Okuyama et al 
2000) 
15 item 5 point 
numeric rating scale 
measuring 3 
dimensions of fatigue: 
physical, affective and 
cognitive. 
Reliability: good internal consistency alphas 
were 0.89 for physical, 0.79 for cognitive 
and 0.88 for the total scale. Test-retest 
correlations of each factor and total score 
between first and second sessions all 
exceeded 0.50. 
Construct validity: a 3 factor solution was 
confirmed by repeating factor analysis.  
Convergent validity: confirmed by 
correlations between CFS and VAS for 
fatigue: each factor significantly correlated 
with VAS score (average r=0.49 p<0.001).  
Intersubscale correlation: significant 
correlations noted for all pairs of subscales, 
mean value of the intersubscale correlation 
were 0.37. 
Simple and easy to complete. 
Designed to assess multidimensional 
cancer-related fatigue. Was 
conducted in Japanese patient 
population and did not consider 
cross-cultural validity. Not developed 
from patients’ perspective.                    
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While gaining insight into the multidimensional fatigue experience provides by far 
the richest information, this method should be balanced with avoiding burdening 
patients who are already fatigued with lengthy and complex questionnaires. 
Although further psychometric testing of some of these instruments within cancer 
populations is desirable (Varricchio 2000; Wu and McSweeney 2001), Table 12 
shows that, while there are no gold standard assessment instruments at this time, 
there are a range of available assessment instruments that are more or less 
appropriate for a variety of purposes. For example, tools such as the Revised Piper 
Fatigue Scale (Piper et al. 1998) meet the in-depth, exploratory needs of researchers 
seeking to understand the multi-dimensional fatigue experience or evaluate the 
impact of specific interventions on various dimensions of patients’ fatigue 
experiences, while the shorter Cancer Fatigue Scale revised version (Schwartz and 
Meek 1999) allows patients, in just 6 questions, to provide clinicians with a 
multidimensional picture of their fatigue experiences. Thus, the current measures to 
assess fatigue, although not perfect and requiring further development and 
evaluation, are of a standard that allows an understanding of fatigue experiences, or 
the impact of an intervention on fatigue, to be obtained in clinical practice.  
However, it is important at this stage to highlight factors, other than the quality of 
the assessment instrument, that can impact on the assessment of fatigue. Firstly, 
social value systems can promote the idea that fatigue is experienced by everybody, 
not just if you have cancer or are having cancer treatment. If these views are 
perceived by people with cancer experiencing fatigue they may chose to stop 
reporting the symptom because they have been made to feel that their fatigue is not 
important or that it is just part of life (Stone et al. 2003). 
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The second factor that complicates fatigue assessment is the misbelief that fatigue is 
an indicator of depression. While a comparison of the multidimensional fatigue 
construct and depression shows a strong overlap of symptoms (Reuter and Harter 
2004) which most probably accounts for the confusion between the two symptoms, 
fatigue and depression represent two distinct phenomena in people with cancer 
(Visser and Smets 1998) and can co-exist (Aas et al. 1997; Aktchi et al. 1999). 
While it is possible that people experiencing cancer-related fatigue can be saddened 
by it, to date there is no evidence of a cause and effect relationship between fatigue 
and depression in people with cancer. This is supported by studies of 
antidepressants and their lack of positive effects on fatigue (Morrow et al. 2003; 
Roscoe et al. 2005). 
Thirdly, discrepancies have been shown to exist between patients, carers and health 
professionals in relation to cancer-related fatigue. Two large studies compared 
patients’; carers’ and health professionals’ perceptions of cancer-related fatigue and 
reported differences in perceptions of fatigue incidence (Vogelzang et al. 1997; 
Stone et al. 2003). For example, in Vogelzang’s study of 419 patients with cancer, 
200 caregivers and 197 oncologists (unrelated to the patients): 78% of patients 
reported that they experienced fatigue, 86% of caregivers thought that the patients 
they cared for experienced fatigue while oncologists perceived that 76% of their 
patients experienced fatigue (Vogelzang et al. 1997). In a similar multicentre study, 
Stone and colleagues involved 576 patients, 454 caregivers and 368 healthcare 
professionals (oncologists, nurses, radiographers and haematologists). They found 
that while 56% of patients reported that fatigue had affected them in the previous 
month, 71% of carers felt that the patient had been fatigued in the previous month 
and 65% of health professionals felt that most or nearly all patients had felt fatigued 
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in the previous month (Stone et al. 2003). These different perceptions of incidence 
were not the only discrepancies between the groups. In the study by Vogelzang, 
patients reported that fatigue negatively affected their lives more than pain (61% 
versus 19%), while oncologists believed that pain had a greater negative effect on 
patients’ lives, compared with fatigue (61% versus 37%) (Vogelzang et al. 1997). 
Moreover, 50% of patients did not discuss fatigue with their doctor (Vogelzang et 
al. 1997). In Stone’s study, although most health professionals reported that they 
recommended or prescribed treatment for fatigue for over half of their patients, only 
14% of patients reported receiving such treatment. These large multicentre studies 
both demonstrate the discrepancies between perceptions of fatigue, as well as the 
outcomes of patient/healthcare professional communications, both of which are 
likely to complicate the assessment of fatigue. 
Response shift is the final factor that can complicate fatigue assessment, or indeed 
any symptom. This relatively novel concept has received little consideration, but 
describes the process by which a person’s point of reference shifts with time and 
experience so that, in relation to cancer-related fatigue, their previous definition of 
extreme fatigue is now what they would consider as moderate, and a previously 
unknown level of fatigue now occupies the position of extreme fatigue (Breetvelt 
and van Dam 1991; Visser et al. 2000). This shift acts to minimise the differences 
that can be observed in the severity of fatigue experienced by people with cancer 
compared with healthy control groups and, although a shift in internalised standards 
can be functional for patients, it is troublesome for both clinicians and researchers 
as it may render assessments made over time incomparable. Further research, both 
quantitative and qualitative, is required to explore whether the concept is helpful to 
further our understanding of adaptation in chronic illness.  
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However, as already highlighted there are a range of assessment instruments for 
assessing fatigue and these, along with being mindful of the factors that can 
complicate such assessments, provide sufficient opportunities to develop an 
understanding of fatigue experiences and evaluate management techniques.  
4.5 Current management techniques for cancer-related fatigue 
While the most effective approach to symptom management is to identify the cause 
of the distress and correct it if possible, it is unfortunate, as shown earlier, that at 
present there is no clear understanding of the causative factors for cancer-related 
fatigue. This lack of understanding prevents the development of targeted 
interventions and the approach taken to fatigue management is a general one. 
Indeed, one of the previous reasons for the lack of interest in fatigue as a topic of 
research has been the lack of any effective interventions to improve it (Stone et al. 
1998). Interventions, as with nausea in chapter 3, can be considered 
pharmacological or non-pharmacological. 
4.5.1 Pharmacological management of fatigue 
4.5.1.1 Correction of anaemia 
As already highlighted, anaemia has been identified as a potential cause of fatigue. 
The traditional method of treating anaemia via a blood transfusion, although 
effective, is associated with risks and is subject to limitations in blood supply. 
Erythropoietin-alpha therapy, the subcutaneous administration of a growth factor to 
stimulate the production of red blood cells, is an effective alternative to blood 
transfusions. Three large community-based non-randomised studies have evaluated 
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the impact of this therapy on quality of life (Glaspy et al. 1997; Demetri et al. 1998; 
Gabrilove et al. 2001). In samples ranging from 2,370-3,012, these 3 studies 
demonstrated that erythropoietin-alpha therapy is effective in reducing fatigue and 
improving functional status and quality of life in anaemic patients with cancer 
receiving chemotherapy, as well as increasing haemoglobin level and decreasing 
transfusion requirements (Glaspy et al. 1997; Demetri et al. 1998; Gabrilove et al. 
2001). These results have been supported by 2 double blind randomised controlled 
trials involving patients (n=349, n=375) suffering from anaemia receiving 
chemotherapy (Littlewood et al. 2001; Osterborg et al. 2002). While fatigue was 
assessed within a quality of life questionnaire rather than as an independent 
symptom, there is clear support from these larger studies that administration of 
erythropoietin-alpha therapy to reduce anaemia subsequently improves fatigue 
levels. Published guidelines also support the use of erythropoietin-alpha therapy in 
clinical practice for the management of anaemia (Turner et al. 2001; National 
Comprehensive Cancer Network 2007b). However, overall, better quality evidence 
is needed that explores the impact of erythropoietin-alpha therapy specifically on 
fatigue, rather than anaemia and quality of life, before the use of such a therapy can 
be unequivocally supported solely as an intervention to improve experiences of 
fatigue, as regular measurement of quality of life outwith a clinical trial has been 
shown to result in improved quality of life (Velikova et al. 2004). 
4.5.1.2 Paroxetine 
Paroxetine is an antidepressant and its effects on cancer-related fatigue have been 
explored in 4 studies with mixed results. Two small trials have shown a trend 
towards a possible benefit for paroxetine  in treating general, emotional and mental 
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fatigue in women with breast cancer experiencing hot flushes (n=13) and in patients 
receiving interferon-alpha (n=18) (Weitzner et al. 2002; Capuron et al. 2002). 
However, two large multicentre randomised controlled double blinded placebo 
controlled trials involving more than 400 patients with solid tumours receiving 
chemotherapy (Morrow et al. 2003) and 94 patients with breast cancer receiving at 
least 4 cycles of chemotherapy (Roscoe et al. 2005) have shown that 20g of 
paroxetine orally on a daily basis had no effect on fatigue experiences, although 
improvements in mood and depression were noted in the paroxetine treatment 
groups. Thus, the level of evidence required to draw conclusions about the 
effectiveness or otherwise of paroxetine in the management of cancer-related 
fatigue is currently unavailable and further research is required.  
4.5.2 Non-pharmacological management of fatigue 
4.5.2.1 Exercise 
Two meta-analyses and 6 systematic reviews support the benefits of exercise in the 
management of fatigue, both during and after cancer treatment in patients with 
breast cancer and solid tumours, as well as those undergoing haematopoietic stem 
cell transplantation (Courneya and Friedenreich 1999; Stevinson et al. 2004; 
Oldervoll et al. 2004; Stricker et al. 2004; Galvao and Newton 2005; Knols et al. 
2005; Schmitz et al. 2005; Luctkar-Flude et al. 2007; Conn et al. 2006; Cramp and 
Daniel 2008). The growth seen in the volume of research in this field is most likely 
because health professionals have become more familiar with the concept of 
exercise as intervention for fatigue and because the safety and benefits have been 
demonstrated. The most recent of these reviews (Cramp and Daniel 2008) noted that 
the majority of studies exploring fatigue and exercise involved individuals 
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diagnosed with breast cancer and reported 16 studies involving 1172 individuals 
with breast cancer, highlighting the relevance of exercise to the population of the 
SNA↔P study.  
However, it is reasonable to question whether the specific beneficial effects of 
physical exercise vary depending on the stage of disease, the nature of the treatment 
patients receive and their current lifestyle. Consequently, more research is required 
that systematically assesses the tailoring of type, intensity and frequency of exercise 
to specific diagnoses, stage of disease and treatments. While many individual 
studies suffer from methodological shortcomings (such as small samples (MacVicar 
and Winningham 1986; Mock et al. 1994; Schwartz 1999; Mock et al. 2001; 
Schwartz et al. 2001), problems with adherence to or monitoring adherence to 
exercise programmes (Mock et al. 1994; Schwartz 1999; Mock et al. 2001; 
Schwartz et al. 2001; Mock et al. 2002), and combination effects of interventions 
(Mock et al. 1994)), there is a sufficient quality of evidence both from large 
systematic reviews and meta-analyses that include a range of cancer diagnoses to 
recommend exercise as an intervention for improving experiences of fatigue. 
4.5.2.2 Education and information provision 
As with exercise, there is a growing body of evidence that supports the 
implementation of education and information provision for people with cancer in 
alleviating fatigue experiences. Given this body of evidence and the focus of this 
thesis, only those studies that include women with breast cancer receiving 
chemotherapy will be evaluated. These studies are presented in Table 13.
 Table 13: Summary of studies exploring effects of education and information on experiences of fatigue 
Author Aim Design Sample Procedure/Instruments Findings Limitations 
Given et al 
(2002) 
To evaluate a 
supportive 
intervention 
delivered by 
nurses 
tailored to 
managing 
fatigue and 
pain during 
chemotherapy 
RCT 113 patients 
with a range 
of diagnoses 
(26% with 
breast cancer) 
Intervention included 
teaching, counselling, 
support, co-ordination 
and communication. 
Conducted over an 18 
week period with 10 
contacts with each 
patient. Fatigue measured 
using the Symptom 
Experience Scale 
Reduced fatigue and pain 
in the intervention group 
as well as improvements 
in physical and social 
functioning at 20 weeks 
Symptom 
Experience Scale 
measures 
presence or 
absence of 
fatigue. 
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 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Jacobsen et 
al (2002) 
To establish 
and compare 
the benefits or 
otherwise of 
professional 
or patient 
administered 
stress 
management 
training 
RCT 411 patients 
about to start 
chemotherapy  
(58% with 
breast cancer) 
Patients randomised to 
receive either usual 
psychosocial care, 
professionally 
administered stress 
management training or 
patient self-administered 
stress management 
training. QoL 
assessments were 
performed before 
randomisation and before 
2nd, 3rd and 4th 
chemotherapy treatments. 
Better physical 
functioning and increased 
vitality and mental health 
in the self-administered 
training compared with 
the professional 
administered stress 
management training 
Fatigue was 
measured as 
‘vitality’ within 
the SF36 
questionnaire 
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 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Ream and 
Richardson 
(2002) 
To test 
feasibility of a 
fatigue 
management 
programme, 
examine 
patients’ 
responses and 
refine the 
intervention  
Pilot 
evaluation 
study 
8 patients 
receiving 
chemotherapy 
(5 had a 
diagnosis of 
breast cancer) 
Patients received the 
‘Beating Fatigue’ nursing 
intervention which is 
comprised of 4 
components: 
assessment/monitoring of 
fatigue, education, 
coaching self-care, 
provision of emotional 
support. Evaluation 
included a daily fatigue 
diary, HADS, SF36, 
Brief COPE and 
interview. 
Self-reported fatigue 
reduced and patients 
were reported to 
appropriate the support 
they received. Patients 
enjoyed being able to talk 
to someone about their 
fatigue. 
Involved a large 
volume of 
assessment for 
already fatigued 
individuals to 
complete. 
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 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Barsevick 
et al (2004) 
To evaluate 
the impact of 
3 telephone 
sessions to 
educate 
patients and 
develop an 
energy 
conservation 
plan 
RCT 396 patients 
receiving 
either 
chemotherapy
, radiotherapy 
or concurrent 
therapy 
(n=282, 71% 
had breast 
cancer) 
Patients in each group 
participated in 3 
telephone sessions with 
an oncology nurse during 
the first 5 weeks of 
treatment to discuss 
energy conservation and 
activity management 
(intervention group). 
Data on fatigue were 
obtained before treatment 
and at 2 points of high 
fatigue for each type of 
treatment. Fatigue was 
evaluated using the 
POMS, Schwartz Cancer 
fatigue Scale and the 
General Fatigue Scale. 
The intervention group 
receiving telephone 
support and education 
experienced a greater 
reduction in fatigue over 
time compared with the 
control group. 
The control 
group received 
education about 
nutrition which 
may have 
impacted on their 
fatigue 
experiences. 
106 
 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Williams 
and 
Schreirer 
(2005) 
To examine 
the effect of 
informal 
audiotapes on 
patients’ self-
care 
behaviours to 
manage 
chemotherapy
-related 
symptoms 
RCT 71 women 
with breast 
cancer 
undergoing 
chemotherapy 
33 women received 
audiotapes on self-care 
that addressed exercise 
and relaxation to manage 
anxiety, fatigue and sleep 
problems. Three 
telephone interviews 
were conducted.  
Women that received 
education demonstrated 
more and a wider range 
of self-care behaviours, 
increased their self-care 
behaviours over time and 
reported less anxiety. A 
higher percentage of 
women in the control 
group reported fatigue 
and the severity ratings 
increased between the 
first and second 
recordings. Patients were 
appreciative of the 
telephone calls. 
Lack of control 
over how much 
information 
patients were 
given at their 
treatment times. 
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 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Yates et al 
(2005) 
To evaluate 
an 
individualised 
fatigue 
education and 
support 
programme 
RCT 109 women 
commencing 
adjuvant 
chemotherapy 
for stages I or 
II breast 
cancer 
Nurses delivered a 
tailored 
psychoeducational 
intervention to improve 
knowledge and skills 
relative to self-care 
behaviours for fatigue in 
clinic and by phone in 4 
weekly sessions. 
Evaluation involved: a 
numeric rating scale 
assessing confidence in 
managing fatigue; an 11 
point numeric scale 
measuring fatigue at best, 
worst and average; the 
Functional Assessment of 
Cancer Therapy – 
Fatigue scale; the Piper 
Fatigue Scale; the Cancer 
Self-Efficacy Scale; the 
EORTC QLQ C-30 and 
the Hospital Anxiety and 
Depression Scale. 
Women who received the 
intervention experienced 
significantly less fatigue 
and less interference 
from fatigue over the 
treatment cycle when 
evaluated one to two 
weeks after the 
intervention. The 
reduction in fatigue and 
fatigue interference was 
not sustained at 6 and 10 
week follow up.  
Battery of 
evaluation 
instruments 
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 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Ream et al 
(2006) 
To evaluate 
the impact of 
the ‘Beating 
Fatigue’ 
nursing 
intervention 
RCT 103 patients 
about to start 
chemotherapy 
(21% had 
breast cancer) 
Conducted over 3 months 
and included a patient 
information pack, a 
fatigue diary that patients 
completed for one week 
following each 
chemotherapy and a 
monthly visit from a 
support nurse at home to 
assess fatigue, provide 
psychological support 
and coach patients in 
self-care. Fatigue 
measured using 4 visual 
analogue scales 
evaluating: quantification 
of fatigue; associated 
distress; effects on work 
and effects on hobbies. 
Intervention group 
reported significantly less 
fatigue, lower associated 
distress and less impact 
of fatigue on valued 
pastimes than the control 
group. They also reported 
less anxiety and 
depression than the 
control group and 
displayed more adaptive 
coping 
Lack of blinding 
for both 
researchers and 
participants 
which may have 
resulted in a 
placebo effect as 
well as a lack of 
control over the 
information 
available to both 
the intervention 
and control 
groups 
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Table 13 shows that 6 randomised controlled trials and 1 non randomised pilot 
study have demonstrated the positive impact of education and information on 
women’s experiences of fatigue during chemotherapy for breast cancer. 
Furthermore, patients have been shown to welcome the additional support and 
contact associated with such interventions (Ream et al. 2002; Williams and Schreier 
2005; Ream et al. 2006) and apply the skills they learn in their daily lives to 
improve their fatigue experiences (Ream et al. 2002; Barsevick et al. 2004; 
Williams and Schreier 2005; Yates et al. 2005; Ream et al. 2006). Indeed, it is not 
solely this evidence base that supports the use of educational strategies: the National 
Comprehensive Cancer Network guidelines for the management of cancer-related 
fatigue recommend that patients with cancer and their families are provided with 
preparatory guidance about patterns of fatigue and recommendations for self-care 
(National Comprehensive Cancer Network 2007b). Consequently, it can be 
concluded that the use of education and information is an intervention that is likely 
to be effective in the management of cancer-related fatigue. 
4.5.2.3 Measures to optimise sleep 
Five studies: 2 feasibility (Berger et al. 2002; Berger et al. 2003), 2 small (n=14 
(Davidson et al. 2001) and n=10 (Quesnel et al. 2003) and 1 randomised controlled 
trial (n=57) (Savard et al. 2005), have provided preliminary evidence that a 
multicomponent cognitive-behavioural intervention designed to optimise sleep 
quality also may improve fatigue. These studies are presented in Table 14.
 Table 14: Summary of studies to evaluate optimising sleep on experiences of fatigue 
Author Aim Design Sample Procedure/Instruments Findings Limitations 
Davidson 
et al (2001) 
To evaluate a 
sleep therapy 
programme 
on sleep, 
fatigue and 
QoL.  
Descriptive 12 cancer 
survivors, 
mixed 
diagnoses 
The six-session group 
programme included 
stimulus control therapy, 
relaxation training, and 
other strategies aimed at 
consolidating sleep and 
reducing cognitive-
emotional arousal. 
Participants kept sleep 
diaries and rated their 
sleep quality, mood and 
functioning at baseline, 
week 4 and week 8 using 
EORTC QLQ C-30. 
Significant 
improvement over 
baseline was 
observed at weeks 4 
and 8 in the number 
of awakenings, time 
awake after sleep 
onset, sleep 
efficiency, sleep 
quality ratings, and 
scores on European 
Organization for 
Research and 
Treatment of Cancer 
(EORTC) QLQ-C30 
role functioning and 
insomnia. Total sleep 
time and fatigue were 
significantly 
improved at week 8. 
Small sample 
size. Preliminary 
evidence only for 
the effectiveness 
of the 
programme. 
Fatigue 
measured using 
subscale within 
QoL 
questionnaire. 111 
 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Berger et al 
(2002 
To evaluate 
the feasibility 
of an 
intervention 
designed to 
promote sleep 
and modify 
fatigue  
Prospective, 
repeated 
measures, 
quasi-
experimental 
study 
25 women 
aged 40-65 
with stage I-II 
breast cancer 
receiving 
doxorubicin 
chemotherapy 
Each woman developed, 
reinforced and revised an 
individualised sleep 
promotion plan including 
sleep hygiene, relaxation, 
stimulus control and 
sleep restriction 
techniques. Assessment 
included a daily diary, 
Pittsburgh Sleep Quality 
Index, wrist actigraph, 
and the Piper Fatigue 
Scale – completed 2 days 
before and 7 days after 
each chemotherapy. 
Intervention was 
feasible . fatigue was 
stable 2 days after 
each chemotherapy  
and mean daily 
fatigue intensity was 
lower at 
chemotherapy 3 than 
at 1 but rebounded at 
chemotherapy 4.  
Small sample 
size, recruitment 
problems meant 
it was difficult to 
implement the 
intervention 
before the first 
cycle of 
chemotherapy. 
Conflicting 
information 
between 
actigraph and 
diary in some 
cases. Adherence 
issues to the 
various 
components of 
the programme.  
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Berger et al 
(2003) 
To evaluate 
outcomes of 
an 
intervention 
designed to 
promote sleep 
and modify 
fatigue after 
adjuvant 
chemotherapy 
for breast 
cancer 
Prospective, 
repeated 
measures, 
quasi-
experimental, 
feasibility 
study 
21 women 
with stage I-II 
breast cancer 
following 4 
cycles of 
doxorubicin 
chemotherapy
. 
Each woman continued 
to revise her 
individualised sleep 
promotion plan 
developed during her 
first cycle of 
chemotherapy that 
included sleep hygiene, 
relaxation, stimulus 
control and sleep 
restriction techniques. 
Assessment included a 
daily diary, Pittsburgh 
Sleep Quality Index, 
wrist actigraph, and the 
Piper Fatigue Scale – 
completed for 7 days 30, 
60 and 90 days after the 
last chemotherapy 
treatment and one year 
after the first 
chemotherapy treatment. 
Adherence rates were 
high for most 
components of the 
intervention. Sleep 
and wake patterns 
were within normal 
limits except for the 
number and duration 
of night time 
wakenings. Fatigue 
remained low: 2.9-3.5 
on a 0-10 scale. 
Small sample 
size, lack of 
control group. 
Conflicting data 
between diary 
reports and 
actigraph. 
Reduced 
adherence to 
stimulus control 
component of the 
intervention. 
113 
 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Quesnel et 
al (2003) 
To evaluate 
the efficacy of 
a multimodal 
cognitive-
behavioural 
intervention  
Pilot 
intervention 
time series 
design 
8 women with 
insomnia 
caused or 
aggravated by 
breast cancer 
Treatment administered 
during 8 weekly group 
sessions of 90 minutes 
that included 
behavioural, cognitive 
and educational 
strategies. Multiple 
objective and subjective 
measures undertaken: 
interviews, sleep diary, 
polysomnography, ISI, 
BDI, STAI, MFI, QLQ-
C30. 
Reduced total wake 
time and increased 
sleep efficiency 
(assessed subjectively 
and objectively)  as 
well as improved 
mood, fatigue and 
quality of life. 
Self-selection of 
patients and 
small sample 
size. Unable to 
determine which 
aspects of the 
intervention, if 
any, were 
responsible for 
the therapeutic 
gains reported. 
114 
 Author Aim Design Sample Procedure/Instruments Findings Limitations 
Savard et al 
(2005) 
To assess the 
efficacy of 
cognitive 
behavioural 
therapy for 
insomnia 
secondary to 
breast cancer 
RCT 57 women 
with insomnia 
caused or 
aggravated by 
breast cancer 
Women randomised to 
therapy or control group. 
Treatment consisted of 8 
weekly sessions 
administered in a group 
and combined the use of 
stimulus control, sleep 
restriction, cognitive 
therapy, sleep hygiene 
and fatigue management. 
Evaluations were 
performed at 3, 6 and 12 
months post-treatment. 
Fatigue was assessed 
using the 
Multidimensional 
Fatigue Inventory. 
Women in the 
intervention group 
showed greater 
improvement in sleep 
and these 
improvements were 
maintained in some 
cases up to 12 
months. The 
treatment of insomnia 
was associated with 
decreased anxiety and 
depression and 
improved global 
quality of life. 
Although 
specific fatigue 
data collected 
this was not 
reported. Patients 
recruited through 
advertisement 
therefore highly 
motivated.  
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In general, the cognitive-behavioural intervention generally included relaxation 
training in tandem with sleep consolidation strategies, such as: avoidance of long or 
late naps and limiting time in bed to actual sleep time; stimulus control therapies, 
such as only going to bed when tired; using the bedroom for sleep or sexual reasons 
only; going to bed and getting up at consistent times; avoiding caffeine and 
stimulating activity in the evenings; strategies to reduce cognitive-emotional 
arousal, such as relaxing for one hour before going to bed; and setting a pre-sleep 
routine to be used every night. The results support the feasibility of this intervention 
being delivered either individually (Berger et al. 2002; Berger et al. 2003) or in a 
group setting (Davidson et al. 2001; Quesnel et al 2003; Savard et al. 2005) to 
women either receiving or having received chemotherapy for breast cancer. Given 
the level of this evidence base it is likely that interventions that optimise sleep do 
have a positive effect on fatigue experiences. However, further research utilising 
randomised controlled trial approach are required to establish which of these 
strategies and techniques are most effective, at what times in the treatment trajectory 
and for what populations they should be used before the intervention can be 
conclusively recommended to patients.  
4.5.2.4 Energy conservation 
Energy conservation is the deliberate planned management of one’s personal energy 
resources to prevent their depletion and involves strategies such as delegation, 
priority setting, pacing, and planning high-energy-use activities at times of peak 
energy. A pilot study of 80 patients receiving chemotherapy or radiotherapy used a 
single group pre-test/post-test design to examine the feasibility of energy 
conservation and activity management (Barsevick et al. 2002). Three telephone 
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sessions were used to educate patients about energy conservation and activity 
management. Using a non-equivalent control group, the authors demonstrated that 
energy conservation potentially offered a successful means of managing cancer-
related fatigue. Following this study, a larger multicentre RCT study (n=396) by the 
same researchers explored this nurse-delivered intervention (Barsevick et al. 2004). 
They concluded that energy conservation had a modest but significant effect on 
patients’ fatigue experiences (71% of whom had breast cancer) (Barsevick et al. 
2004). Given these initially positive results, it is reasonable to propose that energy 
conservation may have a role in managing fatigue. However, at this time there is not 
a sufficient amount of high quality evidence to draw definite conclusions. 
4.5.3 Summary of current management techniques for fatigue 
There is a range of potential interventions for cancer-related fatigue, however, the 
level of evidence for each of these varies. At present, while there is some support 
for the use of pharmacological techniques, that is erythropoietin-alpha therapy or 
paroxetine, for cancer-related fatigue, there remains insufficient high level evidence 
that focuses solely on fatigue to unequivocally recommend these in practice. The 
impact of several non-pharmacological techniques has been evaluated. Of these, and 
based on current available evidence, exercise has a sufficient amount of high level 
evidence to support its implementation in practice. The provision of education and 
information, and measures to optimise sleep and energy conservation, are likely to 
be positive interventions and there is no evidence that any of these interventions 
would cause harm. Consequently, while further research is required before 
unreservedly implementing these interventions in practice, they provide patients and 
health professionals with additional techniques that may improve fatigue 
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experiences. Thus, there is a range of techniques that health professionals can 
suggest and that patients can try to ameliorate fatigue experiences. Indeed, as 
fatigue is experienced multidimensionally, it is likely that a combination of 
techniques that influence different components would be most effective in fatigue’s 
management (Ream et al 2006).  
However, as these potentially effective interventions have been evaluated within 
research settings, one can question whether they can be implemented or have such 
efficacious results in the real world. The following section presents patients’ 
experiences of fatigue and reflects on whether the interventions described above can 
have an impact on preventing or alleviating this symptom in the real world of 
clinical practice. 
4.6 Patients’ experiences of cancer- and chemotherapy-related 
fatigue 
Fatigue has been shown to be a highly prevalent condition among patients with 
cancer (Stone et al. 1998; Portenoy and Itri 1999), with prevalence rates between 
70% to 100% (Watson and Mock 2004). Differences in prevalence rates between 
studies are likely attributable to the variety of study methods and patient 
populations. Methods and characteristics most likely to result in different 
prevalence rates are the inclusion of patients receiving different cancer treatments, 
at differing stages of disease and different cancer diagnoses, the use of various 
different definitions of fatigue and the array of measurement instruments, for 
example, individual items versus lengthy multidimensional fatigue instruments 
(Cella et al. 1998). Moreover, as already highlighted, patients’ and health 
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professionals’ perceptions of cancer-related fatigue differ (Vogelzang et al. 1997; 
Stone et al. 2003). Thus, subjective indicators are likely to be key in understanding 
the fatigue experience (Piper et al. 1987; National Comprehensive Cancer Network 
2007b). There are a few studies that have solely sought patients’ perspectives of 
fatigue experiences as a result of chemotherapy using either survey or qualitative 
methods. 
Survey methods have consistently shown fatigue during chemotherapy to be an 
unpleasant symptom that interferes with patients’ ability to lead a normal life (Curt 
et al. 2000; Donovan and Ward 2005; Byar et al. 2006; de Jong et al. 2006). In a 
range of patient populations either receiving chemotherapy at the time of the survey 
n=27 (Donovan and Ward 2005) and n=157 (de Jong et al. 2006), or who had 
already completed chemotherapy treatment n=379 (Curt et al. 2000) and n=25 (Byar 
et al. 2006), chemotherapy-related fatigue is described as: causing alterations in 
daily routine (Curt et al. 2000; de Jong et al. 2006); distressing and uncontrollable 
(Donovan and Ward 2005); directly correlated with a reduction in quality of life 
(Byar et al. 2006) and responsible for changes in employment (Curt et al. 2000). 
However, these studies utilised a number of tools to reach their conclusions: the 
Symptom Representation Questionnaire (Donovan and Ward 2005), the Piper 
Fatigue Scale (Byar et al. 2006; de Jong et al. 2006), the Hospital Anxiety and 
Depression Scale, SF36 (Byar et al. 2006), and the Multidimensional Fatigue 
Inventory (de Jong et al. 2006). Such diversity in assessment tools prevents the 
evidence from these relatively small surveys being amalgamated to increase 
confidence in the results. Moreover, patients in two studies (Donovan and Ward 
2005; de Jong et al. 2006) had received both chemotherapy and radiotherapy, 
making it impossible to tease out which dimensions of fatigue are particularly 
120 
relevant to chemotherapy. Indeed, the work of Byar et al (2006) was part of a pilot 
study that explored an intervention for sleep that may have affected respondents’ 
perceptions of fatigue. Such secondary data analysis is a feature of the qualitative 
research that has sought to explore fatigue experiences.  
Just a few qualitative studies have explored fatigue experiences. The two largest 
n=910 (Ferrell et al. 1996) and n=127 (Hilfinger Messias et al. 1997) were based on 
secondary analysis of data gathered either from several studies of quality of life 
(Ferrell et al. 1996) or a single study that sought to test the efficacy of an 
intervention on self-care behaviours (Hilfinger Messias et al. 1997), which explains 
the unusually large number of participants for qualitative studies. Nevertheless, 
these two studies have demonstrated the overwhelming effects of fatigue on 
patients’ well-being and daily activities that negatively impact on all dimensions of 
quality of life. Both studies provided rich and striking quotes from patients 
describing their experiences using metaphors and similies such as: ‘it is wet 
cement’, ‘it’s like rubber knees’, ‘I’m tired to the bone’ (Ferrell et al. 1996) and 
descriptions such as: ‘wiped out’, ‘drained’, ‘slumpish’ and ‘blah’ (Hilfinger 
Messias et al. 1997). Three other studies have used original data involving small 
patient numbers, n=15 (Magnusson et al. 1999), n=17 (Holley 2000a), and n=10 
(Wu and McSweeney 2007) to explore experiences of fatigue during chemotherapy. 
All these studies confirmed the negative effects of fatigue on all dimensions of 
quality of life. Holley (2000) described the distress associated with cancer-related 
fatigue (her sample included patients who had received radiotherapy, chemotherapy, 
surgery and biotherapy, making it difficult to know with certainty the relationship 
between fatigue distress and chemotherapy). Nevertheless, the distress and suffering 
reported by patients in relation to their fatigue was evident in all aspects of their 
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lives: physical, social, cognitive, psychological and spiritual (Holley 2000a). 
Indeed, the most recent study continued to provide rich descriptions of patients’ 
experiences: ‘I was just drained, just listless, like a wet fish flopped out, just like a 
rag doll’, demonstrating that patients described fatigue of an unexpected kind and 
degree that was much more than just being tired and that their inability to anticipate 
and appreciate the scope of fatigue, in tandem with their lack of awareness of 
interventions to combat it, caused distress (Wu and McSweeney 2007).  
Thus, irrespective of the techniques implemented to explore patients’ own 
experiences of fatigue the results are consistent: fatigue is an unpleasant symptom 
that negatively impacts on all dimensions of quality of life. Moreover, the fatigue of 
cancer and cancer-treatment is all encompassing and of a kind and degree that 
patients cannot anticipate.  
4.7 Conclusion 
This chapter has defined cancer-related fatigue and briefly described its potential 
aetiologies. It has shown that, despite considerable efforts, current understanding of 
the causes of cancer-related fatigue is less than optimal. However, this lack of 
understanding has not prevented the development of a range of assessment tools 
with which to assess fatigue from both clinical and research perspectives. An 
evaluation of these tools demonstrated that, while there is no gold standard 
assessment tool, and although further refinement and evaluation of most tools is 
necessary, current available tools are sufficient for developing our understanding of 
the fatigue experience and evaluating the relative impact of interventions.  
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Interventions themselves and the available evidence for their support have also been 
considered. Further research is necessary before pharmacological interventions for 
fatigue can be unequivocally recommended, although erythropoietin-alpha therapy 
has potential for improving fatigue experiences. Exercise, education and 
information, measures to optimise sleep, and energy conservation have varying 
levels of research support and, at this time, exercise has sufficient high level 
evidence to recommend it in practice. Both education and optimising sleep are 
likely to improve experiences of fatigue, while more evidence is required before 
energy conservation can be unreservedly presented to patients as an effective 
intervention for improving fatigue experiences. 
Patients’ experiences of fatigue have also been considered. Exploring the results of 
those studies whose primary aim was to describe the symptom experience, fatigue 
has been shown to be an all-encompassing, unpleasant symptom that affects all 
dimensions of patients’ quality of life..  
Chapters 2, 3 and 4 have shown that both nausea and fatigue are symptoms of 
concern for patients with cancer receiving chemotherapy that, despite efforts 
relating to symptom assessment and management, have a deleterious effect on 
patients’ quality of life. The focus of this thesis is the evaluation of a nurse-led 
intervention (SNA↔P) aimed at improving patients’ experiences of nausea and 
fatigue. Chapter 5 will briefly summarise the main points from chapters 2, 3 and 4, 
providing justification for the SNA↔P study before the methods and intervention 
for SNA↔P are presented in chapters 6 and 7, respectively. 
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5 CHAPTER 5 – SUMMARY OF LITERATURE REVIEW AND 
RATIONALE FOR THE SNA↔P STUDY 
5.1 Introduction 
The last three chapters have presented a review of the literature concerning 
chemotherapy-related symptoms in general and nausea and fatigue specifically. This 
chapter will, firstly, briefly summarise the salient points of this literature review 
before going onto present a short rationale for the SNA↔P study. 
5.2 Summary of the literature review 
Symptoms are a subjective experience perceived and verified only by the individual 
experiencing the phenomenon. A significant amount of research has explored the 
symptoms experienced by patients during chemotherapy which has shown that 
patients experience a broad range of physical, psychological and social symptoms. 
Further analysis of this evidence revealed, that not only were nausea and fatigue the 
most frequently reported symptoms, but they were also consistently ranked within 
patients’ top four symptoms. Both nausea and fatigue are non-observable 
symptoms, which is a complicating factor in their assessment and management.  
Indeed, the assessment of nausea and fatigue is not straightforward. The assessment 
of nausea is complicated by its close association with vomiting and lack of 
multidimensional assessment tools that specifically address nausea. In contrast, 
despite a lack of understanding of the aetiology of fatigue, a plethora of fatigue 
assessment tools have been developed. However, many of the assessment tools for 
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nausea (and vomiting) and fatigue are lengthy and research-focused, making them 
unsuitable for day-to-day use in the clinical situation. This lack of structured 
assessment makes the choice and evaluation of appropriate management techniques 
difficult. 
There is currently no gold standard pharmacological intervention for the 
management of nausea, and, while non-pharmacological techniques may be helpful 
in alleviating patients’ nausea experiences, further research is required before 
unequivocally recommending their use in clinical practice. Furthermore, their 
translation from research settings into clinical practice is complicated by factors 
such as health professionals’ unfamiliarity with the techniques, their lack of 
education, as well as the necessary time taken to implement the interventions, and 
the costs associated with their implementation. The aetiology of fatigue is poorly 
understood and there are currently no pharmacological interventions that are 
supported by sufficient evidence to recommend their use in clinical practice. Non-
pharmacological interventions, such as exercise and education, presently offer the 
most improvement in fatigue experiences.  
However, the limitations of the many existing intervention studies for nausea and 
fatigue should be identified. The majority of studies reported within chapters 3 and 
4 that sought to evaluate the impact of particular interventions had a variety of 
design flaws. In the main, studies were small scale, often involving fewer than 50 
patients (and so underpowered) and included heterogeneous populations. Moreover, 
many did not account for the potential of a Hawthorne effect, that is the 
phenomenon by which subjects in behavioural studies change their performance in 
response to being observed, by including an attentional control group in their design 
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and CONSORT (Consolidated Standards of Reporting Trials) guidelines (Moher et 
al 2001, Boutron et al 2008) were rarely followed in the presentation of their results. 
Furthermore, the majority of studies tended to focus on the impact of a single 
intervention on a symptom, rather than the potential for complementary effects of 
multiple interventions and were conducted over a short time frame, for example, 
one or two cycles of chemotherapy.  
Despite some positive interventions, irrespective of the approach taken to exploring 
patients’ experiences, nausea and fatigue have been consistently shown to be 
unpleasant symptoms that have a deleterious effect on patients’ quality of life. 
However, despite this fact and the wealth of research that has been invested in 
developing assessment and management techniques, there is relatively little research 
evidence that focuses solely on patients’ experiences of these symptoms, what they 
mean to them and the impact they have on their daily lives. 
5.3 Rationale for the SNA↔P study 
Given the problems associated with assessing nausea and fatigue and the range of 
management techniques that may or may not be effective, alongside the knowledge 
that both nausea and fatigue have a negative impact on patients’ quality of life, it 
was appropriate to conduct a study to promote structured assessment and practice in 
the real world of clinical practice that would address nausea and fatigue and 
improve patients’ experiences. The SNA↔P study aimed to minimise the 
limitations of previous research studies not only through the design of the study but 
also within the intervention itself. Firstly it utilised a longitudinal time series design 
encompassing longitudinal data collection not only across multiple cycles of 
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chemotherapy (cycles 1-8) but within each cycle of chemotherapy (days 1-14). This 
provided a thorough understanding and description of symptoms over time while 
also accounting for the fact that the intervention may take a period of time to ‘work’ 
or that establishing the most appropriate or effective intervention for an individual 
may be a lengthy process or indeed that different interventions are more or less 
appropriate or effective at different times of the treatment journey. The SNA↔P 
study population was homogenous, women receiving chemotherapy for breast 
cancer, and also included a control group: a site control group as well as a time 
control group, as the study was conducted over a lengthy period of time. The 
SNA↔P study also involved assessment of the total symptom experience 
(incidence, severity and distress) to ensure that patients’ multidimensional symptom 
experiences were considered and evaluated, as the intervention may have impacted 
on differing aspects of the symptom experience at different points in the treatment 
journey. In relation to the intervention, it is important to note that it was conducted 
in a real life clinical situation by clinicians as part of their daily practice in an 
attempt to overcome the potential for a Hawthorne effect. Furthermore, it 
encapsulated total symptom management, that is assessment and management of 
symptoms, cyclically over patients’ entire chemotherapy journey rather than the 
SNA↔P-shot view of previous studies. The evaluation of the intervention was also 
novel in that it not only considered the statistical significance of the impact of the 
intervention but also made judgements on the personal significance of the 
intervention. 
While clinical guidelines provide a method of promoting evidence for clinical 
practice, they are often unwieldy for day-to-day use (see chapter 7). Given the 
problems associated with their implementation, and the fact that the  SNA↔P study 
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was being conducted within the real world of clinical practice, the study had to 
involve more than simply introducing clinical guidelines to promote improved 
assessment and practice in relation to nausea and fatigue. There is some evidence 
that patients who receive a standard treatment as part of a clinical trial have more 
positive outcomes than those receiving the same treatment outwith the clinical trial, 
possibly due to regular structured contact with health professionals (Braunholtz et 
al. 2001). Indeed, exploring patients’ experiences of early clinical trials have shown 
that patients value the structure and continuity of care and assessment (Cox 1999) 
while routine quality of life assessment has been shown to result in better quality of 
life and emotional functioning (Velikova et al. 2004). Consequently, ensuring that 
the SNA↔P study involved a structured cyclical process of assessment that used the 
assessment outcomes to initiate interventions in practice was necessary if the 
intervention was to have an impact on patients’ experiences. 
Chemotherapy nurses have regular contact with patients throughout their course of 
chemotherapy, and an integral part of their role is symptom assessment and 
management. Indeed, they spend a considerable period of time with patients’ during 
the intravenous administration of each cycle of chemotherapy, making 
chemotherapy nurses the most appropriate group of health professionals on which to 
focus the SNA↔P intervention. 
5.4 Conclusion 
This chapter has briefly summarised the literature review of the previous 3 chapters 
showing that the SNA↔P study responded to a need within clinical practice for 
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structured symptom assessment and practice. The following chapters present the 
SNA↔P study in detail. 
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6 CHAPTER 6 – METHOD 
6.1 Introduction 
The following chapter describes the methods used in the SNA↔P (Structured 
Nursing Assessment into Practice) study which evaluated the impact of a nursing 
intervention on patients’ experiences of chemotherapy-related nausea and fatigue. 
The SNA↔P study arose from my involvement in the WISECARE+ study, and as 
such, it inevitably draws on, and at times is constrained by, the design and methods 
of WISECARE+. Such instances will be highlighted in the relevant sections within 
this chapter.   
6.2 SNA↔P study design 
The SNA↔P study aimed to evaluate the impact of a nurse-led intervention 
incorporating structured nursing assessment and practice (SNA↔P) on women’s 
experiences of chemotherapy-related nausea and fatigue during a course of 
chemotherapy for breast cancer. This evaluation involved 2 distinct aims: 
1. To describe and explore the patterns and experiences of chemotherapy-
related nausea and fatigue. 
2. To explore the impact of the intervention on experiences of chemotherapy-
related nausea and fatigue. 
Both quantitative (structured questionnaires) and qualitative (semi-structured 
interviews) methods were used to address these aims (see Figure 4). 
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Figure 4: SNA↔P study aims 
 
Combining research methods in this way is not uncommon in health care research 
(Sale et al. 2002). The term ‘mixed methods’ is summarised as research designs 
using qualitative and quantitative data collection and analysis techniques either in 
parallel or sequential phases (Tashakkori and Teddlie 2003). Research methods, 
however, are based on specific paradigms: a patterned set of assumptions 
concerning reality; knowledge of that reality; and particular ways of knowing in that 
reality (Guba 1990). The quantitative paradigm is based on positivism and seeks to 
measure and analyse causal relationships between variables in a value-free 
framework (Denzin and Lincoln 1994). Sample sizes are larger in quantitative 
research and techniques used include randomisation, blinding, highly structured 
protocols, and written or orally administered questionnaires with limited responses. 
In contrast, the qualitative paradigm is based on interpretivism and constructivism 
where there are multiple realities or truths based on one’s construction of reality 
(Sale et al. 2002). The emphasis of this type of research is on process and meaning 
with samples not meant to represent large populations (Sale et al. 2002). Within the 
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SNA↔P study, structured symptom questionnaire represent the positivist paradigm 
while semi-structured interviews represent the interpretivist paradigm.  
While research has moved beyond the quantitative/qualitative debate, just because 
methods can be combined does not mean that it is always appropriate to do so, and 
mixing research methods should not be used to bolster the weaknesses of one 
method with the strengths of another. Within the SNA↔P study, mixed methods 
were used in a complementary fashion to produce an additive effect: the information 
from structured symptom questionnaire facilitating the exploration of the personal 
significance of nausea and fatigue in interviews, while in turn, interview data was 
used to give insight into the actual personal significance of the intervention when it 
was statistically evaluated. While each of these components is integral to the final 
evaluation of the intervention, for ease of description, qualitative and quantitative 
components of the SNA↔P study will be described separately in the following 
sections.  The analysis plan will be presented thereafter to demonstrate the 
complementarity of the quantitative and qualitative data.  
6.3 Quantitative component of the SNA↔P study 
6.3.1 Design 
The quantitative component of the SNA↔P study followed a quasi-experimental 
interrupted time-series design with a control group. The time series design allowed 
a stable baseline to be established before the introduction of the SNA↔P 
intervention, (structured nursing assessment into practice), so that any change in the 
dependent variable (patients’ nausea and fatigue) would be due to the intervention 
and not other environmental events (Burns and Grove 2005). The design of the 
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SNA↔P study differed from that of the WISECARE+ study as it incorporated a 
control group. The addition of this control group strengthens the validity of any 
findings as it allows examination of differences in trends between groups after the 
intervention (Burns and Grove 2005). There were 4 patient groups in the SNA↔P 
study: 
• Unit A cohort 1 (time control group) 
• Unit A cohort 2 (intervention group) 
• Unit B cohort 1 
• Unit B cohort 2 (site control group) 
The SNA↔P study design is shown in Figure 5. 
Figure 5: Design of SNA↔P study 
6.3.2 Aims 
The quantitative component of the SNA↔P study had two aims: 
1. To describe patterns of chemotherapy-related nausea and fatigue during a 
course of chemotherapy for breast cancer. 
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2. To explore (statistically) the impact of the SNA↔P intervention on 
chemotherapy-related nausea and fatigue. 
6.3.3 Setting  
The SNA↔P study was conducted within two typical chemotherapy out-patient 
Units (Unit A – the intervention site and Unit B – the control site) in the West of 
Scotland. Although these Units were located in different hospitals they were part of 
the same hospital trust, and as such, operated to the same policies and procedures. 
Both Units were responsible for the delivery of out-patient chemotherapy to patients 
with a range of cancer diagnoses, as well as necessary supportive care, such as 
blood transfusions. The Units were nurse-led, that is, the organisation and delivery 
of patient care was led by a team of nurses and supported by medical, pharmacy, 
allied health professionals and secretarial staff. Although they were identical with 
respect to policy, protocols and practice (whilst acknowledging the inherent 
individuality in clinical practice), there was no routine movement of staff between 
each of the Units. 
6.3.4 Sample  
Women receiving chemotherapy for breast cancer were recruited from Units A and 
B. A consecutive sample of eligible patients ensured that the greatest cohort of 
patients would be recruited in the time allocated to recruitment (14 months) and also 
aimed to exclude selection bias, conscious or otherwise. All patient included in the 
SNA↔P study received antiemetic therapy as per hospital policy (identical in Units 
A and B). Patients were eligible for the study if they met the criteria set in Table 15.  
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Table 15: Patient eligibility criteria for the SNA↔P study 
Inclusion criteria Exclusion criteria 
Aware of their diagnosis of breast cancer
 
Deemed by any member of the clinical 
team as being physically or 
psychologically unfit to participate in the 
study 
Chemotherapy naïve  
 
Previously received a course of 
chemotherapy 
Able to read/write English Unable to give informed consent 
Able to give informed consent  
The WISECARE+ study recruited patients with a range of cancer diagnoses that 
reflected the patient populations of the clinical sites involved. However, such 
heterogeneity is likely to be problematic for the analysis in a study that focuses on 
symptom outcomes, as these may differ according to diagnosis and chemotherapy. 
In contrast, the SNA↔P study involved only women with breast cancer. This 
homogenous population was chosen for a number of reasons, as already highlighted 
in the preface to this thesis: breast cancer represented the largest patient population 
in the study sites, so giving access to the greatest number of patients during data 
collection thereby increasing the power of the study; recruiting a homogenous 
population excluded the potential for differences in symptom experiences associated 
with varying cancer diagnosis; and breast cancer was of interest to the researcher 
(hereafter referred to as MM) based on her previous clinical experience.  
To ensure maximum homogeneity within the sample, it was initially planned to 
recruit patients receiving the same chemotherapy regime, however, review of the 
patient lists in both sites prior to the start of data collection showed there were 
insufficient numbers of patients receiving any one chemotherapy regime to allow 
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recruitment of a sufficient sample size within the designated timeframe. Thus, 
patients were recruited on the basis of their breast cancer diagnosis regardless of the 
chemotherapy regime they received. The decision to exclude patients who had 
previously received chemotherapy was based on the evidence that past experiences 
of symptoms impact on current symptoms (Watson et al. 1998; Montgomery and 
Bovbjerg 2001; Montgomery and Bovbjerg 2003). As the main aim of the study was 
to evaluate the impact of the evidence-based intervention on symptom experiences, 
it was felt that patients who had previously received treatment may perceive and 
experience their symptoms differently to patients who were chemotherapeutically 
naïve. Patients were required to be aged 18 years or over to be included in the study, 
however, there was no upper age limit set, as this study aimed to explore the impact 
of the intervention with as many patients as possible. While patients were not 
discouraged from discussing their symptoms with family/friends while they 
completed the symptom questionnaires, they were encouraged to complete these 
themselves, and as such, were required to be able to read/write English.  
6.3.5 Measures 
Two groups of measures were involved in the quantitative component of the 
SNA↔P study: socio-demographic and symptom measures. 
6.3.5.1 Socio-demographic measures 
Socio-demographic data was collected not only to characterise and describe those 
participating in the SNA↔P study, but also to allow comparison between patient 
groups (Units A and B, cohorts 1 and 2). The demographic details collected about 
each participant were: age; level of deprivation using the Carstairs deprivation score 
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(McLoone 2004); and chemotherapy treatment intent, since research has shown that 
each of these characteristics may affect symptom experiences (Stone et al. 2000a; 
Macleod et al. 2000b; Macleod et al. 2000a; Simpson and Rosenzweig 2002; 
Macleod et al. 2004; Goodwin 2007).  
6.3.5.2 Symptom measurement 
It is in the aspect of quantitative symptom measurement that the SNA↔P study was 
most constrained by the methods of the WISECARE+ study. This limitation was 
because the patients participating in Unit A (the intervention site) were also taking 
part in the WISECARE+ study, and so the process of symptom data collection 
necessarily followed that of the WISECARE+ study. Consequently, many of the 
decisions concerning symptom assessment were taken by the WISECARE+ 
Steering Group (MM was an integral member of this Group, but final decisions 
were not her responsibility).  
6.3.5.2.1 Choice of symptom assessment tool 
Given the non-observable nature and subjectivity of both nausea and fatigue, the 
Steering Group unanimously agreed on the importance of a patient self-report tool 
for assessing symptoms. A pan-European study had found that patients complained 
of questionnaire fatigue in response to a battery of questionnaires (Sermeus et al. 
2000). Consequently, a symptom questionnaire that was patient-focused and short 
was required. However, it was also recognised that this should be multidimensional 
in order to fully capture the total symptom experience (as highlighted in chapters 3 
and 4).   
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MM reviewed available assessment tools and found no assessment tool that met 
exactly the needs of the WISECARE+ study: a patient focused, short, 
multidimensional tool that assessed nausea, vomiting, fatigue and oral problems. 
However, the Chemotherapy Symptom Assessment Scale (Brown et al. 2001) was 
identified in the search for a clinically usable and patient-focused tool. This is a 24-
item multidimensional assessment scale, whose development had strong patient 
involvement, was multidimensional in that it evaluated incidence, severity and 
associated symptom distress, and had been developed to be short enough for 
routinely used in clinical practice. The content validity of the C-SAS was 
established through the comprehensive 6-stage approach to item generation (Brown 
et al. 2001), however, although further reliability and validity data were promised, 
none have been subsequently reported. The use of an assessment tool with such 
limited validity data and without any reliability data is unconventional and is an 
area in which the SNAP study is compromised because of its association with the 
WISECARE+ study. However, the Steering Group agreed that the advantages of 
patient involvement in the development of the tool, as well as its clinical usability, 
outweighed the disadvantages of lack of reliability and validity data.  
Permission was granted by the authors to adapt the tool, removing all symptoms 
except nausea, vomiting, fatigue and oral problems, substantially shortening the 
questionnaire and focusing it only on the symptoms of concern within the 
WISECARE+ study. As each of the 24 questions within the C-SAS addressed a 
single symptom, modifying it in this way should not affect the tool’s reliability or 
validity. Each question was comprised of 3 discrete sections evaluating incidence, 
severity and distress (see Figure 6). The full questionnaire can be found in 
Appendix B.  
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Figure 6: Questionnaire presentation 
 
6.3.5.2.2 Frequency of symptom assessment 
Given that the SNA↔P study sought to describe patterns of nausea and fatigue over 
a course of chemotherapy, longitudinal assessment of symptoms was necessary. 
Moreover, this longitudinal assessment necessarily took place both within each 
cycle of chemotherapy and across a course of chemotherapy. The frequency with 
which patients were asked to complete the questionnaire was taken by the 
WISECARE+ Steering Group and was based not only on their previous experience 
of symptom assessment showing that patients continued to experience symptoms 
more than 10 days following chemotherapy administration (Sermeus et al. 2000), 
but also the current evidence concerning patterns of chemotherapy-related 
symptoms - short-lived symptoms such as nausea that occur in the first few days 
following chemotherapy (Kris et al. 1994; Jordan et al. 2005), and those more 
constant symptoms that continue to be felt for days or weeks following 
chemotherapy, such as fatigue (Berger 1998; Schwartz 2000; Molassiotis and Chan 
2001; Miller et al. 2007). Moreover, extending the duration of data collection would 
Nausea …
If yes, how severe was this?
Have you experienced this today? Yes No
Mild Moderate Severe
Not at all A little Quite a bit Very much
How much did it bother you?
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allow the symptom data to be collected over the nadir period. This is the time during 
a cycle of chemotherapy, usually between 7-14 days, at which the patient’s blood 
count drops to its lowest and has been associated with greater levels of symptoms, 
especially fatigue (Pickard-Holley 1991; Irvine et al. 1994; Richardson and Ream 
1996; Boehmke and Brown 2005). Being mindful of the potential for questionnaire 
fatigue, it was decided that patients would be asked to complete this short symptom 
questionnaire for 14 days following each chemotherapy administration. This 
schedule gave patients between 7-14 days between completing their questionnaires 
and returning for their next cycle of chemotherapy. The frequency of symptom 
questionnaire completion is shown in Figure 7. 
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Figure 7: Frequency of questionnaire completion 
6.3.6 Procedures  
6.3.6.1 Pilot study 
A pilot study was conducted to test the adapted version of the patient symptom 
questionnaire in relation to comprehension, usability and compliance during a single 
cycle of chemotherapy. This pilot study was conducted for the SNA↔P study; 
however the WISECARE+ study, which had already begun data collection in a 
number of other clinical sites, benefitted from the minor changes that were made to 
the patient symptom questionnaire (described later).  
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6.3.6.1.1 Design 
The pilot study was descriptive and exploratory.  
6.3.6.1.2 Setting 
The pilot test was conducted within two typical chemotherapy out-patient Units 
(Unit A and Unit B) within the same hospital trust that were to be involved in the 
main study. 
6.3.6.1.3 Sample 
Five patients (2 from Unit A and 3 from Unit B) who met the eligibility criteria of 
the main study (page 134), and who were receiving their first or second cycle of 
chemotherapy for breast cancer, participated in this pilot study. 
6.3.6.1.4 Measures 
Comprehension and usability of the patient symptom questionnaire were explored 
through an informal discussion between MM and each individual patient, the 
schedule for which is presented in Figure 8. 
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Figure 8: Interview schedule for questionnaire pilot 
Compliance with completing the questionnaire was evaluated by assessing the 
amount of missing data in the returned questionnaires. Compliance with returning 
the questionnaires was evaluated by comparing the numbers of questionnaires 
actually returned with those expected to be returned. 
6.3.6.1.5 Procedure 
Ethical approval for the pilot study was obtained within the main submission for 
ethical approval detailed in section 6.3.6.2 ethical considerations and approval, page 
144.  
The patient’s chemotherapy nurse briefly explained the SNA↔P study to them and 
asked whether they would consider piloting the patient symptom questionnaire that 
would be used. It was explained that this would involve completing the 
questionnaire for 14 consecutive days following their chemotherapy and returning 
all 14 completed questionnaires by post in a stamped addressed envelope to MM. 
They were also asked if they would be willing to meet with MM at their next 
How did you find completing these questionnaires (easy, difficult, straightforward, tiresome, worthwhile)?
Did you understand the written instructions on the front cover of the questionnaires?
Were these instructions useful? How often did you look at them?
Was there anything in those instructions that wasn’t clear to you or didn’t make sense?
Did you have any problems or difficulties completing the questionnaires themselves?
Were any questions in the questionnaire unclear to you?
Did you find the questions relevant to your experiences?
Could you understand the responses that you had to choose from?
Was it clear what you had to do with the questionnaires when you had completed them all?
Have you any other comments about the questionnaires?
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chemotherapy appointment to discuss their perceptions of and experiences of 
completing the questionnaire.  
All 5 patients approached agreed to participate and they were subsequently given 
the pack of 14 questionnaires, a stamped addressed envelope and verbal instructions 
(based on the written instructions on the front of the questionnaire) about 
questionnaire completion. They were asked to complete the questionnaires 
according to the written instructions on the front of each questionnaire for 14 
consecutive days following their chemotherapy and then to return them, in the 
stamped addressed envelope, to MM.  
All patients met with MM to discuss their perceptions of the questionnaire on return 
for their subsequent chemotherapy treatment. 
6.3.6.1.6 Analysis plan 
The discussions with patients were guided by a brief set of questions to ensure that 
all aspects of the evaluation were covered (see Figure 8). MM took notes during 
each discussion and, at the end of the discussion, went over these with the patient to 
ensure all their points were recorded. The returned questionnaires were checked for 
missing data. The number of questionnaires returned by each patient was also noted. 
6.3.6.1.7 Pilot study outcomes 
All five patients responded positively about their experiences in this pilot study. 
They found the written instructions on the front cover of each questionnaire a useful 
reminder about how and when to complete the questionnaire, although all reported 
that they became familiar with the process after just a few days. No patients 
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reported any difficulties with completing the questionnaires, nor problems 
associated with understanding or responding to each question. Patients found the 
questions relevant at some time during the 14 days following chemotherapy 
administration, but were unsure about how useful (for MM) it would be to complete 
the questionnaire if they were not experiencing any symptoms. All patients fully 
completed and returned all 14 questionnaires.   
One change was made to the written instructions on the front cover of the 
questionnaire as a result of the pilot study. It now read that patients’ responses to the 
questionnaire were valuable whether they were experiencing symptoms or not. No 
changes were made to the questionnaire itself. 
6.3.6.2 Ethical considerations and approval 
The patients involved in the quantitative component of the SNA↔P study were 
facing a particularly stressful period in their lives. Not only had they received a 
diagnosis of breast cancer (primary or recurrent) within the last three months, but 
those patients receiving adjuvant chemotherapy (n=79, 75.2% of the total sample) 
had also undergone breast surgery as first line treatment for their diagnosis. Both 
surgery and chemotherapy are associated with a period of physical and 
psychological adjustment (Wainstock 1991; Steginga et al. 1998; Lehto and 
Cimprich 1999; Landmark et al. 2001). Participating in the SNA↔P study could 
potentially have added to the stress they were already experiencing.  
Asking patients to reflect and report on their symptom experiences by completing a 
daily questionnaire for 2 weeks following each cycle of chemotherapy may be 
considered excessive. One could argue that in doing so, some patients would be 
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constantly reminded of their diagnosis and treatment and potentially focus too much 
on their symptoms. Alternatively, spending a short time each day reflecting on 
symptom experiences and completing the questionnaire may be helpful to some 
patients when they attend for subsequent chemotherapy. They would be more able 
to explain the symptoms they experienced to the clinicians caring for them and, as 
such, effective symptom interventions could be initiated. The former was not the 
intention of the SNA↔P study, and patients’ willingness to participate and continue 
in the study were repeatedly assessed to ensure that this was not detrimental to the 
patient. To reduce the burden of participation, the questionnaire was designed to be 
as short as possible while gathering clinically meaningful information and being 
relevant to patients’ symptom experiences. 
Ethical approval for the study within Unit A was granted by the Multicentre 
Research Ethics Committee as part of the ethics application for the multicentre 
WISECARE+ study. Local Research Ethics Committee approval was granted for 
Unit B from the hospital Trust in which the research took place. 
6.3.6.3 Recruitment and consent 
Recruitment and patient consent in Unit A was undertaken by a research support 
nurse (hereafter known as JMcL) who was a senior member of the cancer nursing 
staff within the hospital. Her extensive cancer nursing experience as well as being 
known to, and respected by, the nursing staff of Unit A eased these processes. 
Recruitment and consent in Unit B was undertaken by MM.  
An identical two stage process of recruitment and consent was followed in both 
Units as described in Figure 9.  
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Figure 9: Process of patient recruitment 
This two-stage process ensured that patients had the opportunity to consider their 
participation in the SNA↔P study and ask the researcher (either MM or JMcL, 
depending on the Unit) questions before making a decision. Standard patient 
Patient identified in chemotherapy unit diaries by MM/JMcL
Approached by MM/JMcL
Informed consent 
given
Informed consent not 
given
Patient thanked for their time and 
reassured treatment and care 
remains unaffected
Patient given questionnaires and 
verbal/written advice on 
questionnaire completion
Provisional eligibility checked from casenotes
Discussion with clinical staff re appropriateness
Patient given information re SNA↔P study
Eligible Not 
eligible
Eligible Not eligible
Willing to speak to MM/JMcL Not willing to speak to 
MM/JMcL
No further 
action taken
Nursing staff check with patient whether they want to speak to MM/JMcL
Pre-chemotherapy 
assessment visit
First 
chemotherapy 
visit
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information sheets (see Appendices C (Unit A) and D (Unit B)) were given to each 
eligible patient during their pre-chemotherapy assessment visit and they were 
followed up when they returned for their first cycle of chemotherapy, usually about 
one week later. Patients were reassured that they could withdraw from the study at 
any time without affecting their treatment and care and without providing a reason 
for doing so. On agreeing to participate in the SNA↔P study, patients signed a 
consent form: they kept one copy, a second copy was filed in their casenotes and a 
third was kept by either MM or JMcL. This third copy was stored in a secure filing 
cabinet until the end of the study whereupon it was securely archived and will be 
destroyed, as per University of Stirling regulations, in 2012. 
6.3.6.4 Data collection 
A short demographic data collection sheet was developed to ensure standardised 
data collection in both Units and was completed by MM or JMcL as each patient 
was recruited (see Appendix E). These demographic details were subsequently 
analysed to compare the patient groups and establish the impact of these potentially 
confounding demographic variables on the results of the SNA↔P intervention. 
Demographic data collection sheets were stored securely in a locked filing cabinet 
in both Units until the end of the study and were subsequently securely archived. 
They will be destroyed, as per University of Stirling regulations, in 2012. 
Following recruitment to the study, patients were taught about how and when to 
complete the questionnaire, and when and where to return it, by either MM or 
JMcL, depending on the Unit. A patient education schedule (appendix F) was used 
by both researchers to ensure the patient education, instruction and information 
about their involvement and questionnaire completion was standardised across both 
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Units. Patients were actively encouraged to ask any questions they had about 
completing the questionnaires at this initial teaching session. Key issues from the 
teaching schedule were repeated on the front sheet of each questionnaire.  
It was intended that MM (Unit B) or JMcL (Unit A) would meet with each patient 
every time they attended for chemotherapy to check they were still happy to be 
involved in the study, as well as answering any questions they had about the study 
or completing the questionnaires, and giving patients their next set of 14 
questionnaires. This procedure was possible and worked well in Unit A where 
JMcL was based, however, existing work commitments, travel time to Unit B, and 
logistical problems of patients’ appointment times being changed due to deferral of 
treatment or chemotherapy symptoms, meant that it was impossible for MM to be 
present every time each patient returned for chemotherapy. Consequently, on 
recruitment, patients in Unit B were given 8 sets of questionnaires and stamped 
addressed envelopes (one for each cycle of their chemotherapy) and were advised to 
complete a new set of questionnaires each time they began a new cycle of 
chemotherapy. They were also encouraged to contact MM if they had any questions 
or problems about their involvement in the study and their chemotherapy nurse 
undertook to check at each visit for chemotherapy that their involvement in the 
study was not having a detrimental effect on them. Patients were advised to return 
their unused sets of questionnaires to the chemotherapy Unit if they decided to stop 
participating in the study. While these arrangements worked well, if MM was in 
Unit B to recruit a new patient when an existing patient was attending for 
chemotherapy she made every effort to meet with them herself, and informally chat 
about their involvement in the study.  
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Patients returned their completed questionnaires to either MM (Unit B) or JMcL 
(Unit A) who then entered this symptom data into the WISETool, an electronic 
patient record/database that was developed specifically for the WISECARE+ study. 
The WISETool stored individual patient’s symptom data and transferred this to a 
secure data warehouse, as well as providing nurses with information about the 
symptom associated with the chemotherapy regime the patient received, the actual 
symptoms the patient reported, and the most appropriate nursing interventions for 
the patient’s reported symptoms. More detailed information about the role of the 
WISETool in the SNA↔P study is provided in chapter 7 – The SNA↔P 
Intervention. Although MM did not require the variety of WISETool functions for 
patients participating in Unit B (the control site), entering data to the WISETool 
meant it was accessible in the same format as Unit A, and facilitated data analysis. 
Patient questionnaires were stored locally in locked filing cabinets. Following data 
entry and quality assurance checks, these have now been securely archived and will 
be destroyed in 2012, as per University of Stirling regulations. 
6.3.6.5 Quantitative data management 
All questionnaires that were returned either in full or in part were included in the 
analysis. This process of data management made full use of all the data returned by 
patients and recognised that any symptom reported was of value. Data was 
considered ‘missing’ if the patient subsequently returned symptom questionnaires 
later in their course of chemotherapy (see Figure 10 for examples of missing data 
and withdrawal from study).  An analysis of missing data was conducted within 
SPSS. Data from all the patient interviews was used for the analysis.  
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Figure 10: Example of missing data/withdrawal from study 
 
6.3.6.6 Statistical analysis of quantitative data 
The quantitative data generated within the SNA↔P study was used to both: 
• describe and explore patterns of chemotherapy-related nausea and fatigue  
and 
• explore the impact of the SNA↔P intervention on these symptom experiences.  
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Using all data received from every patient mean symptom scores were generated for 
each day (days 1-14) within each cycle of chemotherapy (cycles 1-8) and these were 
plotted graphically to describe and explore longitudinally patterns of patients’ 
experiences of nausea and fatigue. 
Exploring the impact of the intervention involved both primary and secondary 
hypotheses. 
The primary hypothesis was that: 
Unit A cohort 2 would have statistically significantly less nausea and fatigue than 
Unit A cohort 1 
The secondary hypothesis was that: 
Unit A cohort 2 would have statistically significantly less nausea and fatigue than 
Unit B cohort 2. 
Given the volume of data generated as a consequence of this longitudinal data 
collection, mean scores were used to respond to both hypotheses. For each patient, a 
mean symptom score was generated for total nausea and for total fatigue. Mean 
nausea scores were generated using the data from the first 3 days following each 
cycle of chemotherapy (as patterns of nausea demonstrated that the greatest degree 
of nausea was experienced during the first 3 days of each cycle of chemotherapy) 
while mean fatigue scores were based on the fatigue scores reported throughout the 
entire 14 days of data collection following each cycle of chemotherapy. This meant 
that for each patient (n=105) their responses were condensed into a single mean 
score for nausea and a single mean score for fatigue.  
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To ensure the appropriate statistical tests were applied, the distribution of these 
scores was tested using boxplots. If the data for each patient group were normally 
distributed, parametric tests (an ANOVA) would be applied to explore whether 
there were significant differences between the mean scores within each patient 
group. If the data for each patient group were not normally distributed, the 
appropriate nonparametric test would be applied (Kruskal-Wallis test), again to 
establish whether there were statistically significant differences between the mean 
scores of each patient group. Given that mean scores were being compared between 
multiple groups, see Figure 11, it was important that the statistical test compared 
groups simultaneously rather than carrying out multiple tests to compare each 
patient group as the latter process would greatly increase the chance that a 
significant difference would falsely be found.  
Figure 11: Statistical evaluation of the impact of the SNA↔P intervention 
 
A mean score for nausea and fatigue was also generated for each patient group 
(based on each patient’s mean score within each group) to illustrate the level of 
difference in mean total symptom scores between each patient group. 
Unit A
Intervention unit
Unit B
Control unit
Patient cohort 1 
(site control 
group)
SNA↔P 
No 
interventionPatient cohort 1
Patient cohort 2 
(intervention 
group)
Patient cohort 2 
(time control 
group)
Comparison 
4
Comparison 
3
Comparison 
2
Comparison 
1
153 
Given the level of patient attrition within the SNA↔P study, the analysis that 
explored the impact of the intervention was carried out firstly using the full data set 
and then repeated using data from the first 4 cycles of chemotherapy only, which 
incorporates at least two thirds of each patient group from the total sample. 
6.4 Qualitative component of the SNA↔P study 
6.4.1 Design 
The qualitative component of the SNA↔P study followed a descriptive and 
exploratory design using semi-structured interviews. 
6.4.2 Aims 
The qualitative component of the SNA↔P study had 2 aims: 
1. To describe chemotherapy-related nausea and fatigue during a course of 
chemotherapy for breast cancer. 
2. To explore the impact of the SNA↔P intervention on chemotherapy-related 
nausea and fatigue, specifically exploring patients’ ability to perceive 
differences between different symptom scores and what these mean to 
patients. 
6.4.3 Setting  
The semi-structured interviews took place in the two typical chemotherapy Units 
that were involved in the quantitative component of the SNA↔P study (Unit A – 
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the intervention site and Unit B – the control site). These Units are described in full 
in section 6.3.3 page 133.  
6.4.4 Sample  
A purposive sample of women (representative of the total sample with respect to 
age, deprivation and treatment intent as far as possible)  receiving chemotherapy for 
breast cancer in Units A and B who were already participating in the quantitative 
component of the SNA↔P study, and who had reported nausea and fatigue within 
their symptom questionnaires, were recruited.  Patients were considered eligible for 
this component of the SNA↔P study if they met the criteria set out in Table 16. 
Table 16: Patient eligibility criteria for the qualitative component of the SNA↔P study 
Inclusion criteria Exclusion criteria 
Completed at least one set of symptom 
questionnaires as part of the SNA↔P 
study  
Deemed by any member of the clinical 
team as being physically or 
psychologically unfit to participate in a 
semi-structured interview 
Reporting symptom scores of at least 2 
for nausea and/or fatigue within their 
most recent set of symptom 
questionnaires 
Unable to give informed consent 
 
6.4.5 Measures 
Two measures were involved in the qualitative component of the SNA↔P study: 
socio-demographic, and symptom experience data. 
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6.4.5.1 Socio-demographic data 
Socio-demographic data were collected to characterise those participating in the 
semi-structured interviews. As before, socio-demographic data collected were: age, 
level of deprivation, and treatment intent.  
6.4.5.2 Symptom experience data 
Given the individual and subjective nature of chemotherapy-related nausea and 
fatigue, developing an understanding of patients’ perspectives required a method 
that facilitated open discussion with patients on an individual level, giving them the 
opportunity to describe their symptom experiences. One-off semi-structured 
interviews following a cycle of chemotherapy were conducted with a convenience 
sub sample (n=9) of the total SNA↔P sample to develop an appreciation of 
patients’ experiences of nausea and fatigue. A prompt, in the form of the patient’s 
symptom graphs generated by the WISETool of their last cycle of chemotherapy, 
was used throughout the interview.  This presented a clear picture, both to the 
patient and MM of the scores of nausea and fatigue that the patient had reported 
during the previous cycle of chemotherapy. This helped jog patients’ memories of 
their symptom experiences and was used throughout the entire interview to focus 
the patient on their symptom experiences. They were also used to facilitate 
potentially complex discussions concerning the differences between symptom 
scores, that is, the differences between a symptom score of 1 and 4, or 3 and 5, and 
what these differences actually meant to patients.  
Face-to-face interviews were chosen, as they facilitate the discussion of complex 
topics, so giving patients the opportunity to explain and describe their symptom 
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experiences in great depth and clarify any areas of uncertainty, so avoiding 
misinterpretation. Although each patient’s symptom profile was personal to them, 
an interview schedule was developed and used in each interview (see Figure 12 
page 161). This was in keeping with the symptom experience component of the 
Symptom Management Model (Larson et al. 1994; Dodd et al. 2001a), described in 
chapter 2, as it focused on patients’ experiences of symptoms in relation to their 
perceptions, evaluation of the symptoms and responses. Using a schedule ensured 
that all interviews followed the same direction and focused on the crucial issues 
under study (Burns 2000). The interview schedule was identical for both Units A 
and B, as this component of the SNA↔P study did not aim to compare symptom 
experiences between groups of patients. 
6.4.6 Procedures 
6.4.6.1 Ethical considerations and approval 
As in the quantitative component of the SNA↔P study, patients participating in 
interviews were facing a stressful period in their lives. Taking part in this one-off 
interview was not intended to add to any stress they were already experiencing. 
Indeed, that they had already agreed to take part in the SNA↔P study showed their 
willingness to participate in this type of research. Nevertheless, MM checked first 
with the nursing staff caring for the patient before approaching them and inviting 
them to take part in a short informal interview about their symptom experiences 
during their previous cycle of chemotherapy.  
As this qualitative component was not part of the WISECARE+ study, additional 
ethical approval was sought and received from the Local Research Ethics 
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Committee of Unit A. Ethical approval for a sub-sample of semi-structured patient 
interviews had already been granted in the original submission to the ethics 
committee for Unit B.  
6.4.6.2 Recruitment and consent 
Eligible patients from both Units A and B were identified by MM before their return 
for their next cycle of chemotherapy. As the focus of the interview was symptom 
experiences, it was important that the patient had reported at least some nausea and 
fatigue in their symptom questionnaires. Patients were also purposively identified 
on the basis of their demographics to ensure that this sub-sample was as 
representative of the total sample with respect to age, deprivation and treatment 
intent as possible. 
On identifying a patient, MM checked with the nursing staff to ensure that there was 
no reason that the patient should not be approached on the day they returned for 
chemotherapy. During their initial recruitment to the SNA↔P study, patients were 
informed of the interview aspect of the study but were aware that they may or may 
not be asked to participate in this. On approaching eligible patients, MM reminded 
them of this aspect of the study and asked whether they would consider speaking to 
her about their symptom experiences during their previous cycle of chemotherapy. 
As well as this verbal information, patients were given a written information sheet 
that described this component of the SNA↔P study in more detail and were 
reassured that they could stop the interview at any time without giving a reason. If 
the patient agreed to participate, they signed a consent form. One copy of this was 
given to the patient, a second was filed in their casenotes and a third copy was kept 
by MM. This third copy was stored in a secure filing cabinet until the end of the 
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study whereupon it was securely archived and will be destroyed, as per University 
of Stirling regulations, in 2012. 
6.4.6.3 Data collection 
Patients were able to participate in an interview at any stage during their course of 
chemotherapy. While symptom experiences may vary across cycles of 
chemotherapy, interviewing patients at various stages of their course of 
chemotherapy would not impact on the outcome of this component of the SNA↔P 
study, as the aim was to understand, in more depth, the individual experience, 
meaning and significance of chemotherapy-related nausea and fatigue scores. 
Indeed, it was hoped that including patients at various stages in their course of 
chemotherapy would incorporate an even greater breadth of symptom experiences.  
Purposive sampling ensured that ‘information-rich’ cases were identified. Every 
effort was made to conduct the interviews in a quiet area within each chemotherapy 
Unit to ensure that patients felt able to discuss their symptoms and experiences 
without being overheard. All interviews were tape recorded (with the patients’ 
permission) to allow MM to concentrate on what was being said without 
simultaneously taking notes. Patients were reassured that the tape recordings would 
be destroyed at the end of the study (although transcripts of the interview would be 
securely archived for 5 years, in line with good clinical research practice).  
Following informed consent, and immediately prior to the start of the interview, 
patients were reassured that they could stop the interview at any time if they felt 
uncomfortable or upset by the discussion. As each patient was interviewed only 
once, it was important patients felt at ease so that they engaged in more than a 
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question/answer session. MM was relatively unknown to patients (especially those 
of Unit A who were recruited by JMcL), so following informed consent, some time 
was spent chatting informally to patients prior to the interview proper in an effort to 
put patients at ease (Green and Thorogood 2004). A few very general questions 
were asked at the start of the interview to let the patient relax and become less 
conscious of the tape recorder. Thereafter a structured interview schedule (see 
Figure 11), using open questions was used, so that, as far as possible, each patient 
was asked the same questions in the same sequence in a similar manner, while 
allowing patients to give a full account of their symptom experiences in ways that 
were comfortable to them (Green and Thorogood 2004). Figure 12 (page 161) 
shows that the interview was entirely framed around the patient’s symptom report 
and scores. Patients were asked to describe their experiences of symptoms across 
the range of scores they had reported and to describe what each symptom meant to 
them. They were also asked to describe the differences that they noticed between 
symptom scores physically, psychologically, and socially. Patients were asked to 
only reflect on their experiences of the previous cycle to ensure that they were 
commenting on symptom experiences that were fresh in their memories. Each 
interview was divided into discrete sections addressing firstly nausea, and then 
fatigue, and into individual questions about each symptom. This format aimed to 
keep the interview clear for patients with regards to the symptom being discussed 
and the specific issue about that symptom. Throughout each interview, MM tried 
whenever possible to avoid the ‘why’ question as it has been suggested that asking 
‘why’ may imply that a person’s response was somehow inadequate and may 
suggest that the researcher is doubtful that a feeling was justified (Patton 1990). 
Thus, less aggressive wording such as ‘can you tell me more about that’ was used to 
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probe deeper into patients’ symptom experiences. At the end of the discussion of 
each individual symptom, patients were asked if there was anything they wanted to 
say about their experience of that symptom that had not been covered in the 
interview so far. At the end of the interview the patients were again asked if there 
was anything they wanted to add that had not been addressed. Following these 
questions, the patient was thanked for their contribution and time, the interview was 
concluded, and the tape recorder was switched off. 
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Figure 12: Patient interview schedule 
Introduction and aims of the interview
Some general questions about the patient’s story, moving into treatment and symptom experiences
Nausea
Lets look at this picture [showing the patient the symptom graph], can you describe your experiences of 
nausea during this last cycle of chemotherapy?
What did the nausea mean to you when it was at this score [score X]? Can you tell me a bit more about 
that?
How did you feel that day when you scored your nausea at [score X]?
How did that impact on your daily life?
Was there anything that you felt unable for that day because of the way you were feeling? (physically, 
psychologically, socially)
How does nausea at that score compare with nausea at these other scores? (using the symptom graph as a 
prompt)
In your opinion, what score of nausea is manageable or acceptable to you? Can you tell me a bit more 
about that?
Is there anything else that you want to say about your experiences of nausea that we haven’t covered in 
what we’ve talked about so far?
Fatigue
Lets look at this picture [showing the patient the symptom graph], can you describe your experiences of 
fatigue during this last cycle of chemotherapy?
What did the fatigue mean to you when it was at this score [score X]? Can you tell me a bit more about 
that?
How did you feel that day when you scored your fatigue at [score X]?
How did that impact on your daily life?
Was there anything that you felt unable for that day because of the way you were feeling? (physically, 
psychologically, socially)
How does fatigue at that score compare with fatigue at these other scores? (using the symptom graph as a 
prompt)
In your opinion, what score of fatigue is manageable or acceptable to you? Can you tell me a bit more about 
that?
Is there anything else that you want to say about your experiences of fatigue that we haven’t covered in 
what we’ve talked about so far?
Is there anything else that you want to add about your nausea or fatigue that we haven’t talked about yet?
Interview conclusion and thanks
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6.4.6.4 Qualitative data management 
The tape recorded interview data was transcribed by MM. Transcribing audiotaped 
conversations is a translation process in itself, with choices of punctuation and 
detail affecting how it is read by those analysing it (Green and Thorogood 2004). 
While transcribing is a time-consuming and laborious task, it provided MM with the 
opportunity to immerse herself in the data (Green and Thorogood 2004). 
Furthermore, it allowed MM to produce transcripts that included additional non-
verbal information such as pauses, sighing and laughing. 
A number of dedicated software packages have been developed to help manage 
qualitative analysis. Such packages have both advantages (thorough and systematic 
analysis) and drawbacks (time consuming coding of data and formatting 
requirements) (Green and Thorogood 2004). However, given that the SNA↔P 
study involved only 9 structured interviews, such software would have most likely 
been cumbersome and time consuming to use. Instead, as the interviews were 
structured, framework analysis was used to analyse the interviews. Framework 
analysis is facilitated through the introduction of specific issues and themes into the 
interview which are subsequently sought out and identified in the analysis. As such, 
framework analysis provides a structured approach to the complex task of 
organising, analysing and presenting qualitative data (Huberman and Miles 2002). 
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6.5 Data analysis 
6.5.1 Analysis of confounding variables 
Confounding variables for the total sample (age, deprivation and treatment intent) 
were compared between each of the four patient groups using the appropriate 
statistical techniques: ANOVA, Kruskal-Wallis and Chi-square tests. No analysis of 
confounding variables of the qualitative sample was undertaken, as this component 
of the study did not aim to compare between patient groups. 
6.5.2 Analysis of quantitative and qualitative data 
Figure 13 demonstrates how the quantitative and qualitative data were drawn 
together to answer the two distinct research aims: to describe and explore patterns 
and experiences of nausea and fatigue, and to explore the impact of the intervention 
on experiences of chemotherapy-related nausea and fatigue. 
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Figure 13: Complementarity of quantitative and qualitative data 
6.5.2.1 Describing and exploring patterns and experiences of symptoms  
To describe patterns of symptoms, the average of each symptom score for each day 
and each cycle of chemotherapy was calculated for all patients participating in the 
study. These mean scores were then plotted graphically for each day across all 
cycles of chemotherapy and patterns of both nausea and fatigue identified. These 
graphs highlighted the difference in patterns between nausea and fatigue and 
provided important information to enhance the statistical exploration of the 
SNA↔P intervention. During the interviews, the descriptions that patients gave of 
the meaning of symptoms and the impact that symptoms had on their lives were 
used to enrich the description of patterns and experiences of symptoms 
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6.5.2.2 Exploring the statistical impact of the intervention 
It was hypothesised that patients in cohort 2 of Unit A, that is, following the 
introduction of the SNA↔P intervention, would have statistically significantly 
lower symptom scores, thereby demonstrating the effectiveness of the intervention. 
To conduct this evaluation, a single summary statistic was generated for nausea and 
for fatigue for each individual patient participating in the SNA↔P study. The 
summary statistic chosen was the mean (the sum of all the values in the group 
divided by the number of values in the group) of the total symptom score (that is, 
including severity and distress). This value was chosen as it gives a typical or 
average symptom score. These summary statistics were then compared between the 
4 patient groups: 
• Unit A, cohort 1 (time control group) 
• Unit A, cohort 2 (intervention group) 
• Unit B, cohort 1 
• Unit B, cohort 2 (site control group) 
However, it is most appropriate to evaluate the impact of an intervention on a 
symptom at the time when the symptom is experienced most. Consequently, mean 
symptom scores were calculated following the identification of symptom patterns 
(see chapter 8 , Description of chemotherapy-related nausea and fatigue, page 213), 
thereby ensuring they were reflective of the times at which nausea or fatigue were 
experienced most. Consequently, the impact of the SNA↔P intervention on nausea 
was evaluated using data from days 1-3 only, while data from all 14 days was used 
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to evaluate the impact of the intervention on fatigue. Figure 14 demonstrates the use 
of specific data for quantitative analysis.  
Figure 14: Selection of data for quantitative analysis 
The frequencies of patients’ mean symptom scores (range 0-6) across their course of 
chemotherapy was presented graphically, and chi-square analysis used to evaluate 
whether differences existed between patient groups in relation to the 
presence/absence of nausea and fatigue. Descriptive analysis using boxplots within 
SPSS examined the underlying distributions of the mean symptom scores within 
each of the 4 patient groups for each of the symptoms. Given that the data for all 
groups of patients for nausea were not normally distributed, the non-parametric 
Kruskal-Wallis test was used to explore differences between patient groups. Given 
the borderline level of significance from this test, an ANOVA was performed as it 
may have been more sensitive to differences in grades of nausea. The fatigue data 
for all patient groups was relatively normally distributed and an ANOVA was 
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conducted to compare mean fatigue scores between patient groups. The results of 
this statistical test were confirmed using the non-parametric Kruskal-Wallis test.  
The personal significance of the intervention was evaluated using patients’ 
interview data, in which they described their experiences of different symptom 
scores, that is, how did a fatigue score of 1 compare with a 2 or a 3 or no fatigue?  
This technique allowed a rounded evaluation of the intervention to be conducted; 
drawing conclusions that were not only based on statistical evaluations, but that also 
took account of patients’ personal experiences of symptoms and the differences in 
symptom scores that are perceptible to patients. Such analysis meant that even if a 
statistically significant difference was established in mean symptom scores before 
and after the intervention, for example a mean score of 4 before compared with a 
mean score of 3 after, if patients could not personally differentiate between these 
scores in relation to their abilities or functioning, this difference would not be 
considered ‘significant’. 
6.6 Conclusion 
This chapter has presented the methods used to evaluate the impact of the SNA↔P 
intervention on women’s experiences of chemotherapy-related nausea and fatigue 
during a course of chemotherapy for breast cancer. It has shown that both 
quantitative and qualitative techniques have been used in a complementary fashion 
to evaluate the impact of the intervention, statistical and personal perspectives. 
Reference has been made throughout this chapter to the SNA↔P intervention and 
this is fully described in the following chapter. 
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7 CHAPTER 7 – THE SNA↔P INTERVENTION 
7.1 Introduction 
The aim of the SNA↔P study was to evaluate the impact of a nurse-led intervention 
incorporating structured nursing assessment and practice (SNA↔P) on women’s 
experiences of chemotherapy-related nausea and fatigue during a course of 
chemotherapy for breast cancer. The intervention, implemented in Unit A, sought to 
influence the nursing management of chemotherapy-related nausea and fatigue, and 
so improve these symptoms. This chapter will provide full details of the aim of the 
intervention, its content, and implementation in clinical practice.  
7.2 The aim of the SNA↔P intervention 
The SNA↔P intervention provided a structured process for nursing staff to follow 
in their assessment of chemotherapy-related nausea and fatigue, as well as providing 
them with a framework of evidence-based interventions tailored to a range of 
symptom grades generated through the assessment process to support effective 
clinical practice. This continuous and structured process of assessment and 
intervention was implemented cyclically, and continued throughout each patient’s 
course of chemotherapy.  
7.3 The component parts of the SNA↔P intervention 
The SNA↔P intervention can be viewed as two distinct layers: an upper layer 
comprising structured patient assessment and evidence-based interventions, and a 
lower layer supporting these two components in relation to symptom data 
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management (the WISETool) and the provision of evidence-based information. 
Figure 15 depicts the inter-relationships between the component parts of the 
SNA↔P intervention. The following sections describe the purpose and 
development of each of the component parts, as well as explaining their relationship 
to the other components of the intervention. 
Figure 15: The inter-relationship of the component parts of the SNA↔P intervention 
 
7.3.1 The upper layer of the SNA↔P intervention 
The upper layer of the SNA↔P intervention consisted of structured symptom 
assessment and evidence-based interventions.  
7.3.1.1 Structured longitudinal symptom assessment 
Chapters 3 and 4 demonstrated the importance of symptom assessment, not only to 
gain an understanding of the symptoms experienced by an individual, but also to 
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evaluate the impact of an intervention on them. However, symptom assessment 
within routine clinical practice is beset by problems. The reasons for these problems 
are far reaching, including: the lack of patient-focused clinically useable symptom 
assessment tools, as shown in chapters 3 and 4; poor patient recall of symptoms 
over time; patients’ reluctance to report symptoms (Stone et al. 2003); as well as the 
time pressures for clinicians (Davies et al. 2007). Consequently, patients’ symptoms 
go unrecognised and untreated, ultimately reducing the patient’s quality of life and 
potentially leading to the need for urgent medical care or hospitalisation (Du et al. 
2002; Polednak 2004; Chen-Hardee et al. 2006; Kuderer et al. 2006). 
The structured symptom assessment of the SNA↔P intervention differed from 
‘traditional’ symptom assessment in its longitudinal nature. Previous research has 
considered longitudinal symptom assessment as: longitudinal during a single cycle 
of chemotherapy (Richardson et al. 1998); over cycles 1 and 2 of chemotherapy 
(Dibble et al. 2003; Lee et al. 2005); over cycles 1-3 of chemotherapy (Berger 1998; 
Schwartz 2000); baseline, 3 months into chemotherapy and at 6 months (Payne 
2002); before chemotherapy, on completion of chemotherapy and six months post 
chemotherapy (Hurria et al. 2006); or longitudinally over multiple cycles but for a 
shorter period within cycles, for example 48 hours (Rhodes et al. 1987; Rhodes et 
al. 1988). However, these timeframes are based on arbitrary decisions and provide 
limited insight into the true longitudinal symptom experience. In contrast, the 
longitudinal symptom assessment of the SNA↔P study was not only longitudinal 
within each cycle of chemotherapy, spanning days 1-14, it was also longitudinal 
across a course of chemotherapy, with patients asked to participate for the entire 
duration of their chemotherapy treatment. Such assessment of symptoms had value, 
not only for the exploration of symptom patterns over time, but also because the 
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intervention may have required time to build up before having a measurable impact 
on patients’ symptom scores. 
The SNA↔P intervention sought to overcome the many problems of symptom 
assessment in clinical practice. Understanding the gold-standard of self-assessment 
of symptoms as well as the need for multidimensional symptom assessment at the 
time of symptom experience, symptom assessment within the SNA↔P intervention 
involved a structured symptom questionnaire that was completed by patients in the 
evening of each day for 14 days following each cycle of chemotherapy (see 
Appendix B). This method of data collection provided nursing staff with 
longitudinal symptom information both within each cycle of chemotherapy and 
across each patient’s course of chemotherapy. As shown in chapter 6 – Method, the 
symptom questionnaire presented patients with a range of options to describe their 
symptoms and, according to the patient’s response, a score was assigned (see Figure 
16). 
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Figure 16: Symptom scores 
Thus, patients could have a symptom score ranging from 0-6 for each symptom. 
However, the interventions were tailored to symptom grades based on these 
symptom scores. This decision was taken because it was unlikely that there would 
be a substantial difference in the interventions required for, for example, a nausea 
score of 1 or 2, or a fatigue score of 3 or 4. Consequently, the symptom scores 
generated from symptom questionnaires were graded mild, moderate or severe, 
implementing the same process as the NCCN, whereby fatigue scores (0-10) were 
assigned to a fatigue grade (none, mild, moderate, severe) (National Comprehensive 
Cancer Network 2007b). Table 17 shows the symptom descriptors that could 
comprise each score and the subsequent grade given to that score.  
 
Nausea …
If yes, how severe was this?
Have you experienced this today? Yes No
Mild Moderate Severe
Not at all A little Quite a bit Very much
How much did it bother you?
1
0 1 2 3
2 3
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Table 17: SNA↔P intervention: symptom descriptors, scores and grades 
Descriptors 
Severity Distress 
 
Symptom score 
 
Symptom grade 
--- --- 0 No nausea/fatigue 
Mild Not at all 1 
Mild 
Moderate 
A little 
Not at all 
2 
Mild 
nausea or fatigue 
Mild 
Moderate 
Quite a bit 
A little 
3 
Mild 
Moderate 
Severe 
Very much 
Quite a bit 
A little 
 
4 
 
Moderate 
nausea or fatigue 
Moderate 
Severe 
Very much 
Quite a bit 
5 
Severe Very much 6 
Severe 
nausea or fatigue 
 
The symptom scores and subsequent grade of symptom were used within the second 
component of the upper layer of the SNA↔P intervention: evidence-based 
interventions. 
7.3.1.2 Evidence-based interventions 
Practice protocols for nausea and fatigue recommending evidence-based 
interventions, and structured around the symptom assessment and grading systems 
detailed above, were developed by MM. Given that the practice protocols were to be 
used in daily clinical practice, they were succinct and comprised mainly of flow 
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diagrams and figures to make them user-friendly and easy to follow (see 
Appendices G and H).  
The practice protocols were developed following an extensive review of the 
literature concerning chemotherapy-related nausea and fatigue. The protocols 
presented a summary of the baseline assessment required for nausea or fatigue 
(using the structured symptom questionnaire) and then outlined both assessment and 
interventions for the various grades of symptoms. Finally, they presented a figure 
outlining the process of reassessment and interventions intended to continue 
throughout the patient’s course of chemotherapy. Both practice protocols also 
included an appendix section comprised of additional, but brief, information that 
nurses might find useful in managing symptoms, for example factors to aid sleep in 
relation to fatigue, or a script for guided imagery in the management of nausea. 
Following their development, each of the practice protocols was evaluated by three 
expert cancer nurses in the field (of nausea or fatigue) who were asked to comment 
on their content and presentation, and three clinical cancer nurses from Unit A who 
were asked to consider, not only the content of the protocols, but also the feasibility 
of implementing them in practice. The feedback from both expert and clinical 
cancer nurses was positive with respect to content and presentation, and no further 
recommendations were made. However the clinical nurses raised concerns about the 
practicalities of implementing some of the recommended non-pharmacological 
interventions, such as relaxation and guided imagery, explaining that the nurses in 
Unit A had neither the time nor expertise to successfully carry out these 
interventions. MM worked with the nurses to enable them to see that, although the 
intervention was nurse-led, contributions from other members of the 
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multidisciplinary team were essential. Consequently, the nurses approached the 
clinical psychologist for the area, who produced relaxation and guided imagery 
audiotapes for nurses to give to patients for use both in hospital and at home.  
Thus, the upper layer of the SNA↔P study intervention (seen in Figure 17) utilised 
symptom grades (based on patient’s symptom questionnaires) to recommend 
evidence-based assessment and interventions (contained in the practice protocols). 
This process was implemented for every patient involved in the intervention site of 
the SNA↔P study.  
Figure 17: Upper layer of SNA↔P intervention 
7.3.2 The lower layer of the SNA↔P intervention 
The lower layer of the SNA↔P intervention consisted of the WISETool and 
evidence-based information. While the intervention could be implemented by 
practitioners without using the WISETool by manually calculating symptom scores 
and grades or referring to the evidence-based information, both these components 
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added value to the intervention. The WISETool enhanced the intervention by 
visually presenting both symptom and intervention information in a way that 
enhanced communication and prompted use of the practice protocols, while the 
evidence-based information ensured that the background information was available 
to support the interventions recommended within the practice protocols. 
7.3.2.1 The WISETool 
The WISETool was an electronic patient record/database, that could be uploaded to 
any PC, that was originally developed for use within the WISECARE+ study. It had 
three key related functions that were important to the SNA↔P intervention (see 
Figure 18).  
Figure 18: Key WISETool functions 
 
Firstly the WISETool recorded and stored each patient’s symptom experiences from 
their symptom questionnaires. Based on the data entered, it then provided symptom 
graphs of each patient’s symptom scores/experiences for each cycle of 
chemotherapy, as well as across all cycles of chemotherapy (see Figure 19).  
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Figure 19: WISETool symptom graphs 
 
Finally, based on these symptom scores, it supplied an intervention prompt sheet, 
shown in Figure 20, that summarised, in colour, the patient’s symptom experiences 
for their most recent cycle of chemotherapy, and provided recommendations for 
interventions appropriate to the symptom score reported by the patient. These 
recommendations linked directly to the practice protocols. 
One symptom over one cycle of chemotherapy One symptom over two cycles of chemotherapy
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Figure 20: SNA↔P intervention prompt sheet 
 While the WISETool was developed by a software expert (Derek Hoy, see preface), 
MM contributed substantially to the design of the tool, ensuring it could perform the 
three functions detailed above, was easy to use, and produced outputs that were 
clinically meaningful. MM also worked with the nursing staff involved in the 
SNA↔P study to ensure their views on the tool were taken into consideration. Their 
major concern was the time taken for data entry to the WISETool. Consequently, all 
Fatigue
Check for anaemia
Education re causes of fatigue
Give advice on coping strategies
Suggest distraction and exercise
Provide stress management techniques
Give advice re sleep patterns
Give advice re adequate nutrition/refer to dietician
Patient Name: Joe Bloggs
Diagnosis: Breast cancer
Chemotherapy: EPI/CMF
Worst symptom scores this treatment cycle (6)
Nausea – 2 (Mild/moderate)
Fatigue – 5 (Severe)
Recommended nursing interventions                               
Nausea
Re-evaluate anti-emetic therapy
Evaluate compliance with anti-emetics
Provide education and counselling
Provide information about foods to eat and avoid
Encourage use of coping strategies
Consider non-pharmacological methods of management
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patient symptom questionnaires were barcoded and a barcode reader used to enter 
patients’ symptom data. This process of data entry not only substantially reduced 
data entry time, but also reduced the potential for error in the data entry process.  
The symptom graphs and intervention prompt sheets were printable directly from 
the WISETool. They were routinely printed and clipped to the front of the patient’s 
casenotes for review by their chemotherapy nurse when they returned for their next 
cycle of chemotherapy. This procedure meant that it did not need to be the same 
nurse to enter the data and see the patient at their next cycle of chemotherapy.  
7.3.2.2 Evidence-based information 
Practitioner-friendly literature reviews on chemotherapy-related nausea and fatigue 
were developed as part of the SNA↔P intervention. While evidence from the 
healthcare literature should be integral to clinical decision-making (Lewis 2007), it 
is all too easy for current best available evidence to pass clinicians by (Lewis 2007; 
Davies et al. 2007). Indeed, clinicians often lack the time, motivation and 
appropriate skills required to find, critically appraise, and synthesise information, all 
of which are necessary if best available evidence is to be integrated in current 
practice (Davies et al. 2007). Literature reviews, however, provide clinicians with 
the opportunity to interpret and apply research evidence in practice. 
Although systematic reviews that include only evidence from randomised controlled 
trials are considered the gold-standard for evaluating healthcare interventions, such 
reviews of the literature were not undertaken in the SNA↔P study, as randomised 
controlled trials are rarely used within the field of cancer nursing because they are 
not always the best or only way to explore nursing issues. Thus, excluding non-
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randomised controlled trials would have resulted in an extremely small sample size 
and potentially failed to draw meaningful conclusions about the evidence for 
practice.  
The aim of the practitioner-friendly literature reviews was to provide clinicians with 
a broad description of nausea and fatigue, as well as an evaluation of assessment 
and management opportunities. These literature reviews provided support for the 
evidence-based interventions contained within the practice protocols and allowed 
practitioners to easily identify the evidence that supported the practice protocols. It 
was hoped that by presenting the evidence in this way, any potential criticisms of 
the protocols would be overcome, such as those levied at guidelines, describing 
them as cookbook medicine and resenting their prescriptive nature (Graham et al. 
2000; Timmermans and Mauck 2005). In recognition of the pitfalls of descriptive 
and uncritical reviews and to minimise error and bias, principles of systematic 
review were used to guide the review, namely systematic, explicit, thorough, and 
rigorous searching. 
The process and criteria for the reviews was developed by MM and agreed upon by 
the WISECARE+ Steering Group. MM conducted the literature reviews and 
implemented the same structured process for both nausea and fatigue. This process 
involved identifying the questions for the literature reviews, sampling the literature 
to be reviewed, representing the characteristics of the studies and their findings, 
analysing findings, interpreting results and reporting the review (Ganong 1987). The 
process for the development of the literature reviews is presented in Figure 21. 
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Figure 21: Process of developing literature reviews 
 
The inclusion/exclusion criteria for the literature that would be included in each 
review is presented in Table 18. Limiting the literature to that published between 
1980 and the time of the review (2002) ensured that all relevant evidence was 
included. Extending the type of literature that could be included in the review to 
include letters and reports extended the range of evidence included in the review.  
 
Search of electronic databases
Identify potentially appropriate literature
Read abstracts & retrieve full article if appropriate
Read paper and extract data
Draft review
Circulate to European cancer nursing experts
Receive & consider comments
Final review prepared
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Table 18: Inclusion/exclusion criteria for literature reviews 
Inclusion criteria Exclusion criteria 
Published between 1980-present time 
(2002) (inclusive) 
Papers addressing symptoms and 
management within the paediatric 
setting 
Primary research, literature reviews or 
other documents, such as letters, reports 
or commentaries relating to the symptom
 
 
The electronic database search was based on keywords and search terms found in 
Appendix I. Keywords were initially generated by MM and circulated to the 
WISECARE+ Steering Group for additions, of which there were few. The databases 
searched were: CINAHL, MEDLINE, PsychLit, British Nursing Index and Embase. 
Searching these varied databases ensured that literature was identified from a range 
of disciplines, thereby ensuring the review presented as complete a perspective of 
each symptom as possible. As shown in Figure 20 above, abstracts of potentially 
appropriate papers were read, and if they met the inclusion criteria, the full article 
was retrieved. The reference lists of retrieved papers were examined and further 
relevant articles were identified. Reading and data extraction continued until each 
review was constructed. A copy of each draft review was sent to a cancer nursing 
expert in that field (either nausea or fatigue) within Europe. These individuals were 
asked to comment on the review with respect to content, presentation and any 
omissions noted with regards to key papers. This process identified a small number 
of additional papers. The final reviews (see Appendices K and L) were 
comprehensive and presented extensive evidence to guide practice. 
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Given that nurses in Unit A would have limited time in which to read the extensive 
literature reviews, a summary of each was prepared by MM. These summaries (see 
Appendices L and M) followed the same outline as the full reviews, but were 
considerably shorter and provided summarised evidence to support the interventions 
recommended within the practice protocols.  
In tandem with the literature reviews and their summaries, established guidelines for 
nausea and fatigue were also included in the evidence-based information received 
by the nursing staff in Unit A. The guidelines chosen for dissemination were 
developed by the National Comprehensive Cancer Network (NCCN), an alliance of 
19 of the world’s leading cancer centres, which develops, updates and disseminates 
a library of clinical practice guidelines that have become the most widely used in 
clinical practice (www.nccn.org). Permission was sought and granted from the 
NCCN to include the guidelines for antiemesis and fatigue (see appendices N and 
O) within the WISECARE+ and SNA↔P interventions. However, although these 
guidelines meet the criteria for excellence in their development and composition, 
they are lengthy and cumbersome, and as such, were compromised in their 
usefulness within the realities of a busy clinical setting. Ultimately, they were used 
in the SNA↔P intervention as a valuable source of information, supporting both the 
literature reviews and practice protocols. 
Thus, the SNA↔P intervention was comprised of a number of inter-related 
components: structured symptom assessment; evidence-based interventions; the 
WISETool; and evidence-based information, each of which played a greater or 
lesser role in the implementation of the intervention. The following section 
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describes the range of techniques and approaches undertaken to implement the 
SNA↔P intervention in clinical practice.  
7.4 Implementing the SNA↔P intervention 
Lewin, one of the original theorists to study the process of change and its impact on 
individuals, departments or organisations, identified three distinct phases through 
which individuals progress when presented with change: unfreezing; moving to a 
new level; and refreezing (Lewin 1951). These three phases were useful to describe 
the process through which nursing staff passed during the implementation of the 
SNA↔P intervention. Unfreezing, a process which occurs when a change is first 
introduced and which can leave the individual feeling threatened, uncomfortable 
and anxious, related to the introduction of the SNA↔P intervention to the nursing 
staff. The SNA↔P intervention meant they had to modify their current process for 
assessing and managing two common symptoms associated with chemotherapy. 
Moving to a new level begins when the change is incorporated into the normal 
process for an organisation, department or individual, and represents the phase 
where the SNA↔P intervention was integrated into the practice of the nursing staff 
from Unit A. During this stage the individual feels more comfortable and in control 
of the situation. Finally, refreezing occurs when the change is permanently 
incorporated into normal daily operations. At this stage in the process, if the change 
was taken away, individuals would resist, as it has become part of their identity.  
While this theory of change was helpful in providing insight to the various phases 
involved in implementing the SNA↔P intervention and the perceptions of the 
nursing staff as they moved through these different phases, it did not provide 
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specific pointers as to appropriate techniques to facilitate this change. Although not 
a guideline per se, the SNA↔P intervention did provide a structured process for 
nursing staff to follow in their assessment and management of nausea and fatigue. 
Thus, the literature concerning the implementation and utilisation of clinical 
guidelines was a valuable source of information to guide the implementation of the 
SNA↔P intervention in practice. Key techniques for the successful implementation 
of guidelines have been identified as: organisational commitment; raised awareness 
of the rationale for the changes among those on whom the guideline will impact; 
dissemination, education and preparation of staff about the nature and content of the 
guideline; support of practitioners, including outreach work such as provision of 
information and feedback; leadership, the use of local opinion leaders and the 
personal touch to champion the guideline; reminders, and the audit and feedback of 
the results (Duff et al 1996). Each of these techniques was appropriate for at least 
one of the phases of implementing the SNA↔P intervention into clinical practice as 
shown in Figure 22. 
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Figure 22: Implementing the intervention - processes and techniques 
Each of these key phases will now be considered. 
7.4.1 Introducing the SNA↔P intervention to clinical practice 
Introducing the SNA↔P intervention required organisational commitment, creating 
a sense of ownership using opinion leaders and local champions, and education and 
preparation. 
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7.4.1.1 Organisational commitment  
The support of the organisation is essential for a change in practice to be 
implemented as organisational resources must be committed to any necessary 
support systems that result as a consequence (Ockene and Zapka 2000). 
Furthermore, micromanagement may also be necessary by a core team who should 
be available to troubleshoot on a daily basis (Katterhagen 1996).  
MM met with the senior nursing staff responsible for Unit A on several occasions 
before its involvement in the SNA↔P study was agreed. During these meetings she 
explained the aims of the study, the role of nursing staff within it, and the benefits 
of being involved in the study, while answering the questions and concerns of senior 
management. Following senior management approval, a smaller group of nursing 
staff who would have day-to-day responsibility for the SNA↔P study was 
convened. This included MM, JMcL (the research support nurse based in Unit A), 
the ward sister, and two senior staff nurses from Unit A. MM gave them all a full 
explanation of the aims and processes of the SNA↔P study and the intervention, 
and answered their concerns, which focused primarily on the time involved in 
participating in the SNA↔P study.  
7.4.1.2 Ownership – using opinion leaders, local champions  
It was important that the nursing staff of Unit A felt a sense of ownership and 
contribution to the SNA↔P intervention that would encourage them to implement it 
in their practice. The process used to engender this sense of ownership was 
‘localisation’ of the intervention, which involves accommodating any particular 
requirements of the local area in which it is to be implemented (Duff et al. 1996), 
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while ensuring that this fine-tuning process does not reduce the validity of the 
intervention (Mead 2000). 
As highlighted above, MM worked with the nursing staff during the initial 
introductory phase to overcome their concerns about guided imagery and relaxation. 
Developing links with the Unit psychologist not only accommodated the 
requirements of the Unit, but also encouraged new ways of multidisciplinary 
working. Furthermore, MM acknowledged the nurses’ concerns about the time 
consuming nature of data entry to the WISETool and developed a barcoding system 
that both reduced the time and potential for errors associated with the data entry 
process.  
Much of this work was conducted within the micromanagement team who were 
respected, senior members of the nursing staff in Unit A.  Their involvement was 
important as the use of opinion leaders or local champions has been shown to 
increase the uptake of a change in practice (Battista 1991; Davis and Taylor-Vaisey 
1997; Schriefer and Botter 2001). The micromanagement team worked informally 
during this initial period of introducing the SNA↔P intervention to allay any 
concerns that more junior members of the nursing staff had, and indeed, it was 
hoped that these nurses would find it reassuring that the senior staff of the Unit were 
integral in the introduction of the intervention. 
7.4.1.3 Educational preparation 
At a local level, active educational approaches appear to be more effective than 
printed materials for communicating changing practice (Cheater and Closs 1997; 
Davis and Taylor-Vaisey 1997; Thomas et al. 1999). Indeed, group discussion or 
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workshops that facilitate a more interactive approach have been shown to be more 
effective than the traditional lecture in producing behaviour change (Moulding et al. 
1999). The objectives of such education include: improving awareness of the 
intervention and its supporting evidence; beliefs about appropriateness, 
effectiveness and feasibility; and ensuring that practitioners have the necessary 
skills to implement the intervention (Ockene and Zapka 2000).  
The educational sessions to introduce the SNA↔P intervention at Unit A were led 
by MM, supported by JMcL and the micromanagement team. A range of convenient 
times (usually at the start or end of nursing shifts) were set within a period of one 
week, and invitations were extended to all the nursing staff of Unit A, as well as the 
senior nursing management (as it was hoped that the presence of senior 
management at some or all of these sessions would demonstrate their support for the 
SNA↔P study). These education sessions were informal and set out to introduce 
the intervention to the nursing staff. Nurses were encouraged to contribute and 
comment as they felt appropriate. Each component of the intervention: symptom 
assessment; evidence-based interventions; the WISETool; and the evidence-based 
information, was discussed, and its respective role in the intervention described.  
Each component was also circulated around those present and nurses had the 
opportunity to test the WISETool. A fictional scenario was used to demonstrate how 
the intervention would be implemented in practice and a dummy WISETool was 
installed on the ward PC to allow nurses to familiarise themselves with the 
processes of data entry, symptom graphs and intervention prompt sheets.  
Approximately one week later, giving nursing staff the opportunity to reflect on the 
intervention and discuss it amongst themselves, a second meeting was held between 
190 
the micromanagement team and the nursing staff of Unit A. The aim of this meeting 
was to gain nurses’ perceptions about the intervention and answer any questions that 
they had about it. Senior nursing management were not invited to this meeting as 
this may have stifled nurses’ comments. Overall, the nurses accepted the 
intervention and were happy to start the process of integrating it into clinical 
practice.  
7.4.2 Integrating the SNA↔P intervention into practice 
Integrating the SNA↔P intervention into clinical practice involved educational 
preparation, reminders and prompts, and the personal touch. 
7.4.2.1 Educational preparation 
MM proposed an educational model to promote the integration of the SNA↔P 
intervention into clinical practice. This model was discussed during the initial 
educational sessions with nursing staff and aimed to ensure a sense of ownership in 
the integration of the intervention into practice. This model of education involved 
the use of local champions (the two senior staff nurses from the micromanagement 
team) to lead the integration of the intervention for nausea and for fatigue, shown in 
the literature to be important in the integration of change (Davis and Taylor-Vaisey 
1997; Thomas et al. 1999). Furthermore, the model acknowledged the need for 
continual education to keep the intervention alive in the minds of the nursing staff 
and to maintain enthusiasm and motivation for implementing it in practice. The 
nurses from Unit A were asked to consider the proposed educational model and, if 
they wished, to develop a model of their own. The nurses, however, willingly 
accepted the model developed and presented by MM (see Figure 23).  
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Figure 23: Educational model 
 
This model ensured that on a two-weekly basis there was a meeting of nursing staff 
led by a member of the multidisciplinary team who would present an educational 
session on an aspect of nausea or fatigue, such as background information, specific 
interventions or a case study of a particular patient. It was believed that to make 
these session any more frequent would have resulted in fewer staff attending, and 
making them any less frequent would have allowed the SNA↔P intervention to 
fade into the minutiae of daily clinical practice. The two senior staff nurses (from 
the micromanagement team) leading either nausea or fatigue were respected 
members of the multidisciplinary team and had a particular interest in nausea and 
fatigue. Their initial education session involved repeating the intervention for each 
symptom and, thereafter, they were supported by MM and JMcL to develop a 
programme of educational sessions that presented the multiprofessional perspective 
of the assessment and management of both nausea and fatigue.  
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7.4.2.2 Reminders and prompts 
Reminders, such as posters and laminated pocket sized cards or reminder sheets, 
have been shown to be effective in augmenting the uptake of a new intervention in 
practice (Davis and Taylor-Vaisey 1997). Harnessing new technology and 
generating computerised prompts is becoming an increasingly frequent and effective 
strategy (Thomas et al. 1999; Duff and Casey 1999). The use of computer prompts 
has also been highlighted in an effort to increase the clinical use of an intervention 
(Feder et al. 1999).  
A range of reminders and prompts were used within the SNA↔P study to integrate 
the intervention in clinical practice. The lack of funding meant that the use of costly 
reminders such as mugs, pens and post-it notes were not possible. However, 
brightly coloured stickers were made for patients’ medical and nursing casenotes 
alerting health professionals to the fact that the patient was participating in the 
SNA↔P study. The practice protocols were colourful and so were easy to identify 
in the nursing folders located outside each of the 4 bedded chemotherapy bays. 
Coloured posters just above the nurses’ desk outside each chemotherapy bay also 
reminded staff of the SNA↔P study.  
Electronic intervention prompt sheets were generated when patients’ symptom data 
was entered to the WISETool. This colour-coded electronic prompt provided 
information, not only concerning the patient’s grades of symptoms, but also the 
most appropriate interventions for those symptom grades. This prompt could be 
printed directly from the WISETool, and nurses entering patient data were 
encouraged to do this, clipping it to the front of each patient’s casenotes to guide 
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appropriate symptom management when the patient attended for their next cycle of 
chemotherapy.  
Carefully considered placement of the practice protocols around Unit A also acted 
as a reminder for nursing staff. A copy of each practice protocol was stored 
alongside frequently used local nursing guidelines and policies for symptom 
management, such as the policies for pain and constipation, in each of the 
chemotherapy bays. It was felt that storing the practice protocols there would be 
useful, as nurses regularly referred to these policies in their daily planning of patient 
care, and so would be reminded of their use for practice. As well as locating the 
practice protocols in chemotherapy bays, both the practice protocols and the 
evidence-based information were placed, along with the literature concerning 
symptom management, in the ward sister’s office. It was appropriate to locate the 
evidence-based information here, as this was the literature that the nursing staff used 
to obtain further information about symptoms and their management. The summary 
literature reviews were also located with the professional literature found in the 
nurses’ staff room in the chemotherapy Unit. It was envisaged that this careful 
placement of the various components of the SNA↔P intervention would subtly 
remind nursing staff of the SNA↔P study and the intervention, so facilitating its 
integration into the nursing practice of Unit A.  
7.4.2.3 The personal touch 
Personal contact in conjunction with other dissemination methods is important in 
the implementation of a change in practice (Grol 2001). As the SNA↔P 
intervention was taking place in a single chemotherapy Unit, face-to-face contact 
between the micromanagement team and the nursing staff was possible.  
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As researcher for the SNA↔P study, MM was removed from the clinical setting. 
However, her presence at the education session, both during the introduction of the 
intervention, as well as occasional informal visits to the Unit and visits to conduct 
patient interviews, meant that she was often on hand to discuss the study and 
address any queries that nursing staff had about various aspects of the SNA↔P 
study. Also, as she had previously worked clinically in the hospital of Unit A 
(although not Unit A itself) she knew, and was known to, a number of the nursing 
staff. This eased the process of communication in both directions. 
JMcL was a respected member of the senior nursing staff who had worked in cancer 
care for a number of years. She had a constant presence in Unit A as she was 
responsible for patient recruitment and local co-ordination. This meant she was on 
site to ensure the smooth day-to-day management of the study and troubleshoot, if 
necessary. Minor problems, such as computer or printing problems that could have 
impacted on the conduct of the study, were always promptly resolved. This gave 
nursing staff confidence in the day-to-day conduct of the SNA↔P study and 
encouraged their involvement. 
The involvement of the senior staff nurses, who also led each of the symptom 
education sessions, leant further credibility to the SNA↔P study and its 
intervention. As they, too, were a constant presence within Unit A, they were 
available to nursing staff if issues arose with the intervention that staff were unsure 
about. Their involvement in implementing the study in their clinical practice meant 
they also fulfilled a role model function for the intervention’s integration into 
practice. 
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Thus, while educational preparation, reminders and prompts and the personal touch 
all ensured that the intervention was successfully integrated into practice, 
maintaining this change in practice required moving the nurses to the third phase of 
Lewin’s process of change: refreezing – where the change is permanently 
incorporated into normal daily operations (Lewin 1951). 
7.4.3 Maintaining the SNA↔P intervention in clinical practice 
Local implementation strategies shown to be effective in maintaining change in 
clinical practice include: educational materials; educational outreach; audit and 
feedback; reminders; and opinion leaders (individuals identified as influential by 
their peers) (Cheater and Closs 1997; Moulding et al. 1999). Four specific strategies 
were put in place during the intervention phase of this study to support the 
continued use of the intervention in practice in Unit A. These strategies were: the 
educational sessions; the use of opinion leaders; prompts and reminders; and the 
personal touch. Detail concerning each strategy is presented below. 
7.4.3.1 Educational sessions 
Educational session for nausea and fatigue run by the senior staff nurses involved in 
the micromanagement team continued to take place on a two-weekly basis. These 
were informal, multidisciplinary sessions during which more information was 
presented about specific interventions included in the practice protocols. These 
sessions were led by the most relevant member of the multidisciplinary team, 
depending on the subject of concern, and aimed to provide more in-depth 
understanding of the interventions. These sessions were purposefully short 
(maximum 30 minutes) to encourage attendance, and followed an interactive 
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format, encouraging questions from those present and discussion of particular 
instances in which the intervention under discussion could have been, or was, used. 
When possible, MM was present at these sessions and occasionally gave a short 
informal summary of recruitment and some descriptive results of symptom patterns. 
Thus, these sessions not only increased awareness of evidence-based 
multidisciplinary interventions, but also aimed to encourage and motivate nursing 
staff in relation to the study in general. It also gave the nursing staff the opportunity 
to ask MM questions and highlight any issues in relation to implementing the 
intervention clinically.  
7.4.3.2 The use of opinion leaders 
Opinion leaders were crucial for sustaining the use of the intervention in practice. 
The presence of JMcL around Unit A, as well as the senior staff nurses from the 
micromanagement team was important for maintaining the profile of the 
intervention; furthermore, they all acted as acting as role models for more junior 
staff. These nurses were also able to address any problems as they arose. 
7.4.3.3 Reminders and prompts 
The reminders and prompts of the integration strategy described above continued to 
be used. Ensuring the practice protocols and intervention prompt sheets were easily 
accessible and highly visible was important in maintaining their use in practice. The 
education sessions led by the senior staff nurses also served to remind staff of the 
study in general, as well as specific interventions. 
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7.4.3.4 The personal touch 
The local opinion leaders leant a personal touch to the SNA↔P study and the 
intervention. The availability and presence of both JMcL and the senior staff nurses 
served to keep the intervention in the forefront of nurses’ minds. That these senior 
nurses were involved in the day-to-day use of the intervention gave it credibility and 
encouraged the nursing staff to continue with their use of it across time. MM’s 
frequent presence in Unit A also demonstrated the researcher’s commitment to the 
study and intervention to the nursing staff there. 
7.5 Conclusion 
This chapter firstly described the aim of the SNA↔P intervention before 
demonstrating the significant amount of development work invested by MM in the 
construction of the intervention. Each component of the intervention was described 
in detail and their inter-relationships demonstrated. The extensive range of 
techniques and approaches undertaken by MM and the micromanagement team to 
introduce, implement and maintain the implementation of the intervention in 
clinical practice were subsequently presented. It is unfortunate that the SNA↔P 
study did not evaluate the success of the implementation of the SNA↔P 
intervention. Neither was such as evaluation undertaken within the WISECARE+ 
study from which the SNA↔P study arose. This lack of insight complicates the 
evaluation of the impact of the various components of the intervention. Further 
discussion of this limitation of the SNA↔P study is found in chapter 9. 
However, the implementation of the SNA↔P intervention was not an end in itself. 
The purpose of implementing the intervention was to improve women’s experiences 
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of nausea and fatigue during a course of chemotherapy for breast cancer. Thus, one 
can question whether the intervention was successful in achieving this aim. The 
impact of the intervention on symptom experiences is fully evaluated in the 
following chapter.  
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8 CHAPTER 8 – RESULTS OF THE SNA↔P STUDY 
8.1 Introduction 
This chapter reports on the results of the SNA↔P study which utilised a quasi-
experimental interrupted time-series design with a control group. The study 
hypothesised that the implementation of a nurse-led intervention would improve 
women’s experiences of chemotherapy-related nausea and fatigue during a course 
of chemotherapy for breast cancer. Both quantitative and qualitative research 
methods, detailed in Chapter 6, were undertaken to address the 2 distinct aims of the 
SNA↔P study which were: 
1. To describe and explore the reports and experiences of chemotherapy-related 
nausea and fatigue. 
2. To explore the impact of the intervention on experiences of chemotherapy-
related nausea and fatigue. 
It is important to describe the sample and consider its characteristics to evaluate 
whether there are confounding variables within groups of patients that may 
confound the results of the SNA↔P study. This chapter will present details of the 
study sample before moving on to address each of the research aims, then draw 
conclusions on the overarching study aim.  
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8.2 Sample characteristics 
Data collection for this study took place in 2 clinical sites (Units A and B) over 2 
time periods – times 1 and 2. Recruitment to each phase was over 7 months. This 
design resulted in 4 distinct study groups (see Figure 24) 
Figure 24: SNA↔P study patient groups 
Patients from all study groups completed the symptom questionnaire. A subsample 
of patients participating in the second cohort of the study participated in a structured 
interview. Details of each sample are presented below. 
8.2.1 Questionnaire sample 
8.2.1.1 Recruitment and attrition 
Recruitment in Unit A relied on JMcL, the research support nurse who worked 
alongside MM during the introduction, integration and maintenance of the 
intervention, as described in chapter 7. Thirty six patients were identified as eligible 
for participation during cohort 1 with thirty recruited. Four were not approached due 
to JMcL being on annual leave and the remaining two patients declined to take part 
due to feeling already too anxious. Twenty two patients were identified as eligible 
Unit A
Intervention unit
Unit B
Control unit
Unit A
Cohort 1
(site control group)
SNA↔P 
No 
intervention
Unit B
Cohort 1
Unit A 
Cohort 2
(intervention group)
Unit B
cohort 2
(time control group)
June 2002 - Dec 2002 March 2003 - Sept 2003Jan 2003 – Feb 2003
201 
for participation during cohort 2. Two of those patients were missed by JMcL as a 
result of miscommunication from ward nursing staff. Thus, twenty patients were 
recruited. 
In Unit B, recruitment was undertaken by MM. Thirty eligible patients were 
identified during cohort 1 and twenty-five during cohort 2. All agreed to participate.  
Therefore, in total, 105 patients about to start chemotherapy for a diagnosis of 
breast cancer gave their informed consent to participate in the study (see Table 19).  
Table 19: Patient recruitment to Units A and B 
 Unit A Unit B 
Cohort 1 30 30 
Cohort 2 20 25 
Total 50 55 
 
Not all patients continued with their participation in the study throughout the 
duration of their chemotherapy. Table 20 gives detail of the numbers of patients 
returning their symptom questionnaires for each cycle of chemotherapy within each 
patient group. 
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Table 20: Number of patients participating by group and cycle of chemotherapy 
Chemotherapy 
cycle 
Unit A 
Cohort 1 
(n=30) 
Unit A 
Cohort 2 
(n=20) 
Unit B 
Cohort 1  
(n=30) 
Unit B  
Cohort 2 
(n=25) 
 
TOTAL 
 
1 30 20 30 25 105 
2 26 17 28 19 90 
3 26 14 25 18 83 
4 24 13 20 18 75 
5 16 11 14 18 59 
6 13 9 9 18 49 
7 10 8 7 14 39 
8 7 8 5 13 33 
 
As patients were assured at the start of the study that they could withdraw at any 
time, without having to give a reason for it, no data was collected as to patients’ 
rationale for discontinuing their participation in the study. There were differences in 
patient procedures throughout the SNA↔P study between Units A and B. As 
described in chapter 6, patients in Unit A were met by JMcL at each cycle of 
chemotherapy and given their next set of patient symptom questionnaires, as well as 
being assessed for their willingness and ability to continue in the SNA↔P study. 
Patients in Unit B were given all their symptom questionnaires at the start of their 
chemotherapy and advised to contact MM should they have any questions, while 
being assessed on their ability to continue in the study by their chemotherapy nurse 
at each cycle. Although there were slight differences between Units A and B with 
respect to levels of patient attrition, overall there was little difference between the 
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Units with Unit A having 30% of patients completing the questionnaires for the 
duration of their treatment while 32% of patients in Unit B did so. The 
characteristics of the sample that started and those who fully completed the study 
are presented in the following sections.  
8.2.1.2 Age 
Date of birth was recorded for each patient. Ages have been banded into 10-year 
groups for ease of reporting. The age range of the total sample at the start of data 
collection and the age range of those who completed the study to the end is 
presented in Figure 25.  
Figure 25: Age range of questionnaire sample 
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1 = patients starting SNA↔P study  
2 = patients participating in SNA↔P study for total duration of their chemotherapy 
This graph shows that the majority of patients participating in the study (81.9%, 
n=86) were between 35 years and 64 years of age. While 7.6% (n=8) of the sample 
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was between 18-34 years of age, 10.6% (n=11) were aged 65 and over. It also 
demonstrates that the age range of those patients who participated in the SNA↔P 
study for the total duration of their chemotherapy reflects the total study sample. 
8.2.1.3 Social deprivation 
The measure of deprivation used in the SNA↔P study was the Carstairs Score, a 
categorical variable based on postcode ranging from DEPCAT 1 (the most affluent 
postcode sectors) to 7 (the most deprived) (McLoone 2004). The deprivation scores 
for the sample (all those starting the study and those who completed the study) are 
presented below. Figure 26 demonstrates that there was little difference in the level 
of deprivation experienced by those starting the study and those patients who 
continued for the full duration of their treatment. 
Figure 26: Deprivation score for questionnaire sample 
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Figure 27 presents the DEPCAT scores for the total study population and compares 
these with those of the 2001 Scottish Census (McLoone 2004). This graph shows 
that the range of deprivation in the study population is not unlike that of the general 
population.   
Figure 27: Questionnaire sample compared with national statistics 
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8.2.1.4 Treatment intent 
Eight different chemotherapy regimes were administered to patients participating in 
the study and information about the symptom profile associated with each regime 
and its therapeutic use was gathered from the literature as well as through 
discussions with the Clinical Nurse Specialists (CNSs) working in both the 
chemotherapy Units. These discussions with CNSs were particularly useful, as they 
highlighted some idiosyncratic uses of particular chemotherapy regimes in both 
Units A and B. Figure 28 illustrates the percentage of patients receiving each 
chemotherapy regime. 
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Figure 28: Chemotherapy regimes received by questionnaire sample 
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These regimes ranged in emetogenicity: some being mildly emetogenic (FEC, 
FEC/Taxotere, Epirubicin, Taxol-Tango) while others were moderately emetogenic 
(Adriamycin/cyclophosphamide, CMF, Epirubicin/CMF, EC-Tango). Given the 
range of chemotherapy regimes, they were classified into two groups on the basis of 
their intent: curative or palliative. It is important to consider the relative toxicity of 
curative and palliative treatments, as curative treatments are generally more toxic, 
that is, they have greater associated symptoms than palliative treatment. However, it 
may also be the case that those patients receiving palliative chemotherapy are 
experiencing symptoms associated with advanced cancer.  
Figure 29 shows that the majority of patients starting the SNA↔P study were 
receiving chemotherapy with curative intent (n=79, 75.2%) and it was 
predominantly patients receiving curative treatment (n=32, 97%) who continued to 
complete their questionnaires for the total duration of their chemotherapy. Only one 
patient who was receiving palliative chemotherapy continued to complete 
questionnaires for the total duration of their chemotherapy. 
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Figure 29: Treatment intent for questionnaire sample 
0
20
40
60
80
100
120
patients starting study patients participating for total duration of
chemotherapy
Treatment intent
%
 o
f p
at
ie
nt
s
curative
palliative
 
8.2.2 Interview sample 
During time 2 a convenience sample of 9 ‘information-rich’ patients participated in 
a structured interview: four from the intervention site and five from the control site, 
representing 20% of the study sample at this time period. Table 21 presents the 
demographic details of the interview sample. 
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Table 21: Demographic characteristics of the interview sample 
Demographic characteristics of interview sample  
Age range  Deprivation 
category 
 Treatment intent  Participating at 
cycle 
25-34 1  1 0  Curative 6  1 2 
35-44 3  2 1  Palliative 3  2 4 
45-54 4  3 4     3 1 
55-64 1  4 2     5 2 
   5 1       
   6 0       
   7 1       
 
8.2.3 Potentially confounding variables 
The potentially confounding variables identified in this study were that of age, 
social deprivation and treatment intent.  
8.2.3.1 Age 
The age range of the patient groups was relatively normally distributed and is 
presented in Figure 30.  
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Figure 30: Age range of patient groups 
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Comparison of the age ranges between the patient groups was carried out using a 
one-way ANOVA, and showed that the age range of the four groups is not 
statistically significantly different from one another (F=1.408 df=3 p=0.25).  
8.2.3.2 Social deprivation 
The level of deprivation of patient groups is presented in Figure 31.  
Figure 31: Level of deprivation across patient groups 
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This graph demonstrates that the level of deprivation is not normally distributed. 
Given such distribution, a Kruskal-Wallis test was conducted showing that the level 
of deprivation of the four patient groups did not differ significantly (Chi sq. 2.98, df 
3, p=0.39). 
8.2.3.3 Treatment intent 
The treatment intent of the 4 patient groups at the start of data collection is 
presented in Figure 32.  
Figure 32: Treatment intent within patient groups 
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Figure 33: Statistical comparison of treatment intent between patient groups 
These test the null hypothesis that there is no difference between population means. 
The results of each chi square test are presented below: 
Comparison 1: A significant difference in treatment intent between Unit A 
cohort 1 and Unit B cohort 1 (chi sq 8.53, df 1, p=0.003) 
Comparison 2: A significant difference in treatment intent between Unit A 
cohorts 1 and 2 (chi sq 11.1, df 1, p=0.001) 
Comparison 3: No significant difference in treatment intent between Unit B 
cohorts 1 and 2 (chi sq 3.14, df 1, p=0.76)  
Comparison 4: No significant difference in treatment intent between Unit A 
cohort 2 and Unit B cohort 2 (chi sq 0.64, df 1, p=0.423) 
Comparing the symptom scores between those patients receiving curative and 
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associated with higher nausea and fatigue scores. This comparison was undertaken 
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curative chemotherapy is associated with marginally lower mean total scores, as 
well as lower mean severity and mean distress scores (see Table 22). An ANOVA 
for each symptom and for all symptom components showed that there were no 
statistically significant differences between the resulting symptoms from either 
curative or palliative chemotherapy: total nausea scores (F=0.783, df 1, p=0.378), 
nausea severity scores (F=0.536, df 1, p=0.466), nausea distress scores (F=1.107, df 
1, p=0.295), total fatigue scores (F=0.032, df 1, p=0.858), fatigue severity scores 
(F=0.029, df 1, p=0.865) and fatigue distress scores (F=0.031, df 1, p=0.862). 
Table 22: Comparison of mean nausea and fatigue scores according to treatment intent 
Nausea Fatigue  
Minimum Maximum Mean Minimum Maximum Mean 
Total .00 6.00 .9649 .00 5.07 1.3124
Severity .00 3.00 .6012 .00 2.64 .8495 
Curative 
Distress .00 3.00 .3642 .00 2.43 .4650 
Total .00 5.17 1.2134 .00 4.0 1.4764
Severity .00 2.75 .7163 .00 2.4 .9126 
Palliative 
Distress .00 2.42 .4996 .00 1.88 .5655 
 
Thus, the analysis of potentially confounding variables has shown that in relation to 
age and social deprivation, none of the patient groups are statistically significant 
from one another. However, the groups differ statistically in relation to treatment 
intent: Unit A cohort 1 differs from cohort 2 of Unit A and cohort 1 of Unit B, who 
both have a lower proportion of patients receiving chemotherapy with palliative 
intent. However, there are no statistically significant differences between nausea 
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and fatigue experienced as a consequence of chemotherapy given with either 
curative or palliative intent. The remainder of this chapter will address the two 
distinct aims of the study, before coming to a conclusion about the overarching aim 
of the study – the evaluation of the impact of the intervention. 
8.3 Description of chemotherapy-related nausea and fatigue 
The first aim of this study was to describe and explore the reports of chemotherapy-
related nausea and fatigue experienced by women during a course of chemotherapy. 
Both quantitative data, in the form of symptom scores from symptom 
questionnaires, and qualitative data, in the form of patients’ interviews about their 
experiences were used to achieve this aim. Figure 34 demonstrates how these two 
research methods blend to achieve this. This technique was used for both nausea 
and fatigue experiences. Symptom information from the whole dataset was used, as 
this exploration and description did not involve group comparisons. 
Figure 34: Blending of research techniques to describe symptoms 
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As intended, a vast amount of quantitative data were generated from the symptom 
questionnaires. These are presented in Appendix  P – summary of quantitative data. 
These data were longitudinal in nature, both within cycles of chemotherapy (days 1-
14), and across cycles of chemotherapy (cycles 1-8), see Figure 35. 
Figure 35: Longitudinal data collection process 
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Data from the patient interviews during which patients explained their symptom 
experiences across their range of symptom scores were used to illustrate the 
personal significance of the mean symptom scores presented in figures 36 and 38. 
Quotes from patients’ interviews are presented throughout and the number in 
brackets that follows each quote refers to the individual patient’s study number. 
8.3.1 Nausea 
The number of patients reporting nausea (regardless of level of severity or distress) 
is presented in Table 23 below. As already highlighted above, the number of 
patients who continued to participate in the SNA↔P study decreased over time. 
Consequently, the number of patients participating at each cycle is noted below the 
cycle number. Although the study does have a reducing number of patients 
participating with each cycle, the final cycle involved 33 patients, which is a 
reasonable number of patients on which to draw conclusions. The percentages 
presented in Table 23 are calculated on the number of patients participating in each 
individual cycle and show that the incidence of nausea reduces over consecutive 
cycles of chemotherapy during the first few days post-chemotherapy.  
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Table 23: Percentage of patients experiencing nausea across all cycles of chemotherapy 
Day Cycle 1 
n=105 
% (n=) 
Cycle 2 
n=90 
% (n=) 
Cycle 3 
n=83 
% (n=) 
Cycle 4 
n=75 
% (n=) 
Cycle 5 
n=59 
% (n=) 
Cycle 6 
n=49 
% (n=) 
Cycle 7 
n=39 
% (n=) 
Cycle 8 
n=33 
% (n=) 
1 41% (44) 37% (33) 29% (24) 32% (24) 27% (16) 35% (17) 36% (14) 24% (8) 
2 47% (49) 44% (40) 41% (34) 32% (24) 37% (22) 35% (17) 36% (14) 30% (10) 
3 40% (42) 43% (39) 35% (29) 33% (25) 37% (22) 35% (17) 36% (14) 27% (9) 
4 36% (38) 41% (37) 31% (26) 29% (22) 32% (19) 31% (15) 31% (12) 27% (9) 
5 29% (30) 34% (31) 31% (26) 25% (19) 32% (19) 24% (12) 28% (11) 21% (7) 
6 28% (29) 31% (28) 31% (25) 23% (17) 27% (16) 20% (10) 23% (9) 18% (6) 
7 21% (22) 29% (26) 26% (22) 20% (15) 22% (13) 16% (8) 21% (8) 12% (4) 
8 20% (21) 21% (19) 23% (19) 20% (15) 25% (15) 24% (12)  31% (12) 21% (7) 
9 15% (16) 16% (14) 19% (16) 16% (12) 27% (16) 31% (15) 23% (9) 21% (7) 
10 12% (13) 14% (13) 12% (10) 16% (12) 19% (11) 26% (13) 26% (10) 21% (7) 
11 7% (7) 11% (10) 8% (7) 15% (11) 15% (9) 18% (9) 26% (10) 15% (5) 
12 6% (6) 8% (7) 8% (7) 11% (8) 17% (10) 12% (6) 21% (8) 12% (4) 
13 4% (4) 7% (6) 8% (7) 11% (8) 14% (8) 10% (5) 21% (8) 9% (3) 
14 6% (6) 8% (7) 8% (7) 8% (6) 12% (7) 10% (5) 18% (7) 6% (2) 
 
Figure 36 demonstrates the patterns of mean nausea scores reported in the symptom 
questionnaires by all patients participating in each cycle of the study. Mean 
symptom scores for the total nausea experience (range 0-6) and the individual 
subscales of severity (range 0-3) and distress (range 0-3) are shown.  In general, 
there is a peak in nausea during the first few days following chemotherapy 
administration which gradually lessens over time. This pattern changes from cycle 5 
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onwards where a second peak in nausea is seen around day 8-10 following 
chemotherapy. This change is likely to be because 45.8% (n=27) of the sample at 
cycle 5, 53% (n=26) of the sample at cycle 6, 59% (n=23) of the sample at cycle 7 
and 60.6% (n=20) of the sample at cycle 8 received the chemotherapy regime 
EPI/CMF, which entails Epirubicin for cycles 1-4 followed by Cyclophosphamide, 
Methotrexate and 5-Fluoruracil for cycles 5-8. During cycles 1-4, chemotherapy is 
administered on day 1 of the cycle while in cycles 5-8 chemotherapy is 
administered on days 1 and days 8.  
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Figure 36: Mean nausea scores 
Note reducing sample size: n value for each cycle noted above each graph 
The highest mean score for nausea reported throughout all 8 cycles of chemotherapy 
was 1.23 (possible range 0-6), seen at day 2 of the first cycle of chemotherapy. 
Thereafter, it did not reach above 1.2 although it came close on day 2 of cycle 5, 
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reaching 1.19. This pattern may again be due to the proportion of patients receiving 
EPI/CMF, a regime in which drug administration changes at cycle 5. It may be this 
change in drug that resulted in this increase in experiences of nausea. It can also be 
seen from Figure 35 that patterns of severity and distress are relatively similar to 
one another across all cycles of chemotherapy, which suggests that they have a 
positive correlation, that is, as a symptom becomes increasingly severe, the level of 
distress associated with it increases. A Pearson Product Moment Correlation 
Coefficient was calculated to evaluate the degree of the relationship between nausea 
severity and distress scores. A significant relationship between patients’ reports of 
nausea severity and associated distress was shown (r 0.925, N105, p<0.01). 
The total mean nausea score (incorporating mean severity and distress scores) for 
each day (1-14) within each cycle (1-8) was plotted and can be seen in Figure 37. 
This graph shows that there is little variation in total nausea scores between each 
cycle of chemotherapy (1-8) and again highlights the peak in nausea experiences 
between days 1-3 and days 8-10. Such similarity in the patterns of mean nausea 
over each cycle is reassuring, given the reduction in sample size with consecutive 
cycles, as it indicates that those patients continuing to complete and return their 
symptom questionnaires were not reporting greatly different nausea experiences 
from the larger sample at the start of data collection. 
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Figure 37: Mean total nausea scores within and across cycles of chemotherapy 
During each interview, patients were asked a number of questions to describe their 
experiences of nausea. They were asked to describe how they felt (physically and 
psychologically) at each of the nausea scores they had reported and the impact that 
each level of nausea had on their abilities. They were also asked to compare their 
experiences of nausea between scores, for example, how did a score of 1 compare 
with a 2 or a 2 with a 4? They were also asked which score of nausea they believed 
to be acceptable to them, for example, no nausea (score 0), or a score of 1 or 2. 
While some patients referred to nausea as ‘feeling sick’, 
‘I do feel sick later on in the day.’ (2) 
‘I was just constantly feeling sick. It’s very unpleasant.’ (8) 
others used different terms to describe their nausea: 
‘A bile feeling in your mouth and a watery feeling.’ (3) 
‘It felt a bit like travel sickness, as if your head was swimming.’ (5) 
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‘I get a coating in my mouth, a horrible coating.’ (7) 
‘I felt quite squeamish and it kept me awake through the night even though I’d taken 
my anti-sickness tablets.’ (9) 
‘I’d feel a bit seedy.’ (4) 
Patients easily articulated the negative impact that nausea had on their daily life, 
particularly in relation to their functional ability. However, they were less likely to 
reflect on the psychological impact that nausea had on their life in general. In all 
cases, patients had to be prompted to consider the psychological impact of their 
nausea experiences. 
Nausea’s impact on functional aspects of their daily lives included the following: 
‘It actually stops me going out and socialising.’ (8) 
‘It stops me driving, I can’t drive with it like that.’ (4) 
‘I stay in constantly now, I only go out if I have to.’ (8) 
‘I can’t concentrate because that sick feeling sits in your throat.’ (5) 
‘It does stop me doing the things I enjoy for several days.’ (4) 
‘It’s constantly there, you wake up with it, you go to bed with it, you’re up through 
the night with it, it’s absolutely disgusting.’ (8) 
While nausea did have a negative psychological impact on some patients,  
‘It’s several days of misery and feeling quite miserable’ (4) 
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‘Obviously, you start to get depressed, you can’t go anywhere, you can’t go out, you 
can’t do anything.’ (8) 
others seemed to have developed ways of coping with their experiences: 
‘It doesn’t make me feel depressed or anything like that, I just think, it is finite, it 
will end. I just think, oh God, here we go again.’ (5) 
‘it’s not the end of the world.’ (2) 
Patients spoke easily about the ways they had tried to manage their nausea and there 
was no discernable differences between patients from Units A or B, despite the fact 
that patients in Unit A should have been getting tailored symptom advice from their 
nurses from the SNA↔P practice protocols. There was a sense of trying to keep life 
as ‘normal’ as possible in the hope that this would reduce the impact of the nausea.  
 ‘I take the anti-sickness, take them all. No point in being a martyr, I take the drugs 
they give you.’ (5) 
‘I do a lot of reading and stuff like that to try and distract myself from what is going 
on. I’ve got people coming in all the time and the house is always busy and that 
distracts me.’ (4) 
‘I ate a lot of bland food, toast and the like, stuff that wasn’t too flavoured.’ (2) 
‘I read and watch TV and try to relax, I tried to think of something else and not let it 
take over my life. I think it helps to keep a bit of normality in your life.’ (7) 
‘I tried to just be me and do the things I would normally do. I didn’t let it take over.’ 
(3) 
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Patients were also able to evaluate the effectiveness of their self-care in alleviating 
their nausea and again, there were no differences in patients’ responses between 
Units A and B. 
‘I think that the business takes your mind off feeling seedy and you feel OK for a 
wee while.’ (4) 
‘I take everything they give me and I think the anti-sickness tablets, they do work, 
they take the edge off it.’ (5) 
‘We had to try to various drug combinations to get that [nausea] under control and 
certainly with the new stuff [antiemetic] it’s not as bad as before.’ (8) 
‘I had felt sick but once I took my tablets again, I was OK.’ (3) 
‘I definitely think it helped to try and not take [eat] anything that was too highly 
flavoured.  I think that did help.’ (2) 
Thus, in exploring and describing the symptom of chemotherapy-related nausea, 
this study has shown that nausea peaks around days 1-3 following chemotherapy 
administration. The second peak seen in cycles 5-8 at days 8-10 in this study is 
likely to be due to a specific chemotherapy regime (EPI/CMF). No real differences 
in nausea scores were seen between cycles of chemotherapy. Patients can easily 
articulate their experiences of nausea and are able to describe it in many ways. They 
can identify the ways in which it impacts on their functional ability and, with 
prompting, their psychological response to it. Patients also view their self-care 
strategies as helpful in managing their experiences of nausea. 
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8.3.2 Fatigue 
The number of patients reporting fatigue (regardless of severity or distress) is 
presented in Table 24 with the number of patients participating at each cycle noted 
beneath the cycle number. The percentages presented in Table 24 are calculated on 
the number of patients participating in each individual cycle. Table 24 shows that 
there is little fluctuation in percentage of patients reporting fatigue across cycles of 
chemotherapy, however, the incidence of fatigue is much higher than that of nausea. 
Table 24: Percent and number of patients experiencing fatigue across all cycles of 
chemotherapy 
Day Cycle 1 
n=105 
Cycle 2 
n=90 
Cycle 3 
n=83 
Cycle 4 
n=75 
Cycle 5 
n=59 
Cycle 6 
n=49 
Cycle 7 
n=39 
Cycle 8 
n=33 
1 40% (42) 51% (46) 49% (41) 52% (39) 52% (31) 47% (23) 56% (22) 36% (12) 
2 49% (52) 61% (55) 48% (40) 53% (40) 52% (31) 57% (28) 59% (23) 39% (13) 
3 50% (53) 61% (55) 55% (46) 56% (42) 61% (36) 57% (28) 59% (23) 42% (14) 
4 51% (54) 62% (56) 60% (50) 57% (43) 68% (40) 59% (29) 59% (23) 45% (15) 
5 54% (57) 61% (55) 57% (47) 55% (41) 50% (35) 73% (36) 69% (27) 39% (13) 
6 57% (60) 60% (54) 63% (52) 60% (45) 66% (39) 71% (35) 59% (23) 36% (12) 
7 54% (57) 58% (52) 65% (54) 60% (45) 64% (38) 63% (31) 51% (20) 36% (12) 
8 51% (54) 57% (51) 60% (50) 57% (43) 58% (34) 61% (30) 61% (24) 42% (14) 
9 40% (42) 51% (46) 57% (47) 59% (44) 52% (31) 59% (29) 61% (24) 42% (14) 
10 41% (43) 50% (45) 51% (42) 47% (35) 58% (34) 61% (30) 54% (21) 42% (14) 
11 42% (44) 53% (48) 54% (45) 51% (38) 56% (33) 59% (29) 61% (24) 45% (15) 
12 39% (41) 44% (40) 49% (41) 49% (37) 51% (30) 57% (28) 56% (22) 42% (14) 
13 32% (34) 50% (45) 46% (37) 48% (36) 56% (33) 57% (28) 56% (22) 39% (13) 
14 33% (35) 45% (41) 46% (37) 45% (34) 52% (31) 51% (25) 56% (22) 36% (12) 
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Figure 38 demonstrates the patterns of mean fatigue reported in the symptom 
questionnaires by all patients participating in the study. Mean symptom scores for 
the total fatigue experience (range 0-6) and the individual subscales of severity 
(range 0-3) and distress (range 0-3) are shown.  These graphs show a stable pattern 
of mean fatigue that does not fluctuate within cycles of chemotherapy as did nausea. 
Total mean fatigue scores and their component parts (severity and distress) appear 
to have a relatively constant presence within and across cycles of chemotherapy. 
The highest mean score of fatigue is seen in day 9 of cycle 8 where the mean total 
fatigue score was 2.375.  
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Figure 38: Mean fatigue scores 
Note reducing sample size: n value for each cycle noted above each graph 
As with nausea, Figure 38 shows that patterns of severity and distress are relatively 
similar to one another across all cycles of chemotherapy, suggesting they have a 
positive correlation, that is, as fatigue becomes increasingly severe, the level of 
distress associated with it increases. A Pearson Product Moment Correlation 
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Coefficient was calculated to evaluate the degree of the relationship between fatigue 
severity and distress scores. A significant relationship between patients’ reports of 
fatigue severity and associated distress was shown (r 0.865, N105, p<0.01). 
Looking at the plotted data in Figure 37, there is the suggestion of a slight trend for 
fatigue to increase up until day 6 following chemotherapy followed by a gradual 
decrease. To further explore this potential pattern, the data were plotted only to 
show days 1, 6 and 14 following chemotherapy. This clarifies this trend (see Figure 
39). 
Figure 39: Mean total fatigue scores days 1, 6, 14 
The previous plotting of fatigue data (Figures 38 and 39) show that fatigue increases 
with subsequent cycles of chemotherapy. Plotting the total fatigue scores for each 
day for all cycles (Figure 40) clearly demonstrates this incremental increase. This 
graph shows that mean total fatigue scores are almost 3 times greater on day 14 of 
cycle 8 (2.13) when compared with day 14 of cycle 1 (0.76). Caution is required in 
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drawing any major conclusions from this result due to the reducing sample on 
which it is based.  
Figure 40: Mean total fatigue scores across 8 cycles of chemotherapy 
Given this incremental increase in fatigue with subsequent cycles of chemotherapy, 
further exploration was undertaken and a fatigue score was generated for each cycle 
of chemotherapy (the mean total, severity and distress scores for days 1-14 for each 
cycle of chemotherapy). These scores were then plotted (see Figure 41). This graph 
continues to demonstrate the incremental increase in total fatigue scores. However, 
it also shows that the severity scores remained relatively stable during cycles 2, 3, 4 
and 5, increasing slightly at cycles 6, 7 and 8. In contrast, the distress scores showed 
a slight increase with each cycle of chemotherapy. Indeed, while mean total fatigue 
scores almost doubled between cycles 1 (1.09) and 8 (2.05), mean fatigue distress 
scores more than doubled between cycle 1 (0.36) and cycle 8 (0.86). Again, caution 
is required in drawing any major conclusions from this result due to the reducing 
sample on which it is based.  
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Figure 41: Mean total, severity and distress fatigue scores for each cycle of chemotherapy 
 
The symptom of fatigue was discussed in patient interviews following their 
discussion of experiences of nausea. During each interview, patients were asked to 
describe their fatigue experiences, what feeling fatigued meant to them, their 
feelings across fatigue scores, their abilities (physical, psychological and social) at 
various scores and how different scores of fatigue compared with one another. 
Patients were shown their fatigue graph from the 14 days following their previous 
cycle of chemotherapy. Patients were often taken aback by this image. This could be 
seen in their body language rather that what they said, some appeared to physically 
recoil from what they were being shown, others were shaking their heads while 
making puffing sounds through their lips. However, immediately following this 
initial sense of shock, patients acknowledged that their fatigue was entirely different 
from nausea and that it had been a difficult symptom for them. Without exception, 
discussions surrounding fatigue were considerably longer than those of nausea. 
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‘Oh, look at that, the tiredness was something else, I can tell you all about those 
days there [score of 5].’ (1) 
‘Oh aye, I certainly was far more tired [than nauseated].’ (7) 
Patients found a multitude of ways in which to describe their experiences of fatigue. 
General descriptions included: 
‘You have a horrible feeling in your body.’ (1) 
‘I just couldn’t lift my head up.’ (3) 
‘I could have laid down and cried, I felt so tired all over.’ (5) 
‘It was just a feeling that overcame me and I knew I had to go and lie down.’ (6) 
Other descriptions involved a loss of physical strength and energy: 
‘I can’t walk and I can’t drive because I don’t have any strength.’ (1) 
‘I usually had stacks of energy but now I feel if I’m doing anything I have to go and 
sit down for a wee while after.’ (3) 
‘It was an all-over thing, my arms and legs, everything. I just felt I couldn’t move. I 
just wanted to lie in a corner somewhere.’ (5) 
‘I came in from getting the messages [shopping] and just flopped down and when I 
woke up the messages were still lying there and I thought well they can lie there and 
defrost because I’ve no energy to get up and do it.’ (8) 
‘I had no energy. I didn’t want to do anything. I didn’t want to go anywhere.’ (9) 
Almost half the patients related their fatigue to a sensation of weakness in their legs: 
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‘I felt my legs wouldn’t support me.’ (1) 
‘By the time I get to the top of the stairs my legs are shaking.’ (3) 
‘I went a walk and one of the streets is quite a brae [hill] and by the time I got to 
the top of it I thought, God Almighty, my legs are sore…right at the top of my legs.’ 
(3) 
‘I could virtually hardly move my legs I was so tired…even trying to go into the 
kitchen and walk up and down the stairs, my legs weren’t my own.’ (5) 
‘You lie there and say to yourself, give yourself a shake and get up and do 
something. You can’t though, your legs just won’t take you.’ (8) 
Patients were able to describe the impact of their fatigue both on their functional 
ability and their psychological status. Two of the nine patients involved were still 
working, although this was flexible working and they only went to work if they felt 
able to do so. In relation to their functional ability, it is interesting to note that many 
of the patients’ concerns related to the impact of fatigue on their ability to perform 
household chores. 
‘I know that I’ll need to rest after today [receiving chemotherapy] so I washed my 
windows yesterday and my house is all tidied.’ (3) 
‘I wouldn’t even attempt the ironing if the score was a 2 because there’s no point.’ 
(5) 
‘I would maybe Hoover and then have to sit down for an hour before getting up to 
do something else.’ (3) 
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‘I couldn’t even do things like the shopping on my own or go into town. I’m just not 
able to do that. I just wouldn’t attempt it.’ (6) 
‘I couldn’t Hoover and when he [her husband] offered to do it for me, I said no 
because I couldn’t even bear the sound of it.’ (7) 
More general aspects of daily life were affected too. 
‘It’s OK up to a [score of] 3 but when it gets to a [score of] 4 or 5, it did interfere 
with life, probably about 7 or 8 o’clock at night I’d go for a wee lie down instead of 
watching the telly.’ (2) 
‘He [her husband] can come in from work and be talking to me and the next time he 
turns around I’m out for the count.’ (7) 
‘I’m still so tired, I’ve seen me not answer the phone ‘cause I can’t be bothered 
moving or talking to anyone.’ (8) 
‘I didn’t do very much at all.’ (6) 
‘Sometimes I don’t even want to talk.’ (1) 
‘I couldn’t really concentrate much, I usually read a lot but I couldn’t be bothered.’ 
(9) 
Patients closer to the start of their treatment (those interviewed following cycles 1 
and 2) were concerned and unsure about their future fatigue experiences: 
‘I don’t know how it’ll be this time because it was really different [worse] this last 
time from the first time.’ (2) 
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‘I just hope it isn’t like this the whole way through.’ (5) 
‘Some days it’s fine and the next day I fully expect to feel the same but for some 
reason I’m really tired, I don’t understand it.’ (7) 
However, some of the patients who were further on in their treatment (following 
cycles 3 and 5) had identified a pattern in their fatigue and were able to use this 
knowledge to rationalise their fatigue experiences. This did not vary between the 
intervention or control sites: 
‘Oh it definitely gets less [the weeks between cycles of treatment], I still have the 
weakness in my legs although it’s not as bad, nothing to the extent it was the first 
and second weeks after the chemo, because those weeks I don’t walk, I shuffle.’ (1)  
‘It gets worse before it gets better. As the weeks go on [between chemotherapy] I 
feel I have more energy.’ (3) 
When asked about the impact of their fatigue, some patients acknowledged the 
negative impact that their fatigue caused: 
‘Obviously it makes you upset and depressed.’ (8) 
‘It was very frustrating and it got me down that day because I was so tired.’ (5) 
However, patients seemed reluctant to complain about fatigue, and not all patients 
perceived their fatigue negatively. They compared it favourably with other potential 
symptoms. 
‘I know that it’s a side-effect and the way I look at it is at least I’m not being sick.’ 
(1) 
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‘So I really should feel depressed, but I wouldn’t say I was really.’ (2) 
‘I can cope with this better than ulcers and thrush and stuff.’ (4) 
‘I keep saying to myself, if it is only this bad for a few days, then I don’t mind.’ (7) 
‘I try not to let it drag me down, try to have a positive attitude.’ (6) 
Patients had developed a number of self-care strategies to help them manage their 
fatigue. Despite research-based evidence that advises against ‘over-resting’, the 
majority of patients’ self-care focused on resting and going to bed. The reason for 
this self-care action may be because they had not been cautioned against ‘over-
resting’. Alternatively, it may be because resting when tired is such a common sense 
strategy. All patients interviewed mentioned at some point that they had no option 
but to lie down at some point in the days following their chemotherapy. 
‘I had looked at the website and it said don’t fight tiredness, so I just went to bed…if 
you are tired you need to rest, right?’ (1) 
‘When it comes on you, you have to lie down. You can try to fight it a wee bit but it’s 
hard when it comes so severe, you have to lie down.’ (2) 
‘I decided, that’s it, I’m going to sleep, I’m going to lie down I’m that [so] tired.’ 
(6) 
‘There were days when I was really really tired and I was in bed most of the day.’ 
(7)  
‘When I got up in the morning I felt so terrible that I just had to lie back down 
again.’ (3) 
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However, some patients had tried to incorporate exercise into their lives and use 
distraction to alleviate their fatigue. The use of these strategies did not vary between 
the intervention or control sites. 
‘I have quite a big garden and sometimes I’d walk to the end of it and have a wee 
look at the plants and stuff.’ (1) 
‘Well, usually I would try to distract myself, but there [a score of 6] I couldn’t do 
that, I would just go and lie down and not fight it.’ (2) 
‘Even on the days when I’m so tired, I do try to do a bit of walking and stuff like 
that…even if you don’t go far.’ (4) 
‘I have been reading a lot and sitting out and going for runs in the car, that sort of 
thing.’ (7)  
‘I just take each day as it comes, see how I feel when I wake up.’ (3) 
Patients were able to evaluate the effectiveness of their self-care. In the main, 
resting and going to bed was viewed positively.  
‘It made you feel better, even though I still had that lethargic feeling,  I think when 
you wake up you do feel a bit better.’ (1) 
‘The best thing for it is going to bed, I think it does help if you are really tired, aye it 
definitely helps.’ (2) 
‘I felt better there [pointing to a lower fatigue score] because I stayed in and rested 
there [pointing to the four days previously].’ (3) 
‘When you have a sleep you feel better for a wee while, then I still feel tired.’ (5) 
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‘Oh yeah, you always do feel better after a sleep.’ (7) 
‘Oh, I’d sleep no bother but I didn’t feel any better when I woke up, I’m just as 
tired.’ (8) 
Although much less common, distraction and exercise were also viewed positively 
for their impact on fatigue by a small number of patients 
‘Yes, getting out helps.  It is too easy just to go to your bed or lie on the couch or 
whatever, you know? You need to get out and get a bit of fresh air, something like 
that.  Even if you don’t go far it is just the fact of getting out.’ (4) 
‘Just getting out in the fresh air, even if I’m just sitting or in the car, it makes you 
feel so much better, like yourself again.’ (7) 
‘If you try to go out a wee bit it helps.  If you’re sitting in it preys on your mind that 
you’re ill.’ (8) 
As with nausea, the concept of ‘normality’ was raised in relation to trying to live 
with fatigue 
‘I try and do it every day, go in the shower that is, even if I’m really tired because 
that’s part of your normal routine.’ (1) 
‘It’s been better this past week. I’ve even been back at work this past Tuesday, 
Wednesday and Thursday, and that makes me feel that I’m just a normal person 
again.’ (5) 
‘Just the other night we sat out in the garden and I felt fine and we just said, this 
feels like normal again.’ (3) 
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‘When it was a [score of] 2, I could do normal things, just maybe go to bed earlier 
than normal.’ (6) 
‘I was surprised because I didn’t think I could feel like I did, I was just normal.’ (6) 
‘I’m trying to keep my job going, I just work from the house you see, trying to keep 
it normal but concentrating is hard.’ (8) 
‘I just wasn’t myself, wasn’t normal. But I’ve been fine this last week, I’ve felt more 
or less like my normal self.’ (9) 
Thus, exploring and describing chemotherapy-related fatigue has shown that fatigue 
has a relatively constant presence in the 14 days following chemotherapy 
administration with a potential to peak around day 6. Fatigue, unlike nausea, 
increased with each subsequent cycle of chemotherapy with a greater increase in 
patients’ reported distress rather than severity of fatigue although these results 
should be viewed with caution as they are based on a reducing sample. Patients 
were keen to describe their fatigue experiences. Their descriptions focused on a loss 
of strength and energy. When discussing the impact of fatigue on functional ability, 
patients all focused on their ability to undertake household chores – this is perhaps a 
consequence of an all-female sample. Some patients who were at the start of their 
chemotherapy expressed concerns about how they would cope with the fatigue of 
future cycles, whereas those patients further on in their treatment were better able to 
predict their patterns of fatigue. Patients did acknowledge the negative impact that 
fatigue had for them, but tended to compare it favourably with other potential 
symptoms, despite the fact these were not always symptoms that the patients had 
actually experienced. Self-care strategies focused on rest and sleep and these were 
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evaluated positively. Other strategies such as distraction and exercise were also 
rated positively. As with nausea, patients were keen to keep life as ‘normal’ as 
possible and the concept of trying to maintain normality in the face of fatigue was 
frequently raised. 
8.3.3 Summary 
To conclude this section on describing and exploring chemotherapy-related nausea 
and fatigue, it is clear that both these symptoms have a negative impact on the lives 
of the patients in this study. However, there the similarities end. Nausea is 
experienced predominantly in the first 3 days following chemotherapy, whereas 
fatigue has a more constant presence across all 14 days post-treatment, with a slight 
peak around day 6. Furthermore, experiences of nausea remain relatively static over 
cycles of chemotherapy while fatigue shows an incremental increase with each 
cycle (although based on a reducing sample). The scores assigned to nausea were 
also, in the main, considerably lower than those of fatigue, although there was a 
significant correlation between total symptom scores. The results of this exploration 
will be used to inform the exploration of the study’s intervention in the following 
section. 
8.4 Exploring the intervention 
The second aim of this study was to explore the impact of the intervention on 
experiences of chemotherapy-related nausea and fatigue. Quantitative data, in the 
form of symptom scores from symptom questionnaires, and qualitative data, in the 
form of patients’ explanations about their symptom scores, were explored to meet 
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this aim. Figure 42 demonstrates how these two research methods blend to achieve 
this for both nausea and fatigue.  
Figure 42: Blending of techniques to explore the intervention 
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Figure 43: Selection of data for quantitative analysis 
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most, that is, days 1-3 for nausea, and days 1-14 for fatigue, and consequently, the 
time when most extreme scores were recorded. Indeed, it would have been 
inappropriate to explore the impact of the intervention on nausea using data from all 
14 days as the data from days 4-14 would have dampened the mean, making it a 
poor reflection of the true symptom experience. Figure 44 below shows how the 
data was collated and the way in which a mean score was generated for each patient, 
dependent on their questionnaire returns. 
Figure 44: Data collation and generation of mean scores for nausea and fatigue 
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8.4.1 Nausea 
8.4.1.1 Differentiating between levels of nausea 
Patients were able to clearly distinguish between the presence and absence of 
nausea and were consistent in their sense of relief when their nausea was resolved: 
‘I would get a good day [nausea score of 0] and feel better, able to do everything, 
and you think oh that’s it gone, that’s great, and next day you feel that bad again.’ 
(4) 
‘…yes, that was it gone [a score of 0], it seemed to be going on longer this time, but 
that was it gone’ (2) 
‘A couple of days and it settled down [to a score of 0] and I was fine. Thankfully, I 
didn’t experience any more sickness or nausea this time’ (5) 
‘…there, when it went away altogether [a score of 0], I felt great again’ (8) 
‘…you have a good day [a score of 0] and then a couple of bad days, [scores of 1 
and 2] and then good days again and it’s gone and you feel fine again, til the next 
time [cycle of chemotherapy].’ (9) 
They were less able to distinguish between different levels of nausea in terms of 
how they felt in general: 
‘It’s difficult to explain, it’s probably more or less the same [between a score of 1 
and 2]’ (9) 
‘Just a stronger feeling than the day before, I don’t know how else to describe it 
[comparing a score of 1 and 2].’ (5) 
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‘It just felt worse than it did the day before, yeah, just the same feelings but worse 
[comparing a score of 2 and 3].’ (4) 
Patients tried to describe their functional abilities at varying total scores of nausea 
and explain any differences in their abilities, but found it difficult to distinguish 
between scores of 1 and 2:  
‘I have been practically able to do everything I would normally do [at a score of 1], 
but I’d be feeling a bit seedy.’ (4) 
‘…[nausea at a score of 2] didn’t bother me a lot, I could get on with things.’ (2) 
‘You try not to let it get to you, just try to get on with things but it’s always there, 
even when it was a score of one or two, just always there’ (5) 
Although just two patients reported total nausea scores of 3 and above, they were 
able to define the impact of nausea at these higher scores in relation to their 
functional abilities noting,  
‘It actually stops me going out and socialising.’ (8)  
‘It stops me driving, I can’t drive with it like that.’ (4). 
‘you can’t go out, you can’t go anywhere, you can’t do anything.’ (8) 
Thus, while patients found it difficult to distinguish between lower total nausea 
scores, higher scores (whilst less frequent and still being individually experienced) 
had a greater impact on function. 
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8.4.1.2 Exploring the impact of the intervention – cycles 1-8 
A basic evaluation of the impact of the intervention on nausea can be undertaken by 
looking at the range of nausea scores between the patient groups. Figure 45 depicts 
the range of nausea scores in the 4 patient groups.  
Figure 45: Range of nausea scores (cycles 1-8) 
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The most notable aspect of this is the difference in the percentage of patients who 
did not experience any nausea in Unit A, cohort 2 (following the introduction of the 
intervention): 47.8% of patients reported no nausea compared with 16.8% before 
the SNA↔P intervention (see Figure 46).  
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Figure 46: Unit A - presence and absence of nausea (cycles 1-8) 
0
10
20
30
40
50
60
70
80
90
1 2
Patient cohorts
%
presence of nausea
absence of nausea
 
Chi square analysis demonstrates that this is a statistically significant difference (chi 
sq 5.998, df 1, p=0.014). Separate chi square analysis of those patients receiving 
chemotherapy with curative and palliative intent did not demonstrate a significant 
difference (curative intent p=0.116, palliative intent p=0.180). This analysis 
suggests that the significant effect is not restricted to either treatment intent group, 
although this is most likely because of small patient numbers in each group 
(chemotherapy with curative intent: cohort 1 no nausea n=3, nausea n=11, cohort 2 
no nausea n=9, nausea n=10, chemotherapy with palliative intent: cohort 1 no 
nausea n=2, nausea n=13, cohort 2 no nausea n=1, nausea n=1). Chi square analysis 
comparing the presence and absence of nausea between cohorts 1 and 2 of Unit B 
show no statistically significant difference (chi sq 0.415, df 1, p=0.519). 
Nausea symptom outcome data were not normally distributed – see boxplots in 
Figure 47, and mean total nausea scores are presented in Table 25. 
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Figure 47: Boxplots for mean nausea scores (cycles 1-8) 
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The appropriate approach to compare mean total nausea scores was the non-
parametric Kruskal-Wallis test. This test showed no statistically significant 
differences between patient groups (Chi sq 7.154, df 3, p=0.067). Given this 
borderline level of significance, an ANOVA was performed, as it may have been 
more sensitive to differences in grades of nausea. This ANOVA confirmed a lack of 
statistically significant differences in mean total nausea scores between patient 
groups (p=0.203).  
This analysis shows that there is a statistically significant intervention effect in 
relation to the presence and absence of nausea. As patients were able to distinguish 
between having and not having nausea during interviews, this result also has 
personal significance. There is no statistical support for an intervention effect on 
grades of nausea.  
8.4.1.3 Exploring the impact of the intervention – cycles 1-4 
A basic evaluation of the impact of the intervention on nausea during the first 4 
cycles of chemotherapy can be undertaken by looking at the range of nausea scores 
between the patient groups. Figure 48 depicts the range of nausea scores in the 4 
patient groups.  
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Figure 48: Range of nausea scores (cycles 1-4) 
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Figure 49: Unit A - presence and absence of nausea (cycles1-4) 
Chi square analysis demonstrates that this is a statistically significant difference (chi 
sq 4.778, df 1, p=0.029). Separate chi square analysis of those patients receiving 
chemotherapy with curative and palliative intent did not demonstrate a significant 
difference (curative intent p=0.220, palliative intent p=0.161). This analysis 
suggests that the significant effect is not restricted to either treatment intent group, 
although this is most likely because of small patient numbers in each group. Chi 
square analysis comparing the presence and absence of nausea between cohorts 1 
and 2 of Unit B show no statistically significant difference (chi sq 0.013, df 1, 
p=0.908). 
Nausea symptom outcome data were not normally distributed – see boxplots in 
Figure 50, and mean total nausea scores are presented in Table 26. 
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Figure 50: Boxplots for mean nausea scores (cycles 1-4) 
 
Table 26: Mean total nausea scores (cycles 1-4) (range 0-6) 
Unit A 
Cohort 1 
Unit A 
Cohort 2 
Unit B 
Cohort 1 
Unit B 
Cohort 2 
0.91 1.03 1.25 0.72 
 
naus
0.00
1.00
2.00
3.00
4.00
5.00
20
pt_int_group: 1.00
naus
0.00
1.00
2.00
3.00
4.00
5.00
38
pt_int_group: 2.00
naus
0.00
1.00
2.00
3.00
4.00
pt_int_group: 3.00
naus
0.00
1.00
2.00
3.00
4.00
5.00
94
pt_int_group: 4.00Hospital A, Cohort 1 Hospital A, Cohort 2
Hospital B, Cohort 2Hospital B, Cohort 1
251 
The appropriate approach to compare mean total nausea scores was the non-
parametric Kruskal-Wallis test. This test showed no statistically significant 
differences between patient groups (Chi sq 4.006, df 3, p=0.261).  
This analysis shows that there is a statistically significant intervention effect in 
relation to the presence and absence of nausea during the first 4 cycles of 
chemotherapy. As patients were able to distinguish between having and not having 
nausea during interviews, this result also has personal significance. There is no 
statistical support for an intervention effect on grades of nausea during the first 4 
cycles of chemotherapy. 
8.4.2 Fatigue 
8.4.2.1 Differentiating between levels of fatigue 
Fatigue scores varied between patients. Within each patient’s report, fatigue often 
spanned the full range of scores possible (0-6). Patients were able to appreciate 
differences in their fatigue experiences at different scores, most often based on 
functional ability. 
A score of 1 
‘A score of 1 was good. I would be tired but it wouldn’t stop me doing things, but I 
would be tired doing them. I’d just feel like I need a nap, I need a nap.’ (5) 
‘I could live at that level all the time [a score of 1], that would be fine.’ (7) 
A score of 2 
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‘I wasn’t doing the things I’d normally do but I was doing the necessary. I had to 
make myself move to do anything.’ (9) 
‘It was a relief because you felt you were coming back to normal at a score of 2 
[compared with a score of 4].’ (8) 
A score of 3 
‘I am able to do less [at a score of 3 compared with 2], I thought, I’d better put that 
ironing away as I’ve been in bed all morning. I went upstairs and hung up a couple 
of things and was exhausted. I had to sit on the bed.’ (1) 
‘I just don’t feel that I can do the things that I normally can do.’ (4) 
‘I was feeling weak and didn’t want to drive the car and I couldn’t walk far, so I 
didn’t go out those days [when the score was 3 or above] I just stayed in nearly 
every day.’ (9) 
‘I don’t go the gym on days like that [score of 3 or above].’ (2) 
‘I couldn’t go up and down the stairs those days, that made me stay in.’ (3) 
A score of 4 
‘I was definitely more active when the score was 4 than when it was 5.’ (7) 
A score of 5 
‘When it was a [score of] 5 I was sleeping till lunchtime. I remember one of the 
days I woke up and was hungry but I just couldn’t be bothered getting out of bed.’ 
(8) 
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‘It felt much worse [than a score of 4].’ (2) 
‘I was holding onto the [supermarket] trolley, it was a terrible terrible tiredness 
that I couldn’t shake off. It was horrible.’ (5) 
‘All the time the score was a 5 I couldn’t get out of bed.’ (1) 
‘The days it was a [score of] 5 was just the pits, I was so so tired, absolutely no 
energy at all. Even trying to go into the kitchen for a glass of juice was such a 
chore.’ (5) 
A score of 6 
‘I wouldn’t say it was twice as bad [a score of 6 compared with a score of 3] but it 
was definitely worse.’ (2)  
‘I was dead tired, y’ know what I mean?...couldn’t do a thing.’ (6) 
‘A few days into it and I just feel that I am floored there [pointing to a score of 6].  I 
am just so tired.’ (5) 
Thus, while patients described their experiences in their own ways, demonstrating 
the individuality with which the symptom is experienced, there is general agreement 
that scores of 1 and 2 are manageable, scores of 3 and 4 affect functional abilities 
while scores of 5 and 6 have significant deleterious effects on their lives.  
8.4.2.2 Exploring the impact of the intervention – cycles 1-8 
An evaluation of the impact of the intervention on fatigue can be undertaken by 
looking at the range of fatigue scores between the patient groups - see Figure 51. 
Chi square analysis demonstrates that there is no statistically significant difference 
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in the presence or absence of fatigue between cohorts 1 and 2 of either Unit A (chi 
sq 0.77, df 1, p=0.782) or Unit B (chi sq 3.683, df 1, p=0.06).  
Figure 51: Range of fatigue scores (cycles 1-8) 
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Fatigue total symptom score data were relatively normally distributed (see Figure 
52) and the mean total scores are presented in Table 27. 
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Figure 52: Boxplots for fatigue (cycles 1-8) 
Table 27: Mean total fatigue scores (cycles 1-8) (range 0-6) 
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An ANOVA of the 4 patient groups showed that there were no statistically 
significant differences in mean total fatigue scores (p=0.196). This was supported 
by a Kruskal-Wallis test which also reported no statistically significant differences 
between mean total fatigue scores (chi sq 6.492, df 3, p=0.090). Thus, despite the 
fact that the majority of patients from all 4 groups reported some level of fatigue 
during their chemotherapy , no statistically significant results were found to support 
the impact of the SNA↔P  intervention on patients’ fatigue experiences. 
8.4.2.3 Exploring the impact of the intervention – cycles 1-4 
An evaluation of the impact of the intervention on fatigue during the first 4 cycles 
of chemotherapy can be undertaken by looking at the range of fatigue scores 
between the patient groups - see Figure 53. Chi square analysis demonstrates that 
there is no statistically significant difference in the presence or absence of fatigue 
between cohorts 1 and 2 of either Unit A (chi sq 0.926, df 1, p=0.336) or Unit B (chi 
sq 3.554, df 1, p=0.06).  
Figure 53: Range of fatigue scores (cycles 1-4) 
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Fatigue total symptom score data were relatively normally distributed during the 
first 4 cycles of chemotherapy (see Figure 54) and the mean total scores are 
presented in Table 28. 
Figure 54: Boxplots for fatigue (cycles 1-4) 
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Table 28: Mean total fatigue scores (cycles 1-4) (range 0-6) 
Unit A 
Cohort 1 
Unit A 
Cohort 2 
Unit B 
Cohort 1 
Unit B 
Cohort 2 
1.10 1.49 1.47 1.51 
 
An ANOVA of the 4 patient groups showed that there were no statistically 
significant differences in mean total fatigue scores (p=0.441). This was supported 
by a Kruskal-Wallis test which also reported no statistically significant differences 
between mean total fatigue scores (chi sq 4.319, df 3, p=0.229). Thus, despite the 
fact that the majority of patients from all 4 groups reported some level of fatigue 
during their first 4 cycles of chemotherapy , no statistically significant results were 
found to support the impact of the SNA↔P  intervention on patients’ fatigue 
experiences. 
8.4.3 Summary 
The SNA↔P intervention did have a significant effect on the presence and absence 
of patients’ experiences of nausea in the intervention site which was further 
supported by clinical significance data from patients’ interviews. However, this 
positive effect was not demonstrated in the analysis of levels of nausea experiences. 
No statistically significant differences in total fatigue scores were identified in 
relation to not only the presence and absence of fatigue, but also levels of fatigue 
between the 4 patient groups. 
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8.5 Evaluating the impact of the intervention 
The overarching aim of this study was to evaluate the impact of the implementation 
of a nurse-led intervention, incorporating structured nursing assessment and 
practice, on the symptoms of nausea and fatigue experienced by women receiving 
chemotherapy for breast cancer. Figure 55 illustrates how through exploring and 
describing symptoms, in tandem with exploring the intervention, informed 
conclusions about the impact of the intervention can be drawn. 
Figure 55: Evaluation of the intervention 
Key aspects that should be considered in this final evaluation are: 
1. How were nausea and fatigue experienced by patients? What did nausea and 
fatigue mean to them? 
2. Was there any reduction in the percentage of patients actually experiencing 
either nausea or fatigue as a consequence of the intervention? 
3. Was there a reduction in the mean levels of either nausea or fatigue as a 
consequence of the intervention? 
Both nausea and fatigue were experienced by patients and distinct patterns for both 
symptoms were identified. While nausea was, in the main, mild and short-lived 
following chemotherapy administration (whether that was on day 1 or 8 of a 
chemotherapy cycle), fatigue was persistent, scored higher than nausea and 
experienced across all 14 days of data collection. This incidence was reflected in the 
patient interviews – patients tended to accept nausea as a symptom to be tolerated 
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and that would abate, while fatigue appeared to have an increased and sustained 
impact on patients’ functional abilities and psychological well-being. 
The evaluation of the SNA↔P intervention resulted in a statistically significant 
difference in the percentage of patients experiencing nausea, with significantly 
fewer patients experiencing nausea in cohort 2 of Unit A compared with cohort 1. 
Information from patient interviews demonstrates that this difference is not only 
statistically but also personally significant.  
While patients’ descriptions of fatigue were undoubtedly individual, there was 
general agreement about the impact that various grades of fatigue had on their lives. 
No statistically significant differences were seen between patient groups in relation 
to the presence and absence of fatigue, nor levels of fatigue.  
8.6 Conclusion 
This chapter has presented the full results of the SNA↔P study. It has described 
symptoms of chemotherapy-related nausea and fatigue, showing patterns of 
symptoms and providing rich descriptions of the meaning and impact of nausea and 
fatigue experiences for patients. It has also evaluated the intervention in relation to 
the presence and absence of nausea and fatigue between patient groups as well as 
the mean total symptom scores while considering potentially confounding variables. 
Finally, it has drawn conclusions about the overarching aim of the study – the 
evaluation of the impact of the SNA↔P intervention, proposing that, although the 
intervention had a positive effect on chemotherapy-related nausea (in relation to its 
presence and absence), a similar impact was not seen in relation to chemotherapy-
related fatigue. These findings will be discussed in the following chapter. 
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9  CHAPTER 9 – DISCUSSION 
9.1 Introduction 
This chapter gives a brief overview of the results of the SNA↔P study before 
considering both its key aspects, and its limitations. Based on these aspects, 
conclusions are then drawn on the contribution of the SNA↔P study and its 
implications for clinical practice and research are considered. 
9.2 Overview of the results of the SNA↔P study 
The SNA↔P study evaluated the impact of a nurse-led intervention based on 
structured assessment and practice on patients’ experiences of chemotherapy-related 
nausea and fatigue. Using complementary quantitative and qualitative methods, the 
SNA↔P study had 3 key outcomes.  
Firstly, distinct patterns of chemotherapy-related nausea and fatigue were 
demonstrated. Nausea was relatively short-lived, peaking during the first 3 days 
following chemotherapy, whereas fatigue had a more constant presence over the 14 
days  following chemotherapy administration. These patterns were enriched by 
patients’ descriptions of their symptom experiences. Patients’ descriptions of nausea 
reveal that this is an unpleasant symptom, although usually mild. While it does 
impact on patients’ functional abilities, they have difficulty in differentiating 
between shades of nausea. Experiences of fatigue differ considerably from those of 
nausea. Patients were overwhelmed by their experiences of fatigue and were able to 
clearly differentiate between levels of fatigue and the impact each had on their 
functional abilities.  
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Secondly, the SNA↔P intervention had a significant positive effect on patients’ 
experiences of nausea. Statistically fewer patients reported nausea following the 
implementation of the intervention. This result is supported in terms of personal 
significance as, during interviews, patients were clearly able to distinguish between 
experiencing nausea or not. The SNA↔P intervention did not impact on patients’ 
experiences of fatigue. There were no statistically significant differences in patients 
experiences of fatigue between any of the patient groups involved in the SNA↔P 
study.  
Thirdly, the SNA↔P study demonstrated that an evidence-based intervention 
focusing on structured symptom assessment and management can be implemented 
in routine clinical practice. 
9.3 Key aspects of the SNA↔P study 
The following sections will describe the significant nature of specific components 
of the SNA↔P study.  
9.3.1 The intervention 
The SNA↔P intervention sought to influence the assessment and subsequent 
management of chemotherapy-related nausea and fatigue. It ensured structured 
longitudinal, multidimensional symptom assessment, as well as providing a method 
of identifying appropriate interventions for the symptoms reported through the 
structured assessment for each cycle of chemotherapy. While the same intervention 
was used in tandem as part of the WISECARE+ study, this was developed solely by 
MM (researcher and author of this thesis). 
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9.3.1.1 Fundamental aspects of the SNA↔P intervention 
9.3.1.1.1 The relationship between symptom assessment and interventions 
The SNA↔P intervention incorporated both symptom assessment and management, 
whereas previous research has focused on either the development of structured 
assessment tools for nausea (Rhodes et al. 1984; Morrow 1992; Lindley et al. 1992; 
Borjeson et al. 1997; Rhodes and McDaniel 1999) or fatigue (Rhoten 1982; Smets 
et al. 1995; Yellen et al. 1997; Schwartz 1998; Piper et al. 1998; Mendoza et al. 
1999; Holley 2000b), or the implementation and evaluation of specific 
interventions, such as progressive muscle relaxation training (Arakawa 1995; 
Arakawa 1997; Molassiotis 2000; Molassiotis et al. 2002b; Yoo et al. 2005; de 
Carvalho et al. 2007) or psychoeducational support and information (Gaston-
Johansson et al. 2000; Williams and Schreier 2004). The SNA↔P study took this 
link between symptom assessment and management a step further, not only 
implementing and evaluating them simultaneously, but also tailoring the 
recommended symptom management to the specific level of symptoms reported by 
patients within their assessment. Thus the generic ‘one size fits all’ approach to 
symptom management that requires patients to ‘fit’ symptom management 
information to their individual experiences was avoided.  
9.3.1.1.2 Concurrent use of multiple interventions 
A major feature of the SNA↔P intervention was in that it promoted the 
simultaneous use of a range of symptom management techniques, both 
pharmacological and non-pharmacological. Thus, while the intervention literature to 
date has sought to evaluate the benefits of single interventions such as antiemetic 
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drug therapies (Morrow et al. 1995; Roscoe et al. 2000), progressive muscle 
relaxation training (Arakawa 1995; Arakawa 1997; Molassiotis 2000; Molassiotis et 
al. 2002b; Yoo et al. 2005; de Carvalho et al. 2007), psychoeducational support and 
information (Gaston-Johansson et al. 2000; Williams and Schreier 2004), or music 
therapy (Standley 1992; Ezzone et al. 1998; Sahler et al. 2003) for the relief of 
nausea (and vomiting), none have drawn these therapies together and evaluated their 
simultaneous implementation. Likewise, the management of fatigue has tended to 
focus on individual interventions, such as exercise (MacVicar and Winningham 
1986; Mock et al. 1994; Schwartz 1999; Mock et al. 2001; Schwartz et al. 2001; 
Mock et al. 2002; Courneya et al. 2007; Schneider et al. 2007), education and 
information (Given et al. 2002; Jacobsen et al. 2002; Barsevick et al. 2004; Yates et 
al. 2005), and measures to optimise sleep (Davidson et al. 2001; Berger et al. 2002; 
Berger et al. 2003; Quesnel et al. 2003; Savard et al. 2005), with multiple 
interventions, such as music therapy and relaxation for nausea (Sahler et al. 2003) 
or support and education for fatigue (Ream et al. 2006), being employed much more 
rarely. 
9.3.1.2 Positive aspects of the SNA↔P intervention 
9.3.1.2.1 Research-based 
The SNA↔P intervention was evidence-based: the structured assessment, 
recommended interventions and methods of integrating and implementing the 
intervention in practice were all based on rigorous reviews of the literature. The 
multidimensional symptom assessment incorporated severity and distress 
assessment in recognition of the fact that the most intense symptom experiences are 
not consistently the most distressing for patients (Rhodes et al. 1984), and took into 
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account: the need for succinct clinical assessment rather than lengthy, potentially 
arduous assessments (Morrow 1992; Lindley et al. 1992; Rhodes and McDaniel 
1999); addressing nausea as an entity in its own right, rather than as a component in 
nausea and vomiting as with many current assessment tools (Morrow 1992; Lindley 
et al. 1992; Rhodes and McDaniel 1999); the importance of self-assessment, rather 
than that of health professionals (Eisenberg et al. 2003; Grunberg et al. 2004; Liau 
et al. 2005). However, the use of an assessment tool with no evidence of reliability 
and limited validity, while a consequence of the SNA↔P study’s association with 
the WISECARE+ study, can be criticised. 
The interventions were research-based and, although many of these have not been 
evaluated in routine clinical practice (Standley 1992; Arakawa 1997; Ezzone et al. 
1998; Molassiotis 2000; Dibble et al. 2000; Molassiotis et al. 2002b; Roscoe et al. 
2003; Sahler et al. 2003; Yoo et al. 2005; de Carvalho et al. 2007; Molassiotis et al. 
2007), the nurses of Unit A were supported by MM to develop ways of integrating 
some of the more unfamiliar and anxiety-provoking interventions, such as guided 
imagery and relaxation, using techniques previously shown to be successful for 
example, the use of tape recordings (Gaston-Johansson et al. 2000; Williams and 
Schreier 2004). 
The processes of introducing, integrating and maintaining the intervention in 
clinical practice were carefully developed and implemented (see chapter 7). 
Evidence utilisation is particularly challenging, as it requires investment at both the 
organisational and practitioner level (Pearson 2006). The SNA↔P study worked 
with nursing management and senior nurses, as well as those nurses involved in 
providing patient care, to ensure commitment at all levels. A recent systematic 
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review of interventions aimed at increasing research use in nursing identified 
educational sessions led by local opinion leaders and the formation of 
multidisciplinary committees as effective (Thompson et al. 2006), both of which 
had been implemented in the SNA↔P study. It is likely that incorporating multiple 
processes in the introduction and maintenance of the SNA↔P intervention was 
responsible for the lack of opposition to the SNA↔P intervention by the nursing 
staff of Unit A. Indeed, the nurses appeared to welcome the structured and 
prescriptive design that directed their implementation of interventions tailored to 
specific levels of symptoms as well as the necessary structured patient symptom 
assessment to facilitate their evaluation. 
9.3.1.2.2 Cyclical implementation of the intervention 
The SNA↔P intervention was implemented cyclically over each patients’ course of 
chemotherapy. This cyclical approach allowed for the fact that the effectiveness of 
the intervention may build up over a period of time, rather than occurring instantly, 
or that it may take a number of cycles of chemotherapy to establish the most 
effective intervention or combination of interventions for specific patients. This 
process is particularly relevant for fatigue, as it has already been shown that 
identifying the most effective interventions for individual patients can take time and 
occur across a number of cycles of chemotherapy (Ream et al 2006). While this may 
also be the case for nausea, there is currently no evidence to support or refute this 
theory, as existing studies have consistently evaluated interventions over shorter 
timeframes (Arakawa 1995; Arakawa 1997; Dibble et al. 2000; Molassiotis et al. 
2002b; Roscoe et al. 2003; Williams and Schreier 2004; Yoo et al. 2005; 
Molassiotis et al. 2007)  
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9.3.1.2.3 A real-world research environment 
The logistics of implementing the intervention in practice were considered 
throughout the intervention period and efforts were made to make the intervention 
as straightforward and as time efficient as possible. Nurses’ concerns over the time-
consuming nature of data collection were overcome by the use of barcoding within 
the questionnaires that not only considerably decreased the time required for data 
entry, but also reduced the potential for errors during data entry. The intervention 
prompt sheet generated by the WISETool addressed the fact that different nurses 
may have entered the patient’s symptom data to the WISETool than then saw the 
patient when they attended for chemotherapy. The intervention prompt sheet 
provided a summary of the patient’s symptoms during their previous cycle of 
chemotherapy, as well as an overview of the recommended nursing intervention for 
those symptom scores that could be used by any nurse caring for the patient. These 
interventions reflected those within the practice protocols that were strategically 
located throughout Unit A.  
While the intervention was nurse-led, it also required support from the multi-
disciplinary team. Multidisciplinary management of oncology patients receiving 
treatment has been shown to result in improved patient outcomes (Thomas et al. 
2000; Whitmer et al. 2006; Rummans et al. 2006; Wright et al. 2007), and a recent 
research study has demonstrated the key role that nurses can play in co-ordinating 
and managing the multidisciplinary team (McEvoy et al. 2007).  Within the 
SNA↔P study, although the symptom assessment and many of the interventions 
were within the remit of the nursing staff, a multidisciplinary approach was taken 
throughout the study involving all members of the multidisciplinary team 
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(clinicians, nurses, psychologist, dieticians, physiotherapists, occupational therapists 
and pharmacists) that acknowledged their individual contributions to the 
implementation of the intervention. All members of the multidisciplinary team were 
encouraged to be involved in the education sessions that took place in Unit A during 
the integration and maintenance phases of the SNA↔P study, which encouraged 
sharing of expertise for the benefits of patient care. However, no formal evaluation 
of the attendance at these meetings was conducted, nor were the multi-disciplinary 
team’s perceptions of the value of such meetings obtained. Thus, their usefulness 
and contribution to the success of the intervention remains unknown. 
9.3.1.2.4 Positive perspectives of the nursing staff 
Clinicians have been shown to be opposed to, and reluctant to, engage with quality 
improvement initiatives, such as the use of guidelines or protocols, resenting the 
lack of autonomy this gives them (Graham et al. 2000; Timmermans and Mauck 
2005). Lack of time and resources, limited knowledge and understanding of 
methods of quality improvement, differing perceptions about what constitutes 
quality care, and the widespread belief that quality care is already being provided, 
have all been proposed to explain clinician’s opposition to quality improvement 
initiatives, such as guideline implementation (Davies et al. 2007). Indeed, clinicians 
have been shown to have a general sense of indifference towards research-based 
evidence (Lewis 2007).  However, contrary to the evidence above that would 
suggest otherwise, the nursing staff involved with the SNA↔P study welcomed the 
prescriptive, structured processes involved in symptom assessment and intervention 
recommendations, and appreciated the simplicity of the SNA↔P intervention. In 
instances where they did have concerns about the implementation of the 
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intervention concerning, for example, their lack of training or the practicalities 
associated with specific interventions, MM worked with them to overcome these 
initial concerns and develop alternative methods, such as tape recordings of guided 
imagery sessions by the Unit psychologist, to ensure that the interventions 
recommended within the study could be implemented in routine clinical practice. 
Anecdotal reports of nursing staff saying that they ‘didn’t know what they would do 
when the intervention was taken away’ at the end of the study can be seen as 
Lewin’s process of ‘refreezing’ referred to in chapter 7 (Lewin 1951). This suggests 
that the change brought about by the SNA↔P intervention had been permanently 
incorporated into nurses’ daily practice.  
9.3.1.3 Problems associated with the SNA↔P intervention 
9.3.1.3.1 Indentifying the most effective components 
The SNA↔P intervention was complex, involving not only multidimensional 
symptom assessment, but also the simultaneous use of multiple interventions. Thus, 
it was not possible to establish which components of the intervention were the most 
useful for nursing staff and patients, or which components were most responsible 
for the positive impact on patients’ experiences of nausea. Moreover, it may have 
been that some nurses engaged more than others with the SNA↔P intervention, and 
there is no way of knowing who those nurses were, or the reasons why they engaged 
more successfully with the intervention.  
9.3.1.3.2 Lack of patient involvement  
In the United Kingdom, the promotion of the involvement of people with cancer in 
their own care is part of a paradigm shift regarding the relationship between 
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patients, carers and healthcare practitioners (Department of Health 2001; 
Department of Health 2006). Such policy reflects recent moves towards a culture 
where greater patient involvement in healthcare generally, and decision-making and 
management in their own care specifically, are considered essential in meeting 
patients’ healthcare needs, replacing the traditional top-down ‘doctor knows best’ 
model of care (Coulter 1997). Consequently, it was a failing of the SNA↔P 
intervention that patients were not involved in the development of the practice 
protocols (part of the evidence-based intervention) to obtain their perspective of the 
appropriateness and practicalities of undertaking the symptom management 
techniques recommended therein. This level of patient involvement in future studies 
would ensure that any self-care interventions that patients are advised to undertake 
are patient friendly and so, more likely to be performed. 
9.3.2 Methods of evaluating the effectiveness of the intervention 
9.3.2.1 Key aspects and their benefits 
9.3.2.1.1 The study design 
The SNA↔P study employed a rigorous time series design involving a control 
group, homogenous sample, and innovative longitudinal symptom data collection, 
both within and across cycles of chemotherapy. Each component of this design will 
be discussed in turn. 
Before-and-after designs are made stronger with the addition of a control group that 
receives the same measurement but not the intervention (Burns and Grove 2005). 
The addition of a control group to the SNA↔P study strengthened the validity of 
the findings, as it allowed examination of differences in trends between patient 
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groups after the intervention (Burns and Grove 2005). Consequently, this design 
increases the strength of the confidence that any improvement observed in 
symptoms during cohort 2 was due to the SNA↔P intervention, rather than other 
variables, such as a change in policy, between the two timepoints. 
Given that the SNA↔P study focused on patients’ symptoms and involved a 
homogenous population (women having chemotherapy for breast cancer), excludes 
the potential that changes in symptoms before and after the intervention were a 
consequence of patients’ differing diagnoses, rather than the intervention itself. 
While it is not novel to research the experiences of women receiving chemotherapy 
for breast cancer, indeed, they are one of the most frequently researched patient 
groups, it was new to explore the impact of the intervention on a homogenous group 
since the WISECARE+ study, from which the SNA↔P study arose, involved an 
extremely heterogeneous population of 7 diagnostic groups.  
The data used to evaluate the impact of the SNA↔P intervention was longitudinal, 
both within cycles of chemotherapy (for 14 days following each administration of 
chemotherapy), and across cycles of chemotherapy (up to 8 cycles depending on 
how long patients participated in the study), and so encompassed patients’ whole 
experience during chemotherapy. Testing the impact of the intervention on such 
longitudinal data allowed for the fact that the intervention may require time to 
‘build up’, as well as the fact that it may take a period of time for the ‘right’ 
intervention or combination of interventions to be established for each symptom and 
each patient (Ream et al. 2006). Indeed, although the evaluation of the impact of the 
intervention on nausea experiences was eventually based on patients’ reports of 
nausea over the first 3 days following chemotherapy (and so excluded nausea 
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reported for days 4-14), this was an informed decision based on a full understanding 
of patients’ experiences over time. 
9.3.2.1.2 The combination and complementarity of quantitative and 
qualitative data 
Data collected to evaluate the SNA↔P intervention was both quantitative from 
structured symptom questionnaires, and qualitative, from structured interviews 
involving a sub-sample of the population.  
Data from patients’ structured symptom questionnaires provided information 
regarding patients’ longitudinal, multidimensional symptom experiences, 
incorporating symptom incidence, severity and distress. Statistical analysis of this 
data allowed the exploration of symptom patterns that, although interesting and 
informative in their own right, ultimately informed the evaluation of the impact of 
the intervention. It was then possible to draw conclusions with regards to the 
statistical significance of the intervention. 
While traditionally, research has relied on statistical approaches using hypothesis or 
probability testing to determine the statistical significance of findings (Estabrooks 
and Hodgins 1996), the first misinterpretation of the test of significance is the 
confusion of statistical significance with practical significance (Slakter et al. 1991). 
While significance testing is important and goes some way towards determining the 
likelihood of a true treatment effect (Whitney 2002), tests of statistical significance 
do not provide any information about the importance or meaningfulness of research 
findings (LeFort 1993). Structured patient interviews complemented the 
longitudinal, multidimensional symptom questionnaire data, as they were guided by 
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patients’ symptom graphs and focused on discussing symptom scores, the meaning 
and impact of symptoms at specific scores, and comparing symptom experiences 
between scores. This approach provided insight into the symptom experiences that 
patients had described using structured questionnaires, and allowed the evaluation 
of the personal significance of the intervention: showing that patients were clearly 
able to distinguish between the presence and absence of nausea but less able to 
differentiate between shades of nausea, while there was a general consensus of the 
overwhelming nature of fatigue and its impact on their daily lives at various scores.  
Combining quantitative and qualitative approaches to develop understanding of the 
personal significance of symptom experiences facilitated an important evaluation of 
the SNA↔P intervention that was used alongside traditional statistical techniques 
and allowed a more rounded evaluation of the impact of the intervention. For 
example, the statistically significant difference between the presence and absence of 
nausea before and after the intervention was supported by personal significance in 
that patients could easily differentiate between the presence and absence of nausea, 
allowing confident conclusions to be drawn concerning the effectiveness of the 
SNA↔P intervention on experiences of nausea.  
9.3.2.1.3 Undertaken in the ‘real-world’ 
Exploring and testing symptom management interventions is routinely performed 
within research studies that often fail to consider the practical implications of 
implementing their interventions within the real world of clinical practice (Standley 
1992; Troesch et al. 1993; Mock et al. 1994; Arakawa 1995; Arakawa 1997; 
Schwartz 1999; Molassiotis 2000; Mock et al. 2001; Schwartz et al. 2001; Mock et 
al. 2002; Molassiotis et al. 2002b; Sahler et al. 2003; Yoo et al. 2005; Billhult et al. 
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2007; de Carvalho et al. 2007).  However, the SNA↔P study was undertaken in the 
real world of clinical practice, and the intervention and data collection was 
performed by regular nursing staff during their day-to-day practice. Evaluating the 
intervention in the real world of clinical practice ultimately demonstrated its 
applicability and usability.  
9.3.2.2 Problems and difficulties associated with evaluating the intervention 
There were, however, a number of issues that complicated the evaluation of the 
intervention. These issues focus on the study sample, the lack of patients’ 
perspective in the evaluation of the intervention, and difficulty establishing the most 
effective components of the intervention. 
9.3.2.2.1 The SNA↔P sample 
It was not difficult to recruit patients to the SNA↔P study, however, retaining them 
was problematic. Just 33 patients (31.4%) of the original 105 patients recruited 
continued to return their completed symptom questionnaires throughout their entire 
course of chemotherapy. This attrition is not likely due to the procedures of 
administering questionnaires that differed between Units A and B, as there was little 
overall difference in attrition rates between the 2 Units. Comparing SNA↔P study 
attrition rates with other longitudinal research studies is complicated by the fact that 
no other longitudinal studies follow the longitudinal pattern of the SNA↔P study: 
data collection within and across cycles of chemotherapy. For example, the 
‘longitudinal’ nature of a study has previously referred to measures conducted: at 
baseline, 3 months into chemotherapy and at 6 months (Payne 2002); before 
chemotherapy, on completion of chemotherapy and six months post chemotherapy 
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(Hurria et al. 2006); or measures conducted over a 2 month period (Dibble et al. 
2003; Lee et al. 2005). While it would have been helpful to compare the patient 
attrition of the SNA↔P study with that of the WISECARE+ study, from which it 
arose, such data is unavailable. 
The problem of sample attrition in longitudinal studies is not simply deterioration of 
the sample in terms of size, although a decrease in the sample size can be 
problematic in that it lowers a study’s power (Huck 2004).  The main issue that 
makes sample attrition detrimental to research is when those who drop out have 
unique characteristics such that the remaining sample ceases to be representative of 
the original sample (Boys et al. 2003; Dodds et al. 1989) which may lead to the 
potential bias of the final result. In the case of the SNA↔P study however, analysis 
showed that the characteristics of those patients continuing to complete and return 
their symptom questionnaires were similar to that of the overall sample (see chapter 
8, px-x). Thus, one can conclude that the results are representative of the total 
sample. 
The SNA↔P sample was sizable (n=105) although this number reduced over time, 
and consequently, the numbers of patients within each patient group grew smaller. 
While the sample size could have been increased by extending the duration of data 
collection, data collection, including the time of the intervention, had spanned 16 
months and extending this may have resulted in adding confounding variables as 
changes in symptom protocols and policies. Moreover, it was constrained by the 
WISECARE+ study data collection schedule. Recruiting patients with breast cancer 
from other clinical sites, although increasing the sample size, would have further 
complicated the study, as these areas would not have been operating to the same 
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policies and procedures as Units A and B of the SNA↔P study, adding a further 
variable to the comparison of symptom experiences. The reducing sample size also 
contributed to the problems associated with confounding variables and comparing 
symptom experiences between patient groups. The lack of a matched control group 
complicated comparisons and affects the conclusions that can be drawn. 
Furthermore, while homogeneity of the sample (women receiving chemotherapy for 
breast cancer) was the aim of sample selection, this sample was not homogenous 
enough, as it included women receiving chemotherapy with both curative and 
palliative intent. Future research would be well advised to recruit a matched control 
group. 
The power of the SNA↔P study should also be considered. The power of a study 
refers to its ability to detect differences if the research hypothesis is true. As the 
SNA↔P study sample for Unit A was based on patients recruited to the 
WISECARE+ study who also met the criteria for the SNA↔P study, MM had little 
influence over the numbers of patients recruited or the recruitment timeframe. 
However, efforts were made to recruit similar numbers of patients from Unit B 
during times 1 and 2, although they were not matched in relation to potentially 
confounding variables. The main issue is that the non-significant results of the 
SNA↔P study may have been due to low power, meaning that a larger sample with 
power calculations based on the results of the SNA↔P study is required to 
determine this. However, while results from the WISECARE+ study were based on 
a larger sample size, and as such, had greater power, they also demonstrated a lack 
of statistically significant improvement in fatigue experiences as a consequence of 
the intervention.  
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9.3.2.2.2 Lack of patients’ perspectives 
Patients’ viewpoints on the effectiveness of the intervention were not sought. Given 
the drive to involve patients in their care highlighted above (Coulter 1997; 
Department of Health 2001; Department of Health 2006), and, as many of the 
interventions, such as relaxation and dietary modification for nausea or exercise and 
distraction for fatigue, relied on patients undertaking these while at home without 
the direct supervision or advice from specialist health professionals, exploring 
patients’ perspectives of the relative effectiveness of interventions would have 
provided additional insight into the effectiveness of the intervention in general. 
Indeed, while patients did reflect on the ways in which they managed their 
symptoms during the structured interviews, this issue was not the focus of the 
interviews and, as such, was not specifically assessed.  
9.3.2.2.3 Establishing the use of, and the most effective, components of, the 
intervention 
As already identified, the complex nature of the SNA↔P intervention complicated 
its evaluation, as it was not possible to establish which components of the 
intervention were most clinically effective, useful and usable. Addressing this issue 
in future research, including both health professionals’ and patients’ perspectives, 
would provide added insight and facilitate the future development of complex 
interventions. 
As the SNA↔P study was undertaken in the real world of clinical practice it was 
not possible, without constant observation, which would have been logistically 
impossible and may indeed have resulted in altered nursing practice, to know 
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whether the nursing staff in Unit A adhered to the intervention. While the nursing 
staff were not openly hostile to the SNA↔P study and its intervention and appeared 
to welcome the simplicity of the system, no patients from Unit A (the intervention 
site) behaved as though they had previously seen their symptom graphs, or referred 
to the nursing staff making any of the specific recommendations included in the 
practice protocols, during their interviews. 
9.3.3 The effectiveness of the intervention 
In exploring the effectiveness of the intervention, it is important to consider the key 
aspects as well as problem areas of the various components that make up the 
SNA↔P study. These are: the sample; data collection; symptom patterns; the 
analyses; and the results. 
9.3.3.1 The sample 
The SNA↔P study was conducted in two chemotherapy Units within a single NHS 
Trust which ensured that the policies and procedures between the two Units were 
identical. The use of a control group strengthened the design of the study and its 
subsequent conclusions. However, while the sample involved a relatively 
homogenous group of patients: women receiving chemotherapy for breast cancer, it 
can be criticised, as it involved women receiving a range of chemotherapy regimes 
with either curative or palliative intent. While analysis conducted within the 
SNA↔P study demonstrated no statistically significant differences in nausea and 
fatigue between chemotherapy given with either curative or palliative intent, a 
matched control group would have increased confidence in the results.   
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Consecutive recruitment to the study ensured that the sample was representative of 
the general population of women with breast cancer, and it also reflected the general 
population according to 2001 Scottish census data (McLoone 2004). Analysis of 
potentially confounding variables also showed that the four individual patient 
groups within the sample were not statistically significantly different in relation to 
age or social deprivation however, there were significantly more patients receiving 
chemotherapy with palliative intent in Unit A cohort 1 than any other patient group. 
The sample was sizable (n=105 starting the study and n=33 continuing throughout 
their entire chemotherapy treatment), indeed, conclusions concerning symptom 
management are frequently drawn within studies of much smaller sample sizes 
(Arakawa 1995; Dibble et al. 2000; Mock et al. 2001; Schwartz et al. 2001; 
Molassiotis et al. 2002b; Berger et al. 2003; Williams and Schreier 2004; Savard et 
al. 2005; Molassiotis et al. 2007). However, given the level of patient attrition 
experienced, the numbers of patients in each of the four patient groups were small, 
especially for analyses comparing confounding variables. A larger sample size 
would have afforded the study greater power to detect differences in symptom 
experiences where they existed. 
9.3.3.2 Data collection 
The longitudinal design of symptom data collection undertaken in the SNA↔P 
study provided a fundamental change in the way in which symptoms are explored. 
Symptom data was collected by means of a multidimensional symptom assessment 
questionnaire longitudinally within each cycle of chemotherapy and across multiple 
cycles of chemotherapy. Although no complaints were received about this 
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longitudinal data collection, one should consider the level of patient attrition 
highlighted above before judging the acceptability of this method of data collection.  
Previous research has taken a more limited view to ‘longitudinal’ data collection, 
collecting data: during a single cycle of chemotherapy (Richardson et al. 1998); at 
cycles 1 and 2 of chemotherapy (Dibble et al. 2003; Lee et al. 2005); at cycles 1-3 
of chemotherapy (Berger 1998; Schwartz 2000); at baseline, 3 months into 
chemotherapy and at 6 months (Payne 2002); before chemotherapy, on completion 
of chemotherapy and six months post chemotherapy (Hurria et al. 2006); or 
longitudinally over multiple cycles but for a shorter period within cycles, for 
example 48 hours (Rhodes et al. 1987; Rhodes et al. 1988). These approaches, 
based on arbitrary decisions about when to collect symptom data, fail to provide 
insight into patients’ total experiences during chemotherapy. Consequently, 
conclusions or recommendations based on such evidence are as limited as the 
evidence itself.  
The longitudinal data collection of the SNA↔P study is an improvement on these 
more limited, snapshot views as it collected patients’ entire symptom experience, 
during a course of chemotherapy, both within and across cycles, to describe and 
better understand patients’ symptom patterns, as well as to evaluate whether these 
change over time was a consequence of intervention techniques. Although the 
evaluation of nausea was eventually based on patients’ nausea experiences during 
the first 3 days following chemotherapy, this was an informed decision based on a 
full understanding of patients’ experiences.  
However, it is also important to note that the SNA↔P study did not include 
patients’ entire symptom experiences of nausea and fatigue, as data collection 
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spanned just days 1-14 of a 21- or 28-day cycle of chemotherapy. This is, again, a 
constraint as a result of its association with the WISECARE+ study. Consequently, 
data was not collected for either 7 or 14 days of each cycle of chemotherapy. This 
decision was based on current evidence concerning patterns of chemotherapy-
related symptoms (short lived symptoms such as nausea that occur in the first few 
days following chemotherapy (Kris et al. 1994; Jordan et al. 2005), and those more 
constant symptoms that continue to be felt for days or weeks following 
chemotherapy, such as fatigue (Berger 1998; Schwartz 2000; Molassiotis and Chan 
2001; Miller et al. 2007), as well as the potential for questionnaire fatigue. Indeed, 
completing a questionnaire for 14 consecutive days across multiple cycles of 
chemotherapy requires considerable commitment from patients and may have 
contributed to the level of attrition within the study. Consequently, one can 
appreciate the need for balance between gleaning as much symptom information as 
possible without over-burdening patients. While there is no evidence to suggest that 
patients experience significant symptoms between days 15-21 or 15-28 of a cycle of 
chemotherapy, it is possible that important information regarding patients’ symptom 
experiences may have been lost, especially that information concerning anticipatory 
nausea that can occur in the days immediately prior to subsequent chemotherapy 
administrations (Hickok et al. 2001; Figueroa-Moseley et al. 2007) and that have 
been shown to affect up to one third of patients receiving chemotherapy (Hickok et 
al. 2001). 
The longitudinal data collection of symptom data also encompassed the total 
symptom experience as it involved not only multidimensional quantitative symptom 
data of incidence, severity and distress from the symptom questionnaire, but also 
involved an innovative method of establishing an in-depth understanding of 
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patients’ symptom experiences at various symptom scores through focused 
discussion facilitated by patients’ symptom graphs during structured interviews. The 
importance of appreciating the component parts of the symptom experience was 
highlighted in the SNA↔P data that showed, although in general, there was a 
significant correlation between symptom severity and distress for both nausea and 
fatigue, as well as between total nausea and fatigue, during chemotherapy cycles 2-5 
there was a slight increase in distress associated with fatigue despite relatively 
stable fatigue severity scores. Appreciating the factors that contribute to patients’ 
total symptom experiences can facilitate the selection of the most appropriate 
interventions. However, while this is an interesting finding, it is based on a reducing 
sample and should be confirmed using a larger sample before focusing too much on 
it.  
9.3.3.3 Symptom patterns 
Establishing the patterns of symptoms over multiple cycles of chemotherapy 
spanning patients’ entire courses of chemotherapy, produced illuminating results 
because, as already highlighted, much ‘longitudinal’ research is based on arbitrary 
decisions about the duration of longitudinal data collection. The longitudinal data 
collection of the SNA↔P study, however, allowed comparison of symptom patterns 
over multiple cycles of chemotherapy, establishing that while there were no 
differences in the nausea reported by patients over time, patients’ experiences of 
fatigue increased with each cycle of chemotherapy to the point that mean total 
fatigue on day 14 of cycle 8 was almost 3 times greater than that on day 14 of cycle 
1, and mean fatigue distress scores more than doubled between cycles 1 and 8. 
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However, caution should be applied before drawing major conclusions from these 
results due to the reducing sample size on which they are based.  
Again, it is important to highlight the missing symptom data from days 15-21 or -
28, as this may have continued to provide illuminating information about patients’ 
experiences during this time. Evaluating the balance between increasing the 
available symptom data and of over-burdening patients applies here, too. 
9.3.3.4 The analyses 
Understanding the patterns of symptoms over time within each cycle of 
chemotherapy, as well as across cycles of chemotherapy allowed informed decisions 
to be made about the data used in the evaluation of the intervention. It is most 
appropriate to evaluate the impact of an intervention at the time of greatest symptom 
experience, as this is the time when differences in symptoms are most likely to be 
seen. In addition, the qualitative data from patient interviews confirmed that 
patients’ experiences of nausea were focused during the first few days following 
chemotherapy, while their experiences of fatigue spanned the 14 days of data 
collection. Consequently, informed decisions based on both quantitative and 
qualitative data were made to use data from days 1-3 of each cycle of chemotherapy 
for nausea, and data from days 1-14 for all cycles of chemotherapy for fatigue.  
Utilising both quantitative and qualitative methods to explore symptom experiences 
facilitated a thorough evaluation of the impact of the intervention. While traditional 
statistical techniques were used to evaluate the statistical significance of the 
SNA↔P intervention, this was complemented by qualitative data from structured 
interviews that focused on patients’ symptom graphs and explored the meaning and 
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impact of symptoms at the various scores patients had reported, as well as 
encouraging them to compare their experiences of differing symptom scores. These 
interviews allowed insight into the personal significance of patients’ symptom 
experiences. This method of evaluating the impact of the intervention allowed 
conclusions to be drawn that were not only statistically sound, but also considered 
the personal significance of symptom experiences.  
9.3.3.5 The results 
Patients were able to complete a multidimensional assessment tool to report their 
experiences of nausea that demonstrated distinct patterns of nausea within and 
across cycles of chemotherapy. The general patterns of nausea (total, severity and 
distress) from the SNA↔P study illustrated a peak during the first 3 days following 
chemotherapy, followed by a marked, then gradual, decrease over the remaining 
data collection period. These patterns are supported by a small evidence base: the 
peak in nausea in the days immediately following chemotherapy (Rhodes et al. 
1987; Rhodes et al. 1988; Dibble et al. 2003; Lee et al. 2005), followed by a 
decrease over time (Dibble et al. 2003; Lee et al. 2005). It is unfortunate that, 
although the early work was longitudinal across 6 cycles of chemotherapy, it 
involved only the first 48 hours following chemotherapy (Rhodes et al. 1987; 
Rhodes et al. 1988), while the later evidence, although longitudinal within a cycle of 
chemotherapy measuring nausea for 11 consecutive days following chemotherapy, 
only explored nausea during the first 2 cycles of chemotherapy  (Dibble et al. 2003; 
Lee et al. 2005). 
The SNA↔P study was successful in improving patients’ experiences of nausea 
with statistically significantly fewer patients reporting nausea following the 
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implementation of the intervention than before. This statistically significant result is 
supported by data from the structured interviews during which patients’ could 
clearly distinguish between the presence and absence of nausea, making this 
positive outcome both statistically and personally significant. The difference in 
mean total nausea scores before and after the intervention was not statistically 
significant (a reduction of 0.71). Moreover, as patients found it difficult to 
differentiate between shades of nausea, for example between a score of 1 and 2 
during their interviews, it is unlikely that they would have been able to perceive a 
reduction in their nausea of 0.71. Thus, the intervention had neither a statistically or 
personally significant impact on patients’ experiences of grades of nausea. While 
one can question whether the intervention can be deemed a success on the basis of 
these results as indicated, during the interviews, patients clearly preferred to have no 
nausea as opposed to even minimal nausea so, one could argue, would ultimately 
prefer to have their nausea eradicated rather than somewhat reduced. Consequently, 
the SNA↔P intervention can be deemed successful. 
Patients were able to complete a structured multidimensional assessment tool for 
fatigue that showed fatigue had a relatively constant presence in the 14 days 
following chemotherapy with gentle peaks and troughs seen throughout all cycles of 
chemotherapy. Mean scores for all components of the symptom experience (total, 
severity and distress) increased with each subsequent cycle of chemotherapy. These 
trends replicate the patterns of fatigue identified in the WISECARE+ study (Miller 
et al. 2007), the study from which the SNA↔P study arose. The undulating picture 
is also supported by the ‘rollercoaster’ pattern of fatigue reported within 2 studies of 
women (n=72, n=27) during their first 3 cycles of chemotherapy for breast cancer 
(Berger 1998; Schwartz 2000). However, the peak in fatigue immediately following 
286 
chemotherapy that has been identified by patients in a number of studies (Berger 
1998; Richardson et al. 1998; Schwartz 2000; Wu et al. 2007) was not reported by 
patients in the SNA↔P study. 
No statistically significant differences in relation to experiences of fatigue were seen 
between patient groups before and after the SNA↔P intervention, either in relation 
to the presence and absence of fatigue, or in levels of fatigue scores. During 
interviews, however, patients were able to differentiate between different fatigue 
scores and although each had their own ways of describing their individual 
experiences of various fatigue scores, there was general agreement about the 
experience of various scores of fatigue and the impact that these had on their lives. 
This finding suggests that the assessment tool was sensitive enough to detect 
changes over time, had they been experienced. Thus, it is important to consider the 
interventions that were recommended within the SNA↔P intervention for fatigue 
that were supported by the literature review and NCCN fatigue guideline (National 
Comprehensive Cancer Network 2007b). Chapter 4 demonstrated that while 
physiological and biochemoical factors, psychosocial factors and demographic 
factors most probably all have a role in the development of fatigue, the necessary 
level of evidence to allow firm conclusions to be drawn about the exact aetiology of 
fatigue is not currently available. Consequently, one can question whether current 
interventions, although the best to date, have the ability to significantly reduce 
patients’ fatigue experiences. Indeed, it is likely that as our understanding of the 
aetiology of fatigue becomes clearer and more specific, so will our interventions. 
Furthermore, the sustainability of interventions for fatigue should be considered. 
Many studies of interventions have chosen to evaluate their impact over apparently 
arbitrary time periods, for example, over 10 weeks (MacVicar and Winningham 
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1986), across cycles 1-3 (Schwartz et al. 2001), over 18 weeks (Given et al. 2002),  
and during cycles 2-4 (Jacobsen et al. 2002). Indeed, cases evaluating the 
sustainability of fatigue interventions have not shown positive results, for example 
an education and support programme that proved initially successful after 1-2 weeks 
was unable to sustain this positive effect at 6- and 10-week follow up (Yates et al. 
2005). Thus, it could be any positive effects of the interventions employed within 
the SNA↔P study were short lived and, as such, were not statistically identifiable.  
9.3.4 Additional findings of the SNA↔P study 
Patients in the SNA↔P study were overwhelmed by their experiences of fatigue 
and spoke passionately and at great length about this. They were able to describe 
their abilities and feelings, both physical and psychological, at various fatigue 
scores. Patients often felt unable to fight their fatigue, and without exception, 
resorted to going to bed and sleeping: ‘I felt so terrible that I just had to lie back 
down again’, despite evidence to show that this is counterproductive and can 
increase feelings of fatigue (Winningham 1991; Winningham et al. 1994), a fact that 
some patients in the SNA↔P study recognised: ‘I’d sleep no bother, but I didn’t 
feel any better when I woke up, I’m just as tired’. Their fatigue clearly impacted on 
their quality of life, ability to work, care for their family and home, as well as their 
ability to participate in social activities. In themselves, these are not new findings: 
numerous studies, both qualitative and quantitative, have already shown fatigue to 
be a very troublesome symptom, for example, the studies explored within chapter 2 
and those of Ferrell et al (1996), Hilfinger Messias et al (1997), Magnusson et al 
(1999), Holley (2000) and Wu and McSweeney (2007). The SNA↔P study can add 
to these findings as it not only allowed patients to describe their overwhelming 
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experiences, but was also able to quantify these through the use of symptom scores 
from patients’ structured symptom questionnaires. What is important though, is the 
lack of improvement in this situation during the last decade, raising questions 
concerning fatigue education, assessment and interventions.  
While patients’ expectations of symptoms were not a focus of the SNAP study, 
patients’ expressiveness during discussions of their experiences suggested that the 
levels of fatigue they experienced and its impact on their lives were not expected. 
This unexpectedness supports the findings of Wu and McSweeney (2007,) who 
highlighted patients’ lack of preparedness for the level of tiredness they experience. 
Given the richness of earlier research that has shown how patients experience 
fatigue (Ferrell et al. 1996; Hilfinger Messias et al. 1997; Magnusson et al. 1999), as 
well as the plethora of studies showing that patients receiving chemotherapy 
identify fatigue as one of the most troubling symptoms (Coates et al. 1983; Love et 
al. 1989; Tierney et al. 1991; Tierney et al. 1992; Cooper and Georgiou 1992; Sitzia 
et al. 1995; Griffin et al. 1996; Foltz et al. 1996; de Boer-Dennert et al. 1997; 
Lindley et al. 1999; Carelle et al. 2002), it is important to explore potential reasons 
for this lack of preparedness.  
One explanation could be that chemotherapy nurses are unaware of the impact of 
fatigue on a patient’s quality of life and simply do not emphasise fatigue as a key 
symptom during their patient education. Alternatively, it could be that nurses do 
appreciate the significance of fatigue for patients but feel at a loss for effective 
interventions. Consequently, due to their feelings of helplessness, they gloss over 
fatigue during patient education. Finally, it may also be that the terminology used 
within patient education, that is, ‘tiredness’, does not adequately describe the level 
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of fatigue that patients are likely to experience. Because ‘tiredness’ is a feeling that 
people are familiar with in their daily lives, patients may fail to appreciate the extent 
of the tiredness associated with chemotherapy that health professionals and other 
sources of information, such as the internet, try to convey. Patients may assume that 
their experiences of tiredness will be of a level that they are familiar with and that 
everyday commonsense methods to alleviate it, such as rest or sleep, that have been 
effective in the past, will be effective. However, from the literature and from the 
SNA↔P study, the most tired one has ever felt does not compare with the level of 
tiredness associated with cancer and cancer treatment (Irvine et al. 1994; Glaus et al. 
1996; Holley 2000a; Johnston and Coward 2001).   
Given the extent of fatigue patients reported, one can consider the appropriateness 
of lengthy assessment tools. Chapter 4 presented a range of fatigue assessment tools 
that were more or less appropriate for a variety of settings, proposing that scales, 
such as the Revised Piper Fatigue Scale (Piper et al. 1998), were appropriate for the 
in-depth multidimensional evaluation of fatigue required for research purposes, 
while the shorter Cancer Fatigue Scale revised version (Schwartz and Meek 1999) 
allowed patients, in just 6 questions, to provide clinicians with a multidimensional 
picture of their fatigue experiences. The suitability of currently available fatigue 
assessment tools for potentially fatigued individuals should be considered before 
utilising them for research or practice purposes, and clinicians should be mindful of 
the somewhat under-explored concept of response shift bias (Breetvelt and van Dam 
1991; Visser et al. 2000) identified in chapter 4, when measuring patients’ symptom 
experiences over time. 
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Finally, one can question how realistic some of the fatigue interventions are in real 
life. For example, taking a short walk to reduce fatigue would have been utterly 
impossible for patients in Wu and McSweeney’s study (2007), whose fatigue was so 
significant that they were unable to walk to the bathroom in the next room, and for 
patients in the SNA↔P study who, ‘could virtually hardly move my legs, I was so 
tired…even trying to go into the kitchen and walk up and down the stairs, my legs 
weren’t my own’. It may also be unrealistic to expect patients experiencing anything 
other than mild fatigue to have the concentration to read information leaflets or 
participate in educational interventions. Being unable to participate in an 
intervention, regardless of its appropriateness, could have negative psychological 
consequences for patients.  
9.4 Limitations 
The discussions above have alluded to a number of limitations of the SNA↔P 
study. These relate predominantly to 2 distinct aspects of the study: the sample, and 
the complex intervention.  
9.4.1 The sample 
Patient attrition was a major issue with just 31.4% of those starting the study 
participating for the entire duration of their chemotherapy treatment. As the 
SNA↔P study failed to follow up patients who dropped out to establish their 
reasons for doing so, it is difficult to draw definite conclusions about the rationale 
for the attrition seen within the study. That said, while undoubtedly beneficial in 
understanding patients’ experiences of symptoms, the longitudinal evaluation of the 
SNA↔P study required considerable and lengthy co-operation from patients over 
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extended periods of time which may have contributed to the attrition rates seen. 
Moreover, the patients involved in the SNA↔P study were receiving chemotherapy 
and as such were experiencing both physical and psychosocial issues/concerns. 
Indeed, it could have been that the fatigue that patients experienced as a 
consequence of their chemotherapy (and that was a key focus of the study) was a 
contributor to their withdrawal. This unfortunately means that the most fatigued 
patients (and those who may have benefitted most from the intervention) may have 
been too fatigued to continue their participation in the SNA↔P study. 
Consequently, the potential impact of the intervention may have been reduced. 
Although the demographic variables of patients who participated for the duration of 
their chemotherapy treatment did not differ significantly from those who dropped 
out, the degree to which the symptom profiles of those who dropped out differed 
from those patients who continued to participate in the study remains unknown. 
Although relatively sizable in comparison to existing research studies that explore 
symptom management, the sample of the SNA↔P study, when split into 4 patient 
groups for analysis, was fairly small, which created difficulties with regards to the 
power of the study to detect differences between patient groups as well as 
considering the issues associated with confounding variables. It is a limitation of the 
SNA↔P study that a power analysis was not conducted during the planning phase. 
This failing relates to the SNA↔P study’s association with the WISECARE+ study 
and its subsequent reliance on patients recruited to the WISECARE+ study at Unit 
A. While it is positive that the number of patients recruited from Unit B was 
relatively similar to that of Unit A, this does not overcome the fact that the SNA↔P 
study was underpowered. Indeed, given the number of patients participating in the 
SNA↔P study, power calculations suggest that the study had an 80% chance of 
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detecting a large effect (0.8) at a significance of p=0.05 (with 26 patients in each 
patient group) (Faul et al 2007). Indeed, in order to detect a medium effect (0.5), 64 
patients would have to have been recruited per patient group while 394 patients per 
group would have been necessary to detect a small effect (0.2) (Faul et al 2007). It 
is essential that future studies of this kind undertake such a power analysis to ensure 
that definite conclusions and recommendations for practice can be made. 
Finally, although homogeneity was the aim of sample selection (involving only 
women receiving chemotherapy for breast cancer), the inclusion of women 
receiving chemotherapy with either curative or palliative intent added another 
confounding variable for consideration in the analysis. Future such studies should 
attempt to achieve greater homogeneity within the sample. 
9.4.2 The SNA↔P Intervention 
The use of the SNA↔P intervention and its maintenance in clinical practice was not 
monitored and, given the complexity of the intervention in that it included 
assessment and multiple interventions over a prolonged time period, this means it is 
impossible to know which aspects of the intervention were the most effective, used 
or preferred by nurses and patients. Given the real world environment in which the 
study was conducted, it was impossible to evaluate nurses’ adherence to the 
intervention and the recommendations for practice therein, as to observe this in 
practice may have induced a Hawthorne effect with nurses changing their behaviour 
in response to being observed. It may have been that some nurses engaged more 
than others with the intervention, however, there is no way of establishing whether 
this was the case, or if it was, who those nurses were, and the reasons why they 
engaged more successfully with the intervention. While a questionnaire to nursing 
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staff may have elicited some ideas with regards to their preferred components of the 
intervention and its use in practice, this too could have been flawed with nurses 
giving the responses they believe to be ‘expected’ or ‘correct’ rather than reporting 
actual clinical practice. The use of interviews or focus groups with nursing staff 
throughout the study and at its end may have provided some valuable insight into 
the most effective or favoured components of the intervention while a questionnaire 
to patients about their perceptions and preferences may also have been helpful. 
Future research of this kind should consider a combination of techniques that would 
provide a clearer understanding of the various aspects of such a complex 
intervention in practice. 
Given the recent moves towards greater patient involvement in their care and in 
health care generally, a lack of patient involvement is also a limitation of the 
intervention in relation to its development and evaluation. There was no patient 
involvement in the development of the practice protocols, nor did patients have the 
opportunity to comment on the appropriateness or usefulness of the self-care 
interventions that nursing staff should have recommended they undertake whilst at 
home. 
Finally, it is important to highlight that although longitudinal, the SNA↔P data did 
not include all patients’ experiences of nausea and fatigue, as no data was collected 
between days 15-21/28 of 21 or 28 day chemotherapy cycles (again, a constraint 
from the WISECARE+ study). Although this design may have resulted in a loss of 
symptom data, especially relating to anticipatory nausea, the decision to limit the 
data collection period was based on ensuring a balance between over-burdening 
patients and obtaining meaningful symptom data. Indeed, relieving anticipatory 
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nausea was not an aim of the study, as it requires significantly different 
management approaches to that of post-chemotherapy nausea (Morrow and Roscoe 
1998; Morrow et al. 1998).  
9.4.3 Lessons learnt from the SNA↔P study 
Given the limitations highlighted above, there are a numbers of ways in which such 
a study could be improved were it to be repeated in the future. Firstly, in relation to 
the sample a power calculation and subsequently larger sample would ensure more 
definite conclusions could be drawn about the impact of such an intervention while 
a matched control group would overcome issues associated with confounding 
variables. Likewise, greater homogeneity would ease the complexity associated 
with confounding variables. A structured approach to exploring reasons for patient 
attrition would also be beneficial. 
Secondly, while the complementary use of structured questionnaires and interviews 
allowed a rounded evaluation of the intervention, longitudinal interviews would 
provide illuminating information to evaluate the symptom experience over time as 
well as potentially exploring patients’ perceptions of the most effective or useful 
interventions. Exploring and comparing whether treatment intent influences 
symptom experiences may also be possible through such longitudinal qualitative 
investigation. 
Finally, in relation to the intervention itself, future research should make every 
effort to establish which aspect of the intervention, that is structured assessment or 
specific interventions, that patients’ found most useful or effective. Undertaking 
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various techniques to explore nurses’ perceptions of the intervention and its various 
components would also be beneficial for future research. 
9.5 Conclusions that can be drawn 
Considering the design, analyses, results and limitations of the SNA↔P study, one 
can conclude that the SNA↔P study demonstrates the use of multidimensional 
symptom assessment to identify, describe and compare patterns of symptoms, and 
their component parts, over multiple cycles of chemotherapy. It also presents 
sufficient evidence to argue that an intervention comprised of structured assessment 
in tandem with specific evidence-based interventions can not only be implemented 
in routine clinical practice, but also has significant potential to improve patients’ 
experiences of chemotherapy-related nausea. Further testing of the intervention 
involving a large homogenous sample and a matched control group would ensure 
the necessary power with which to draw final conclusions.  
While the SNA↔P intervention did not positively impact on patients’ experiences 
of fatigue, results from the study that explore and describe patients’ experiences of 
fatigue, both quantitatively and qualitatively, identify a need for improved fatigue 
education, as well as appropriate assessment tools and intervention techniques. 
9.6 Recommendations for practice and further research  
A number of recommendations based on the outcomes of the SNA↔P study can be 
made for both practice and research that focus on symptom management in general, 
the management of nausea and fatigue specifically, as well as research utilisation. 
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9.6.1.1 General symptom management 
The SNA↔P study demonstrated the feasibility of succinct, longitudinal, 
multidimensional symptom assessment in clinical practice and illustrated the 
benefits of this in identifying patterns and comparing these over time to truly 
understand patients’ symptom experiences. While understanding total symptom 
experiences, more in-depth appreciation of the component parts would allow 
practitioners to implement interventions that are appropriate to the level of symptom 
component that is most troubling the patient. For example, exercise may be 
appropriate for patients experiencing mild fatigue, while energy conservation may 
be more realistic for patients with severe fatigue. Working with patients to explore 
their symptom patterns would facilitate patient education regarding symptom 
management, as well as identifying times of high and low symptom burden that 
would allow patients to better plan their daily lives and choice of interventions to 
perform during a course of chemotherapy.  
Further research can build on current understanding of symptom patterns. Symptom 
assessment using sensitive, multidimensional assessment tools within homogenous 
patient populations will allow the identification of common symptom patterns that 
can be used, not only to predict periods when patients’ lives may be compromised 
by high levels of symptoms, but also to ensure the implementation of appropriate 
and timely interventions. While some research began to explore the different 
symptoms and their patterns related to specific chemotherapy (Buckingham et al. 
1997; Sitzia and Dikken 1997; Sitzia and Huggins 1998), these studies can be 
criticised for their small sample sizes and the use of a lengthy 61- (Sitzia and 
Huggins 1998) or 75- (Buckingham et al. 1997; Sitzia and Dikken 1997) item 
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symptom questionnaire. Moreover, although longitudinal in that they assessed 
symptoms across a course of chemotherapy, symptom assessment was conducted 
once at the end of each cycle, and so relied on patient recollection of their symptom 
experiences during the previous 3-4 weeks. Also, as these studies were conducted 
around a decade ago, they involve chemotherapy regimes that are now obsolete, and 
research that includes recently developed chemotherapeutic agents is necessary.  
Harnessing technology, such as handheld computers or mobile phones to transfer 
patients’ structured symptom experience data to their health professionals has 
already been shown to be feasible, and has potential for ensuring timely and 
appropriate interventions (Maguire et al. 2005; Kearney et al. 2006). Extending 
these exploratory studies to include longitudinal data collection over a course of 
chemotherapy, rather than cycles 1-2 (Kearney et al. 2006) or 1-4 (Maguire et al. 
2005), would ensure patients’ entire symptom experiences were understood. Risk 
modelling provides a powerful mechanism for identifying patterns and predicting 
what will happen in the future and early work employing such predictive risk 
modelling techniques has involved women with breast cancer receiving 
chemotherapy (Cowie et al. 2008). Developing and extending such predictive risk 
modelling to incorporate a variety of cancer diagnoses and treatments would mean 
that patients could be provided with information concerning their specific risk of 
developing certain symptoms and their likely levels throughout a course of cancer 
treatment.  
Exploring patterns of symptoms should now involve whether it is possible to 
identify relationships between specific symptoms, known as symptom clusters. 
Symptom clusters are defined as three or more concurrent symptoms that are related 
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to each other (Dodd et al. 2001b) and, to date, research on symptom clusters in 
patients with cancer has focused primarily on fatigue, insomnia, pain and depression 
(Sarna 1993; Gaston-Johansson 1996; Broeckel et al. 1998; Bower et al. 2000; 
Redeker et al. 2000; Chan et al. 2005; Beck et al. 2005). One could argue that 
establishing relationships between symptoms would be helpful for symptom 
management, in that alleviating or ameliorating one symptom could have a ‘knock 
on’ effect on others. Consequently, exploring symptom patterns in isolation should 
no longer be an option for health professionals, and research exploring symptom 
patterns should consider whether some symptoms always occur together or whether 
the presence of specific symptoms makes others more or less likely to occur.  
9.6.1.2 Management of nausea 
Patients in the SNA↔P study were able to assess their nausea independent of 
vomiting. However, many assessment tools include assessment of nausea in tandem 
with vomiting and are lengthy, and so require considerable patient effort to 
complete, for example, the Morrow Assessment of Nausea and Emesis (Morrow 
1992) has 17 items and the Functional Living Index – Emesis (Lindley et al. 1992) 
has 18 items. Current clinical practice using the Common Toxicity Criteria 
(National Cancer Institute 1999; Trotti et al. 2003), although positive as it identifies 
nausea as distinct from vomiting, grades it unidimensionally mild, moderate or 
severe, according to patients’ ability to eat. The SNA↔P study has shown that 
nausea has many more implications for patients over and above impacting on their 
oral intake. As such, the assessment of nausea in practice should be succinct and 
multidimensional, and should consider incidence, severity and associated distress.  
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Given the results of the SNA↔P study that have shown that patients can assess their 
nausea, independently of vomiting, using a succinct multidimensional longitudinal 
questionnaire, there is a need for a concentrated body of research that incorporates 
such assessment in the development and testing of specific nausea-related 
interventions with the aim of improving patients’ experiences. Such assessment 
would also allow the greater understanding of patients’ longitudinal experiences of 
nausea. Involving patients in both assessment and intervention development will 
ensure that both are not only manageable, but also effective.  
9.6.1.3 Management of fatigue 
The appropriateness of fatigue assessment and current management techniques 
should be considered in practice. Lengthy questionnaires are inappropriate for those 
patients already fatigued and, like nausea above, fatigue assessment in clinical 
practice should be longitudinal, succinct, multidimensional and consider incidence, 
severity and associated distress. Research to develop such tools should involve 
patients who are, or who have, experienced fatigue, to ensure that they are within 
patients’ abilities to complete longitudinally, as well as including issues that are 
relevant to patients’ experiences.  
The suitability of interventions for fatigue, as well as their sustainability, should 
also be considered in practice. As already highlighted, many interventions for 
fatigue, such as exercise or education may be difficult, or indeed, impossible, for 
those already compromised by fatigue to undertake. Recommending such 
inappropriate interventions may have detrimental effects on patients’ psychological 
well-being, resulting in a downward spiral effect leading to poor communication 
about fatigue and a lack of understanding of fatigue experiences between patients 
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and those caring for them. Thus, in practice, the appropriateness of interventions 
and the patients’ level of fatigue, as well as the sustainability of the intervention, 
should be considered, and interventions that are most appropriate for the patient’s 
level of fatigue recommended, with regular re-assessment. 
Patient education in clinical practice is also important to consider, as patients in the 
SNA↔P study appeared to be surprised by the levels of fatigue they experienced. 
Earlier in this chapter it was suggested that the terminology that is currently used to 
describe fatigue, that is ‘tiredness’, may be responsible for patients’ lack of 
appreciation of the extent, level, and impact of fatigue they experience. Using day-
to-day language, such as ‘tired’, does not adequately portray cancer-related fatigue. 
Further development of the terminology is required, and working with patients who 
are, or who have, experienced fatigue as a consequence of cancer or cancer 
treatments, would be helpful in developing the terminology used to describe this 
symptom which adequately reflects their experiences. 
Continued efforts should be made within research that explore the potential 
aetiologies of fatigue in relation, not only to cancer, but also to specific cancer 
treatments. A better understanding of the causes of fatigue will allow the 
development of specific targeted interventions that would be more likely to be 
effective in overcoming this overwhelming symptom. Research that develops and 
tests such interventions within the real world of clinical practice would ensure that 
they were feasible to implement at the clinical level, while working with patients 
during their development and testing would also ensure that these were both 
realistic and manageable for patients.  
301 
9.6.1.4 Improving research utilisation 
Nurses constitute the largest group of healthcare providers, and their care influences 
patient outcomes (Blegen et al. 1998; Aiken et al. 2002; Estabrooks et al. 2005b). 
Indeed, the SNA↔P study demonstrated the positive impact that chemotherapy 
nurses can have on patients’ experiences of nausea. Despite their potential to 
positively impact on patient outcomes through evidence-based practice, it has been 
shown that nurses often fail to incorporate research into their practices, preferring to 
use knowledge gained through personal experience and interaction with co-workers, 
rather than journal articles or textbooks (Estabrooks et al. 2005a). Evidence 
utilisation is particularly challenging, as it requires investment at both 
organisational and practitioner levels, as well as the use of multiple interventions 
(Pearson 2006), all of which were considered and included within the SNA↔P 
study. A recent systematic review of interventions aimed at increasing research use 
in nursing identified educational sessions led by local opinion leaders and the 
formation of multidisciplinary committees as effective (Thompson et al. 2006), both 
of which again were implemented in the SNA↔P study. 
Nurses should be encouraged to find ways of implementing research in their clinical 
practice. In so doing, they could demonstrate the impact that they have on patient 
outcomes and highlight their unique contribution to patient care, as well as 
evaluating new interventions to improve patients’ experiences. There is a growing 
amount of understanding and expertise concerning research utilisation in nursing 
aimed at ensuring that research knowledge is reflected in the care that patients 
receive. The multidimensional Promoting Action on Research Implementation in 
Health Services (PARIHS) framework suggests that the quality of evidence, context 
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and facilitation, and the interplay among them, are fundamental ingredients to 
promote research uptake (Kitson et al. 1998; Rycroft-Malone et al. 2002; Rycroft-
Malone 2004). However, a review of barriers to research utilisation identified 
primary barriers as: lack of time; lack of relevant skills; poor team-working; and 
aspects of nursing culture, such as ritualistic care, no authority and no incentives 
(Sitzia 2002). The SNA↔P study demonstrated that these aspects can be overcome, 
for example, although guided imagery and relaxation were not within the remit of 
nursing staff in the SNA↔P intervention sites, MM worked with them to overcome 
their initial reticence and develop alternative methods (tape recordings from the 
Unit psychologist) to ensure that the intervention was implemented in routine 
practice. This process is supported by the finding that inter-personal contact 
improves the likelihood of behaviour change when introducing innovations to health 
settings (Thompson et al. 2006). Moreover, the multidisciplinary educational 
sessions as part of the SNA↔P study gave nurses the opportunity to explore 
evidence-based interventions for specific symptoms and encouraged them to 
implement these in practice. Initiating and supporting similar sessions within 
clinical areas would stimulate discussion of research-based evidence between 
nursing staff, potentially leading to its implementation in clinical practice.  
However, the responsibility for ensuring research is implemented in practice does 
not lie solely with practitioners. Within symptom management, it is important that 
researchers consider the applicability of the interventions developed, as well as the 
practicalities of implementing them in the real world of clinical practice. Aspects 
such as intervention costs, appropriate locations, and staff training, should be 
included in their evaluation of an intervention before presenting it as a realistic 
means of improving patients’ symptom experiences in clinical practice. One could 
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argue that research findings are more likely to be adopted by practitioners if they are 
sensitive to and have considered the limitations and boundaries within which 
practitioners work.  
9.7 Conclusion 
The SNA↔P study was a longitudinal study that evaluated the impact of a complex 
evidence-based intervention incorporating structured multidimensional symptom 
assessment and multiple symptom management techniques on patients’ experiences 
of nausea and fatigue during a course of chemotherapy for breast cancer. Using 
complementary quantitative and qualitative research methods allowed a rounded 
evaluation of the intervention that incorporated both statistical and personal 
significance. This design provided insight into patients’ experiences of nausea and 
fatigue during chemotherapy, as well as allowing informed and confident 
conclusions to be drawn on the study outcomes.  
The study results have provided understanding of patterns and experiences of 
nausea and fatigue across a course of chemotherapy. The intervention shows 
significant potential for improving patients’ symptom experiences, and further 
testing in a large homogenous population with a matched control group is 
necessary. However, as a research study successfully conducted within the real 
world of clinical practice, the SNA↔P study has identified a number of 
implications for practice and research in relation to symptom management 
generally, the management of nausea and fatigue specifically, as well as promoting 
research utilisation.  
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Thus, in conclusion, the SNA↔P study has demonstrated the potential of structured 
assessment and practice in routine clinical care for improving patients’ symptom 
experiences during chemotherapy. In so doing, it has highlighted a number of 
significant areas in which clinical practice can be influenced, and research 
conducted, to further improve patients’ symptom experiences.  
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APPENDIX B - PATIENT SYMPTOM QUESTIONNAIRE 
 
 
 
To be completed by nursing staff 
Name  
WISECARE+ 
number 
 
Chemotherapy 
regime 
 
Cycle number 
(circle) 
1         2         3         4         5         6         7         8   
Reporting on day 
(circle) 
1      2      3      4      5      6      7      8      9      10     11      12  
13      14 
 
 
Below you will see a list of symptoms that are sometimes associated with 
chemotherapy. You may not experience all of these symptoms but it is useful for staff to 
know which symptoms you have experienced. The information you provide will be used 
by nursing staff to help plan your care. 
 
You should complete this questionnaire daily for 14 days following each cycle of 
chemotherapy you receive. It is best completed in the evening and when you are 
completing it, think of your experiences throughout the day. 
 
Please answer all the questions. Please answer all the questions. Firstly, tick whether 
you have experienced a symptom and then if you have experienced the symptom, please 
tick the boxes that best describe your experience that day.  
 
There is also a list of activities that you may or may not have tried in relation to any 
symptoms you have experienced. Please tick ‘yes’ or ‘no’ to show whether you have 
tried these activities that day. 
 
Thank you for completing this questionnaire. 
 
NAUSEA
If yes, 
Have you experienced NAUSEA today? Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
I took my anti-sickness tablets regularly
I ate small, frequent meals
Yes No
Yes No
Self-care activities
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Today’s date is ……………………………………… 
 
 
 NAUSEA (feeling sick)
If yes, 
Have you experienced NAUSEA today? Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please turn over…. 
VOMITING (being sick)
If yes, 
Have you experienced VOMITING today? Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
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I took my anti-sickness tablets regularly
I ate small, frequent meals 
I tried to relax 
I tried to distract myself, for example, watching 
television, talking with friends, listening to music etc 
I avoided very hot or very cold foods 
I ate bland tasting foods 
I contacted the hospital for further advice 
Other (Please describe)
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Self-care activities for nausea and vomiting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please turn over….
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 Feeling unusually tired
If yes, 
Have you experienced TIREDNESS today? Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I rested when I felt tired 
I did some physical activity 
I tried to eat a balanced diet 
I tried to get into a good sleeping routine 
I tried to distract myself, for example, 
watched television, reading, gardening 
etc 
I contacted the hospital for further advice 
Other (Please describe)
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Self-care activities for tiredness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please turn over…. 
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 Oral problems (problems with your mouth or throat)
If yes, 
Have you experienced PROBLEMS WITH 
YOUR MOUTH OR THROAT today? (e.g. 
sore or dry mouth/throat, mouth ulcers)
Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I used my mouthwash regularly (at least 
twice a day) 
I brushed my teeth using a soft toothbrush 
I used dental floss 
I removed my dentures
I avoided very hot or very cold foods 
I avoided smoking
Other (Please describe)
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Self-care activities for oral problems
I avoided drinking alcohol 
I avoided spicy foods Yes No
Yes No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Please turn over… 
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Please complete this questionnaire by ticking the box in the right hand column that best 
represents how your mouth feels or looks today. 
                 TICK HERE 
Voice Normal  
Deep or raspy   
Difficulty talking/painful  
  
Swallow Normal swallow  
Some pain on swallow   
Unable to swallow  
   
Lips Smooth, pink and moist  
Dry and cracked   
Ulcerated or bleeding  
   
Tongue Pink, moist and papillae present  
Coated or loss of papillae with shinny 
appearance with or without redness 
  
Blistered or cracked  
   
Saliva Watery  
Thick or ropy   
Absent  
   
Mucous membranes 
(inside skin of lips 
and cheeks) 
Pink and moist  
Reddened or coated (increased whiteness) 
without ulceration 
  
Ulceration with or without bleeding  
   
Gingiva (gums) Pink and stippled and firm  
Oedematous with or without redness   
Spontaneous bleeding or bleeding with 
pressure 
 
   
Teeth/dentures Clean and no debris  
Plaque or debris in localised area (between 
teeth if present) 
  
Plaque or debris generalised along gumline 
or denture bearing area 
 
 
 
 
 
 
        Please turn over…. 
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Other symptoms
What was it……………………………………..
Have you experienced any other symptoms
today?
Yes No
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
What was it……………………………………..
Mild
Moderate
Severe
Not at all
A little
Quite a bit
Very much
How severe was this?
How much did it bother you?
 
 
 
 
 
 
 
 
Thank you for completing this questionnaire. 
 
 
If you are in hospital, please return this to your nurse.  
 
 
If you are at home, please keep this with your other questionnaires and post it back 
when you have completed all 14 days of questionnaires. 
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APPENDIX C – STANDARD PATIENT INFORMATION SHEET – 
UNIT A 
 
 
‘Hospital/Institution headed paper’ 
Date ………………. 
 
You are invited to take part in the above research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
Patients receiving chemotherapy frequently receive it as an out-patient or stay in 
hospital for a short period of time. As a consequence nurses have less time to spend 
with patients and patients are more likely to experience symptoms and side-effects 
when they are at home without the direct care of a health professional. 
 
The purpose of this study is to provide nurses with information that will help them care 
for their patients and to find out how patients feel about participating in their own self-
care. The project will last for 2 years. 
 
You have been invited to take part in the project because you are scheduled to receive 
chemotherapy and have never received chemotherapy before. Patients from both the 
United Kingdom and mainland Europe are taking part in the project and it is hoped that 
over 600 patients will be involved. 
 
Should you choose to take part in the project, your treatment will be no different than if 
you choose not to participate. If you do take part, you will be asked to complete a short 
questionnaire for 14 days following each cycle of chemotherapy you receive. This will 
ask questions about your symptoms of nausea, vomiting, fatigue and any mouth 
problems you have. It will also ask you what self-care you have been performing. This 
questionnaire will take about 5-10 minutes to complete. You may or may not be given 
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some extra information about your self-care. Whether you do or do not receive this 
additional information will be determined by a completely random process that will be 
initiated if you decide to join the project. Your nurse will have no control over whether 
you are allocated to receive this information as this decision will be computer 
generated. You will not have to visit the hospital more than usual but you will have to 
visit your GP for a simple blood test 10 days after your chemotherapy. There are no 
lifestyle restrictions when participating in the project. We hope that the results from 
your questionnaires will help nursing care to be tailored to your individual needs and 
help you express the symptoms that you have been experiencing. The extra self-care 
information you may be given will tell you about some symptoms you may experience 
and what you can do to help manage these. You may also be asked to complete a short 
questionnaire about how you found your care. 
 
All the information which is collected about you during the course of the project will be 
kept strictly confidential. Any information about you will have your name removed so 
you cannot be recognised from it. 
 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form, of 
which you will get a copy. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a decision not 
to take part, will not affect the standard of care that you receive. Similarly, should you 
chose not to take part, your care will not be affected. 
 
For further information, please contact ………………… 
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APPENDIX D – STANDARD PATIENT INFORMATION SHEET – 
UNIT B 
 
 
Patient Information Sheet 
 
Study title: An exploration of patients’ symptoms and self-care  
activities following chemotherapy 
 
Invitation 
You are being invited to take part in a research project. Before you decide, it is 
important that you understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you would like to take part. 
 
Thank you for reading this. 
 
What is the purpose of the project? 
Patients receiving chemotherapy often experience some side effects associated with the 
drugs used in their treatment. It is more common now for patients to spend a lot of time 
not in hospital, but at home, in between their chemotherapy treatments. This means that 
patients have to deal with their side effects while they are at home, without the direct 
care of the specialists from the hospital. 
 
This project aims to collect information about patients’ symptoms related to their 
chemotherapy treatment. As well as this, it will collect information about what patients’ 
do at home to help their side-effects. It will also compare these results to those of 
another similar study. 
 
Why have I been chosen? 
The project aims to collect as much information about patients’ symptoms as possible 
and so we want to include as many patients as are willing to take part. You have been 
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chosen because you and your doctor have agreed that you will have a course of 
chemotherapy and because you have not had chemotherapy before. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do take part you will be given 
this information sheet to keep and be asked to sign a consent form. You will also be 
given a copy of the signed consent form. If you decide to take part, you are still free to 
withdraw at any time (even once you have started the project) and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care that you receive. 
 
What will happen to me if I take part? 
Taking part in this project involves filling out questionnaires about your symptoms and 
any activities that you have tried to make the symptoms better. The questionnaire does 
not take long to complete and is very simple. You can see the questionnaire before you 
decide whether to take part or not. It asks you some questions about your symptoms that 
day and focuses on nausea (feeling sick), vomiting (being sick), tiredness and mouth 
problems. These are symptoms that your doctor and nurse will talk to you about. You 
will be asked to complete this short questionnaire in the evening for 14 days after your 
chemotherapy. We would like you to complete these questionnaires for each cycle of 
chemotherapy that you have. Your doctor or nurse will be able to tell you how many 
cycles of chemotherapy you can expect to have. There are no right or wrong answers in 
the questionnaire, it is only your experience that we would like to know about. You may 
also be asked to take part in a short interview about the symptoms that you have 
reported but you don’t have to take part in an interview if you don’t want to. 
 
The project will be just over a year long but you will only take part for the length of 
time that you are having chemotherapy (or until you decide that you want to stop 
completing the questionnaires). 
 
What do I have to do? 
Taking part in the project will not change what you are able to do. You will be able to 
eat, drink, exercise, drive and take part in any activities that you would normally do. It 
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also will not affect any medication that you normally take or that your doctor advises 
for you. 
 
What are the side effects of taking part? 
There are no side effects or risks associated with taking part in this project. 
 
What are the possible benefits of taking part? 
Your treatment and care will not be affected whether you take part or not in this project. 
However, answering the questionnaire might make you think more about your 
symptoms and help you remember certain symptoms more clearly when it comes time 
to speak to your doctor or nurse at the hospital. 
 
What happens when the project stops? 
Because taking part (or not) in this project does not affect the treatment and care that 
you will receive, there will be no change to your treatment and care when the project 
stops.  
 
Will my taking part in the project be kept confidential? 
If you take part in the project, a nurse researcher from the Nursing and Midwifery 
School at the University of Glasgow will collect some information about your 
diagnosis, chemotherapy, age, postcode and gender. All the information that is 
collected about you during the course of the project will be kept strictly 
confidential. Any information about you that leaves the hospital will have your name 
and address removed so that you cannot be recognised from it. 
 
Your General Practitioner (GP) will be sent a letter, telling him/her that you are taking 
part in this project. Your doctor in the hospital will also be sent a similar letter. 
 
What will happen to the results of the project? 
The results of the project will be used to build a picture of the common symptoms that 
patients receiving chemotherapy experience and the activities they try to make these 
symptoms better. They will also be compared with the results of another similar study. 
The results of the project are likely to be available in July 2003 and any patient who has 
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participated in the project will be able to see these results by asking their hospital 
doctor. No patients will be identified in any reports or publications about the project. 
 
Who is organising the research? 
Dr Dunlop at Glasgow Royal Infirmary and Morven Miller, a nurse researcher at the 
Department of Nursing and Midwifery of the University of Stirling are organising the 
research project. 
 
Who has reviewed the project? 
The Research Ethics Committee of Glasgow Royal Infirmary has reviewed this project. 
 
Contact for further information 
Should you have any further questions about the project, please contact either: 
 
Dr Dunlop,      Morven Miller 
Consultant Oncologist,    Research Fellow 
Department of Medical Oncology  Department of Nursing and Midwifery  
Glasgow Royal Infirmary,    University of Stirling 
Telephone: 0141 211 1160    Telephone: 01786 466104 
 
You may also ask to speak to someone who is not directly involved with the project for 
advice. 
 
Thank you for taking the time to read this information sheet. 
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APPENDIX E – DEMOGRAPHIC DATA COLLECTION SHEET 
 
 
Patient Registration Form 
 
 
Date   …………………… 
 
 
Patient project …………………… 
number 
 
 
Patient name  ………………………………………. 
 
 
Date of birth  …………………… 
 
 
 
Postcode  …………………… 
 
Tel no.  …………………… 
 
 
 
Diagnosis  Stage of disease 
 
Breast cancer  ………………………………………………………….. 
 
 
Treatment  …………………… 
 
 
Therapeutic intent (   )    curative 
 
   (   )    palliative 
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APPENDIX F – PATIENT EDUCATION SCHEDULE 
 
 
Patient education schedule for questionnaire completion 
 
Have you:        COMPLETED 
 
1. given a demonstration of how to complete the questionnaire  (   ) 
 
2. highlighted the importance of there being no right or wrong answers (   ) 
 
3. explained the timing of questionnaire completion, i.e. in the 
      evening, reflecting on the symptoms that were experienced  
      throughout that day       (   ) 
 
4.   stressed the importance of putting the correct date on the questionnaire (   ) 
 
5. explained what to do if the questionnaire is forgotten about  (   ) 
 
6. explained that it is important to complete the questionnaire even if  
they have no symptoms        (   ) 
 
7. given details of how to return the questionnaires once completed (   ) 
 
8. shown patient where your contact details are (on patient information  
sheet) and reassured them that they should call if they have any  
questions or problems with completing the questionnaire  (   ) 
 
9. reassured the patient that they can withdraw at any time,  
without reason, without their subsequent care and treatment being  
affected         (   ) 
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APPENDIX G – NAUSEA PRACTICE PROTOCOL 
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APPENDIX H – FATIGUE PRACTICE PROTOCOL 
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APPENDIX I – ELECTRONIC KEYWORD DATABASE SEARCH 
 
Key words used in database search of literature reviews 
 
 
 
Nausea Fatigue  
Subject headings Subject headings 
Nausea Fatigue 
Keywords Keywords 
Anti-emetics Activity 
Assessment Assessment 
Behavioural interventions Chemotherapy 
Cancer Distress 
Chemotherapy Exercise 
Distress Guided imagery 
Guided imagery Incidence 
Incidence Interventions 
Interventions Management 
Management Non-pharmacological 
Non-pharmacological Patient attitudes 
Patient attitudes Patient experience 
Patient experience Patient perceptions 
Patient perceptions Pharmacological 
Pharmacological Psychological 
Progressive muscle relaxation training Self-care 
Psychological Severity 
Relaxation Treatment 
Self-care Quality of life 
Severity  
Treatment  
Quality of life  
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APPENDIX J – NAUSEA LITERATURE REVIEW 
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